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 G-protein coupled receptors (GPCRs) are the largest family of 
transmembrane proteins, constituting 2% of the human genome. They mediate signaling 
from a diverse set of ligands, ranging from photons to large peptides. Their intracellular 
signaling cascades are complex and highly malleable depending on cellular context. Yet, 
GPCR signaling in vivo is highly specific. Cells maintain this tight control over GPCR 
signaling through the expression of adaptor proteins. These adaptors regulate GPCR 
function and activation on many levels - they localize receptors to specific subcellular 
domains, assemble functional signaling complexes, alter the specificity of G-proteins 
coupling to the receptor, or regulate receptor traffic to and from the plasma membrane. 
By balancing the expression of these adaptor proteins, cells control where, when and 
how long GPCRs signal.  
 
Na+/H+ Exchanger Regulatory Factor 1 (NHERF1), also known as Ezrin binding 
phosphoprotein 50kDa (EBP50), is the prototypical PDZ adaptor protein. Expression of 
NHERF1 clusters parathyroid hormone type 1 receptor (PTH1R) and frizzled (Fzd) along 
actin stress fibers in non-polarized cells at the apical actin cap in polarized cells. In 
addition to proper localization, interaction with NHERF1 has several signaling 
manifestations. For PTH1R, interaction with NHERF1 can cause either a G-protein 
iv 
switch or can scaffold a PTH1R-PKA-calcium channel signaling complex. For Fzd, 
interaction with NHERF1 blocks Wnt-induced -catenin activation.  NHERF1 knockout 
mice exhibit PTH-resistant phosphate excretion and enhanced PTH-induced vitamin D 
synthesis, as well as increased mammary duct density secondary to heightened Wnt-
Fzd signaling. NHERF1 is a prime example of how PDZ adaptor proteins regulate GPCR 
localization and diversify GPCR signaling in physiologically significant ways. 
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PREFACE 
 
Some luck lies in not getting what you thought you wanted but getting what you have, 
which once you have got it you may be smart enough to see is what you would have 
wanted had you known.  -Garrison Keillor 
 
He who does not tire, tires adversity. – Martin Tupper 
 
Some of the world's greatest feats were accomplished by people not smart enough to 
know they were impossible.  -Doug Larson 
 
Mas sabe el diablo por viejo que por diablo. 
(The devil knows more because he's old than because he's the devil.) 
 
Brick walls are there for a reason. The brick walls are not there to keep us out. The brick 
walls are there to show how badly we want something. Because the brick walls are there 
to stop the people who don’t want something badly enough. They are there to keep out 
the other people. - Randy Pausch  
 
He who would learn to fly one day must first learn to stand and walk and run and climb 
and dance; one cannot fly into flying.  - Friedrich Nietzsche 
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I. REGULATION OF GPCRS BY PDZ PROTEINS 
 
 
G-protein coupled receptors (GPCRs) are the largest family of transmembrane 
proteins, constituting 2% of the human genome [1, 2]. They mediate signaling from a 
diverse set of ligands, ranging from photons to large peptides. Their intracellular 
signaling cascades are complex and highly malleable depending on cellular context. Yet, 
GPCR signaling in vivo is highly specific. One way that cells maintain this tight control 
over GPCR signaling is through the expression of adaptor proteins. These adaptors 
regulate GPCR function and activation on many levels - they localize receptors to 
specific subcellular domains, assemble functional signaling complexes, alter the 
specificity of G-proteins coupling to the receptor, or regulate receptor traffic to and from 
the plasma membrane. By balancing the expression of these adaptor proteins, cells 
control where, when, and how long GPCRs signal.  
 
Most adaptor proteins interact with their targets via well-conserved modular 
protein-protein domains (e.g. SH3, PTB, PDZ). The most abundant of these domains are 
PDZ domains, named for the first three proteins in which they were discovered (PSD-95, 
Discs-large and ZO-1). These 80-90 amino-acid long domains fold into a globular 
structure composed of six -sheets and 2 -helices [3]. Although internal PDZ ligands 
have been described (e.g. the –K-T-x-x-x-W- motif in Frizzled receptors [4]), the majority 
are located at the C-terminus of the target protein. The PDZ ligand docks in a groove 
between the second -sheet (B) and the second -helix (B), with the terminal 
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hydrophobic amino acid of the ligand occupying a hydrophobic cavity at the top of the 
groove (Figure 1) [5, 6]. Class I PDZ domains interact with proteins terminating in the 
consensus sequence –x-3-S/T-2-x-1-L/V/M0  (where x represents any amino acid, numbers 
represent position from C-terminus) [7].  Class II domains prefer a hydrophobic amino 
acid in position -2 [7]. Structural comparison of class I and class II PDZ domains 
demonstrates this ligand preference results from the presence of a histidine in class I 
(which favors serine or threonine) or hydrophobic pocket in class II (which favors a 
hydrophobic amino acid) at the distal end of B. Based on the particular amino acid 
sequence, a PDZ domain of either class may favor specific ligands based on residues 
located at the -3, -4 and -5 position [7, 8]. For example, the PDZ domains of Na/H 
Exchanger Regulator Factor 1 (NHERF1) contain an arginine that can electrostatically 
interact with a glutamate or aspartate at the -3 position (Figure 1) [5, 6]. While preferring 
targets with Glu/Asp at the -3 position, NHERF1 is still able to interact with targets that 
have a different amino acid at -3 (i.e. Npt2a which terminates in –A-T-R-L-) [9].  
 
In addition to GPCRs, PDZ adaptor proteins interact with a wide range of 
proteins including transporters, ion channels, receptor tyrosine kinases and enzymes. 
Regardless of the partner, the most universal function of PDZ adaptor proteins is to 
localize their targets to the correct domain at the plasma membrane. In polarized 
epithelial cells, different PDZ proteins can be found along the apical, junctional, lateral 
and basal membrane domains with their partners likewise distributed. For example, the 
human somatostatin receptor 3 is targeted to epithelial tight junctions by multiple PDZ 
domains of MUPP1 [10]. The receptor tyrosine kinase Her2 and the potassium channel 
Kir2.3 are both maintained at the basolateral membrane by binding the PDZ proteins 
ERBIN and Lin-7/CASK, respectively [11, 12]. A subset of PDZ proteins (42 of 141 found 
in the human genome) contain multiple PDZ domains. The presence of multiple domains 
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allows these proteins not only to direct sub-cellular localization, but also to scaffold 
protein complexes. In neurons, the multi-PDZ protein PSD-95 is responsible for 
clustering several receptors (NMDA [13], 1-adredergic [14]) and ion channels (Shaker 
K+ channel [15]) at the synapse. 
 
  The Na/H Exchanger Regulatory Factor family of PDZ adaptor proteins consists 
of four family members, NHERF1-4, which contain 2 or 4 tandem PDZ domains (Figure 
2A). Initially arising in invertebrates, they remain highly conserved throughout all higher 
order organisms (Figure 2B). NHERF1, also known as ezrin-binding phosphoprotein 
50kDa (EBP50), was the first of the family to be discovered and is the prototypical PDZ 
adaptor protein. NHERF1 contains two tandem class I PDZ domains and a C-terminal 
moesin-ezrin-radixin-moesin (MERM) binding domain (Figure 2a). The first known 
function of NHERF1 was as a co-factor essential for cAMP/PKA-induced inhibition of 
Na/H exchanger isoform 3 (NHE3) [16], but numerous other functions have been 
identified over the past decade. NHERF1 is expressed by all polarized epithelial cells 
and by a small subset of non-polarized mesenchymal cells (i.e., osteoblasts and 
macrophages) (Figure 3). NHERF1 localizes to the apical membrane of polarized cells 
and is found along actin fibers neighboring the plasma membrane in non-polarized cells. 
Numerous GPCRs (PTH1R, 2-AR, k-opioid), transporters (CFTR, NHE3, EAAT1), 
receptor tyrosine kinases (PDGFR, EGFR), and enzymes (PLC, nNOS) interact with 
NHERF1 (reviewed in [9]), although the physiologic consequences of many of the 
interactions are not well characterized. In the most well-studied cases, NHERF1 
functions by targeting proteins to the apical membrane and scaffolding protein-protein 
complexes. For example, the apical localization of CFTR and inward rectifier K+ channel 
ROMK depends on interactions between their PDZ ligands and NHERF1 or 2. At the 
4 
apical membrane, NHERF coordinates a ternary complex containing ROMK and CFTR 
that alters the functional properties of the ion channels [17]. Furthermore, recent studies 
show that NHERF1 can interact with itself and other members of the NHERF family in 
vitro, but in vivo evidence supporting this phenomenon is lacking [18, 19].     
 
 One extensively studied binding partner for NHERF1 is the parathyroid hormone 
type 1 receptor (PTH1R). This family B GPCR is the main regulator of calcium and 
phosphate homeostasis (reviewed in [20]). Decreases in serum calcium trigger the 
release of parathyroid hormone (PTH) into the circulation. PTH activates PTH1R, 
expressed in bone and kidney, stimulating bone breakdown and calcium reabsorption 
from the urine. Renal PTH1R activation also upregulates transcription of the enzyme 1-
OHase, which increases production of 1,25 (OH)2 vitamin D. Active vitamin D acts on the 
intestine to increase calcium absorption. These three processes increase serum 
calcium, which provides negative feedback on PTH secretion. The distribution and 
signaling of PTH1R is highly variable and depends on both the sub-cellular 
microenvironment and cell type. In the distal convoluted tubule (DCT) of the kidney, 
PTH1R localizes to the basolateral membrane and mainly signals through Gs and 
adenylyl cyclase to produce cAMP. In the proximal convoluted tubule (PCT) of the 
kidney, PTH1R is expressed on both the apical and basolateral surfaces and signals 
though both cAMP and intracellular calcium transients [21-23]. In osteoblasts, the main 
cellular target in bone, PTH1R activation generates both cAMP and prolonged 
intracellular calcium bursts [24]. A major breakthrough in our understanding of the cell-
specific behaviors of PTH1R was the discovery that PTH1R binds NHERF1 [23, 25]. 
Expression of NHERF1 causes PTH1R signaling to “switch” from exclusively cAMP to 
cAMP and phospholipase C (PLC)-dependent calcium flux [23, 25]. Since NHERF1 is 
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expressed in osteoblasts and PCT cells, but not in DCT cells, this may explain the 
variability in PTH1R signaling [26]. The quintessential proof that NHERF1 was critical for 
PTH1R function was that a NHERF1 knock-out mouse exhibited a constellation of 
phenotypes consistent with PTH1R dysfunction (disturbed mineral ion homeostasis, 
altered vitamin D level, and improper bone morphology) [27]. 
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II. NHERF1 AND PTH1R: A CASE STUDY 
 
 
A. DIFFUSION, DYNAMICS AND DISTRIBUTION 
 
 NHERF1 contains two PDZ domains and a C-terminal MERM domain that 
interact with the cytoskeleton. Therefore, it was logically assumed that NHERF1 
functions by tethering its targets to the actin cytoskeleton. Prior work using co-
immunoprecipitation and GST-pulldowns showed that NHERF1 interacts with MERM 
[28, 29] proteins and with PTH1R, [23, 25] but ability to assemble the ternary complex 
was only inferred. If NHERF1 tethers PTH1R to the actin cytoskeleton, then expression 
of NHERF1 should decrease the receptor’s mobility on the plasma membrane. 
Furthermore, this decrease in mobility should depend on the integrity of PDZ – PDZ 
ligand interaction and the actin cytoskeleton. In several non-polarized cell lines, 
NHERF1 expression significantly decreased the diffusion coefficient of the PTH1R 
(Figure 4, column 2) [30, 31]. Depolymerization of the actin cytoskeleton with latrunculin 
A increases, but does not completely restore, the mobility of the receptor, suggesting 
that PTH1R still interacts with NHERF1 but is no longer tethered to the cytoskeleton 
(Figure 4, column 4). NHERF1 failed to decrease the diffusion coefficient of PTH1R 
M593A (Figure 4, column 2), a receptor construct containing a non-functional PDZ ligand 
[31, 32].  This proves that the interaction between NHERF1 and PTH1R is mediated by 
the receptor’s PDZ ligand. Addition of PTH increases the average diffusion coefficient of 
the receptor in a time-dependent manner [31]. This demonstrates that ligand-induced 
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activation of PTH1R causes the dissociation of NHERF1 and disruption of the ternary 
complex.  
 
The ability of NHERF1 to tether PTH1R to the actin cytoskeleton can be 
qualitatively observed by imaging surface PTH1R with total internal reflection (TIRF) 
microscopy. In the absence of NHERF1, PTH1R is diffusely spread across the entire 
membrane (Figure 5A). Expression of NHERF1 clusters the receptor along actin stress 
fibers (Figure 5B). These bundles are not seen when PTH1R M593A is coexpressed 
with NHERF1 (Figure 5C) or when cells are pre-treated with latrunculin A [30, 31]. 
Interestingly, the receptors confined to the “bundle” regions diffuse significantly faster 
than receptors in the bulk membrane [31]. Furthermore, receptor motion is not isotropic, 
but movement along the bundles occurs four times faster than movement across the 
bundles [31]. This suggests that tethered PTH1R is being moved along the bundles by 
actin treadmilling. Although further evidence would be needed to support such a 
hypothesis, this is a novel mechanism for the regulation of GPCR dynamics.  
 
 Although most studies investigating interaction between NHERF1 and PTH1R 
have been conducted in non-polarized cells, the majority of cells that express both 
proteins are polarized epithelial cells. In the kidney, PTH1R is expressed on both apical 
and basolateral membranes of NHERF1-expressing cells, but only on the basolateral 
membrane of cells lacking NHERF1. This suggests that NHERF1 has a role in the apical 
localization of PTH1R. The majority (~60%) of endogenous PTH1R is apically localized 
in MDCK cells expressing endogenous levels of NHERF1 (Figure 6A). Not surprisingly, 
70% of ectopically expressed PTH1R-GFP also localizes to the apical membrane 
(Figure 7). Only 20% of PTH1R M593A GFP is found on the apical surface, indicating 
that the PDZ binding domain of PTH1R is critical for apical localization (data not shown). 
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Finally, knockdown of NHERF1 using shRNA causes a redistribution of PTH1R-GFP to 
the basolateral membrane (Figure 7). In the absence of NHERF1, the receptor density is 
constant, indicating random distribution of the receptor (Figure 6B). These data strongly 
support a model where PTH1R is sorted randomly to the apical or basolateral 
membrane. Interaction with NHERF1 at the apical membrane stabilizes PTH1R at the 
membrane and inhibits constitutive internalization.  
 
 
B. SIGNALING THROUGHOUT THE SCAFFOLD 
 
 The initial characterization of the NHERF “signaling switch” in non-polarized cells 
showed that expression of NHERF2 decreases PTH-induced cAMP generation and 
triggers a PTH-dependent calcium transient. Further studies established that NHERF1 
expression causes this signaling switch by increasing the affinity of PTH1R for Gi [33]. 
Activation of Gi results in inhibition of adenylyl cyclase, while the release of G 
subunits activates PLC resulting in a calcium transient [23]. However, unanswered 
questions still remained, including whether NHERF1 causes PTH1R to signal differently 
from apical and basolateral membranes within the same cell and if the NHERF1 
“signaling switch” is the same in all cell types. 
 
 In the proximal convoluted tubule, NHERF1 localizes to the apical membrane, 
whereas PTH1R is expressed on both apical and basolateral surfaces [21-23, 34]. 
Therefore, NHERF1 should “switch” apical PTH1R signaling from cAMP generation to 
formation of a calcium transient. Consistent with this hypothesis, addition of PTH to the 
apical membrane of polarized MDCK cells stimulates both cAMP and a calcium 
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transient, whereas addition to the basolateral membrane only stimulates cAMP (Figure 
8A, 9A). At saturating concentrations of PTH the total amount of cAMP generated is 
higher for the apical membrane (Figure 8A). However, normalization to receptor density 
reveals that basolateral receptors generate four fold more cAMP per receptor. 
Furthermore, the EC50 for PTH-induced cAMP is significantly higher for the apical 
membrane than the basolateral membrane (approximately 30nM for apical vs. 4nM for 
basolateral). This difference in EC50 is thought to be a consequence of the interaction 
between PTH1R and NHERF1 and is discussed in detail below. Consistent with 
observations made in non-polarized cells, the calcium transient is sensitive to both 
pertussis toxin and gallein, implicating the G subunits of Gi (Figure 9B). Addition of 
PTH to the apical membrane of NHERF1 knockout cells results in minimal cAMP 
generation and no measurable calcium transients (Figure 9C). However, addition of PTH 
to basolateral surface stimulates a robust 6-fold increase in cAMP. In the absence of 
NHERF1, the EC50 for cAMP generation and average cAMP generated per receptor are 
comparable for both the apical and basolateral membranes (Figure 8B). Clearly, 
NHERF1 expression is the major determinant in the polarized distribution and signaling 
of PTH1R.   
 
PTH increases intracellular calcium in a number of NHERF1-expressing 
osteoblastic cell lines (UMR-106, ROS cells stably expressing NHERF1), as well as in 
primary rat and human osteoblasts [35-39]. Unlike cells of renal origin, PTH-induced 
calcium transients in bone are relatively long (200 sec in ROS vs. 20-50 sec in MDCK or 
OK) and are insensitive to pertussis toxin [30, 40, 41]. Furthermore, in renal cells 
NHERF1 expression decreases PTH-induced cAMP generation, whereas in bone 
NHERF1 expression increases cAMP [30]. Clearly, NHERF1 regulates PTH1R signaling 
differently in these cell types. In bone, activation of aggregated PTH1R creates high 
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local concentrations of cAMP, which activates PKA in a spatially restricted manor. 
Activated PKA phosphorylates neighboring L-type calcium channels, increasing channel 
activity and producing a prolonged calcium transient (Figure 10) [42]. Consistent with 
this, PTH-induced calcium transients are blocked by chelation of extracellular calcium or 
L-type calcium channel inhibitors [30]. Two isoforms of the L-type calcium channel (1C 
and 1D) terminate in PDZ ligands (-Y-V-S-S-L and –C-I-T-T-L respectively), so it is 
possible that in osteoblasts NHERF1 nucleates a signaling complex containing both 
PTH1R and L-type calcium channels.  
 
In both polarized and non-polarized cells, NHERF1 augments PTH1R signaling 
by creating new protein complexes at the plasma membrane. On the apical membrane 
of polarized cells, NHERF1 brings together PTH1R and Gi causing a PTH-induced PLC- 
mediated calcium burst (Figure 11). In osteoblasts, NHERF1 clusters PTH1R together 
with L-type calcium channels causing a prolonged calcium transient (Figure 10).  In 
addition to the role of NHERF1 in PTH1R localization, it also induces differential 
signaling at opposite sides of the membrane within the same cell and can produce 
distinct effects on PTH second messenger systems in different cell types. 
 
 
C. THE PCT PARADOX 
 
 NHERF1 knockout mice exhibit a complex phenotype linked to PTH1R function 
in the proximal convoluted tubule. Although serum PTH levels are normal, these mice 
exhibit PTH-insensitive renal phosphate wasting and elevated levels of 1,25 (OH)2 
vitamin D [27, 43]. This phenotype is paradoxical because it requires PTH1R signaling to 
be both inhibited and enhanced, respectively, in the same cell. PTH-insensitive 
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phosphate reabsorption suggests that PTH signaling is defective, yet high levels of 
vitamin D imply enhanced PTH1R activation. The key to understanding this phenotype is 
NHERF1’s ability to regulate both the distribution and signaling of the PTH1R. Under 
normal conditions, NHERF1 targets the majority of PTH1R to the apical surface. 
Activation of this apical pool of PTH1R generates a small amount cAMP and PLC-
dependent calcium transients, which inhibits phosphate reabsorption but does not 
induce expression of 1-OHase (Figure 12). Activation of the PTH1R on the basolateral 
membrane induces expression of 1-OHase but has minimal effect on phosphate uptake 
(Figure 12). The loss of NHERF1 causes a redistribution of PTH1R from the apical to 
basolateral membrane. The depleted pool of apical receptors is unable to produce a 
calcium burst in response to PTH and thus cannot regulate phosphate reabsorption 
(Figure 11). The increase in receptor density on the basolateral surface causes 
enhanced PTH signaling, elevated transcription of 1-OHase and increased levels of 
1,25 (OH)2 vitamin D (Figure 13). Because NHERF1 expression is critical for the proper 
distribution and signaling of polarized PTH1R, it is fitting that NHERF1 knockout mice 
exhibit a phenotype reflecting dysfunction in both apical and basolateral signaling.  
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III. NHERF1 AND FRIZZLED: NOVEL PARTNERS  
 
 
A. TETHERING THE TAILS 
 
 Frizzled receptors (Fzds) are a family of seven-transmembrane proteins that bind 
to Wnt and activate numerous signaling cascades (reviewed in [44]). They have a 
characteristically short intracellular tail that encodes both an internal PDZ ligand and, in 
some isoforms, a terminal PDZ ligand. Fzds 1, 2, 4 and 7 all terminate in the sequence 
E-T-x-V, which is predicted to have high affinity for class I PDZ domains (Figure 14) [7, 
45]. All four of these Fzd receptors interact with PSD-95 in a yeast-2-hybrid assay [46]. 
In mammalian cells, Fzds 4 and 7 interact with the PDZ adaptor protein MAGI-3 [47], 
and Fzd 7 functionally binds syntenin [48].  
 
As with PTH1R, NHERF1-Fzd interactions were demonstrated using multiple 
methods. NHERF1 co-immunoprecipitated with Fzd 4 but not with Fzd 4 containing a  
mutated PDZ ligand (Fzd 4 V573A) [49]. Similarly, NHERF1 expression decreased the 
diffusion coefficient of Fzd 4-GFP but had no effect on the mobility of Fzd 4 V573A-GFP. 
When expressed in NHERF1-containing cells, Fzd 4 clustered along phalloidin-positive 
fibers while Fzd 4 V573A remained uniformly distributed regardless of the presence of 
NHERF1 (Figure 15 A,B). Interestingly, Fzd 4 bound only to the second PDZ domain of 
NHERF1; transfection of a NHERF1 construct with a scrambled PDZ2 domain failed to 
influence the dynamics or distribution of Fzd 4 [49]. These results indicate that NHERF1 
interacts with the C-terminus of Fzd 4 and tethers the receptor to the actin cytoskeleton. 
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Given the great similarity of the intracellular tails of Fzds 1, 2, 4, and 7 and the functional 
data below, it is reasonable to speculate that NHERF1 interacts with all four Fzds.  
 
 
B. DUELING PDZ DOMAINS 
 
 The internal Dvl binding motif (K-T-x-x-x-W) interacts with the PDZ domain of 
disheveled (Dvl) and is necessary for signal transduction [4]. This internal PDZ ligand is 
separated from the terminal PDZ ligand by as few as 12 amino acids. Therefore, it is 
likely that binding of one PDZ protein will preclude binding of a second PDZ protein to 
the neighboring PDZ ligand. Fluorescently-tagged Dvl2 adopts a membrane-like 
distribution when expressed with Fzd 4.  Co-expression of NHERF1 displaced Dvl2 from 
the membrane to the cytosol (Figure 16A). This suggests that NHERF1 and Dvl compete 
for the C-termini of Fzd receptors and under basal conditions there is higher affinity for 
NHERF1. The addition of Wnt induces the dissociation of NHERF1 allowing Dvl to be 
recruited to the membrane (Figure 16B).  
 
Both canonical (i.e. -catenin activation) and non-canonical (i.e. activation of 
small GTPases Rac and Rho) Wnt signaling appear to be mediated by different domains 
of the Dvl protein (reviewed in [50, 51]). If NHERF1 antagonizes Dvl-Fzd binding, then 
expression of NHERF1 should alter some aspects of Wnt signaling. Expression of 
NHERF1 profoundly inhibited Wnt-induced -catenin affinity for Fzd 2, 4 and 7 (Figure 
17A). As expected, it had no effect on Wnt signaling through Fzd 3, as Fzd 3 does not 
terminate in a PDZ ligand (Figure 17A) [49]. Inhibition of Wnt signaling was entirely 
mediated by interaction between the PDZ ligand of Fzd and PDZ2 of NHERF1 because 
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mutation in either of those domains blocked the effect (Figure 17B,C). In the human 
breast cancer cell line MCF7, shRNA knockdown of NHERF1 dramatically increased -
catenin signaling (Figure 17E). This increase in signaling is accompanied by a significant 
elevation in cyclin-D1 expression (a -catenin response gene) and cellular proliferation 
(Figure 17F,G). This result has been confirmed in vivo by a proteomic study showing 
elevated levels of cytosolic -catenin and increased expression of -catenin responsive 
genes at the brush border of NHERF1 -/- mice [52]. Although previous reports show PDZ 
adaptor proteins can regulate non-canonical Wnt signaling [48], NHERF1 is currently the 
only PDZ protein known to regulate canonical Wnt signaling.  
 
 
C. DISTORTED DUCT DENSITY 
 
Expression of NHERF1 regulates cellular proliferation and migration (reviewed in 
[29]). Loss of NHERF1 increases cellular proliferation and invasion in multiple human 
breast cancer cells lines [49, 53-55]. This growth suppressive / tumor suppressive role 
for NHERF1 is consistent with the observation that NHERF1 is a key regulator of 
canonical Wnt signaling. In vivo, abnormal Wnt signaling manifests itself as a 
hyperproliferation of mammary ducts [56]. Consistent with this, the duct density of the 
mammary glands of virgin 10-week old NHERF1 knockout mice was four times greater 
than that of wild type littermates (Figure 18A). Almost 25% of the NHERF1 null 
mammary epithelium stained positive for the proliferation marker BrdU compared to 5% 
in wild type controls(Figure 18B). Immunofluorescence confirmed increased levels and 
increased nuclear localization of -catenin in the ductal epithelium of NHERF1-null mice 
(Figure 18C). Interestingly, heterozygous mice also exhibited increased duct density 
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implying that both copies of NHERF1 are needed for complete regulation of Wnt 
signaling. This is especially significant because over 50% of human breast cancers 
exhibit loss of heterozygosity at the NHERF1 locus (17Q25.1) [53]. Thus, even a 50% 
decrease of NHERF1 expression can contribute to deregulated Wnt signaling and 
hyperproliferation.  
 
Tamoxifen, an ER antagonist, is a standard treatment for ER(+) breast 
malignancies. A subset of tamoxifen-treated patients develops highly aggressive 
recurrent tumors that are resistant to hormone therapy. Although clinically difficult to 
treat, a recent study shows these recurrent tumors are inhibited by low-dose estrogen 
treatment [57]. This paradoxical phenomenon may result from altered NHERF1/Wnt 
dynamics. NHERF1 expression is known to be estrogen-dependent and is inhibited by 
chronic tamoxifen treatment [58]. Reduced expression of NHERF1 would enhance Wnt 
signaling, increasing tumor proliferation and invasion (Figure 20A). Low-dose estrogen 
stimulates NHERF1 expression, dampening Wnt signaling. Consistent with this scheme, 
MCF7 cells made resistant to tamoxifen by chronic exposure (MCF7 LY2) express 75% 
less NHERF1 than the parental cell line (Figure 20B). As expected, these cells 
demonstrate enhanced Wnt-induced -catenin activation and proliferation (Figure 20C). 
Ectopic expression of NHERF1 blunts the enhanced Wnt response, returning it to levels 
found in parental line (unpublished observation). If NHERF1 expression could be 
increased pharmacologically in the absence of estrogen, we propose that heightened 
Wnt responses would not occur and these hormone-resistant tumors would fail to form.  
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IV. DISCUSSION 
 
 
 A universal model of the biological roles of PDZ adaptor proteins must include 
three basic aspects of their cellular functions. First, PDZ adaptors direct delivery of their 
targets to specific subcellular regions. This requires the adaptor proteins to contain at 
least two domains – one (the PDZ domain) to interact with the target and another to 
determine the subcellular location (i.e. the MERM binding domain of NHERF1). Second, 
PDZ adaptors assemble and organize protein complexes in a dynamic manner. This 
dynamic scaffolding requires low affinity interactions that can be rapidly established or 
broken in response to extracellular cues. Finally, PDZ adaptors regulate downstream 
signaling by altering receptor-ligand affinity, modifying the second messenger cascade, 
or changing downstream effectors. The following discussion will elaborate on specific 
aspects of this model using the interactions of NHERF1 as an example.  
 
 
A. DIRECTED DISTRIBUTION 
 
In both non-polarized and polarized cells, NHERF1 clusters its targets to actin-
rich domains. In non-polarized cells, NHERF1 co-localizes with phalloidin-positive actin 
fibers [31]. The distribution of NHERF1 in polarized cells is more complex. Although 
phalloidin-positive actin structures are found on the apical, lateral and basal surfaces, 
NHERF1 expression is limited to the apical surface (Figure 21). NHERF1 lacking the C-
terminal MERM domain is homogeneously expressed in the cytoplasm, suggesting that 
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interaction with MERM proteins is critical for polarized localization (data not shown). 
Thus, I hypothesize that this confined distribution of NHERF1 is the result of its 
interactions with MERM proteins, because these proteins are also restricted to the apical 
surface. Consistent with this, staining of both mouse and human polarized epithelium 
shows that ezrin is primarily located at the apical membrane (data not shown). The 
reason for the apical localization of ezrin and other MERM proteins is unknown. One 
potential explanation is a disparity in phosphorylation states. Ezrin’s binding to the actin 
cytoskeleton is driven by PKA-dependent phosphorylation [59, 60]. Therefore, the apical 
distribution of ezrin may reflect enhanced PKA activity at the apical membrane, which 
may be due to increased apical signaling, higher PKA levels at the apical surface, or to a 
lack of inactivating phosphodiesterases at the apical end of the cell. Although the 
mechanism is not clear, it is likely that the apical distribution of actin-binding proteins 
causes the same apical localization of NHERF1.  
 
 Although NHERF1 is the main adapter protein that targets PTH1R to actin fibers, 
it is not the only adapter protein capable of doing so. In fact, in CHO cells lacking 
NHERF1 approximately 30% of PTH1R clusters in bundles that run parallel to actin 
fibers (Figure 5A) [31]. Mutation of the PTH1R’s PDZ ligand further reduces this 
clustering, suggesting that a second PDZ adaptor protein may be involved (Figure 5C). 
A prime candidate for this second PDZ protein is NHERF2, which interacts with PTH1R 
and binds the actin cytoskeleton [25, 61, 62]. Other adaptor proteins such as Dvl, ezrin, 
Tctex-1, and 4.1G could also target PTH1R along actin fibers as they bind both PTH1R 
and the actin cytoskeleton [63-67]. Given that all of these PTH1R partners bind 
downstream of residue 470, their contribution to PTH1R targeting could be 
experimentally tested using a PTH1R construct truncated at residue 470 (470Stop  [63]). 
Finally, the potential for PTH1R to heterodimerize with other actin-directed membrane 
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proteins cannot be excluded. Previous work suggested that PTH1R heterodimerizes with 
the TGF receptor, which terminates in a class II PDZ ligand (-G-I-K-M) [68]. Therefore, 
it is possible that low affinity heterodimerization with other membrane proteins that 
themselves terminate in a PDZ ligand could recruit a fraction of PTH1R to the actin 
cytoskeleton.  
  
In polarized cells, some PTH1R is still retained on the apical membrane following 
NHERF1 knockdown (Figure 6A, 7A). A similar fraction of PTH1R M593A localizes to 
the apical membrane implying that this apical pool is not the result of interaction with 
PDZ proteins (unpublished observation). Previous work suggested that in the absence of 
NHERF1 these receptors are held at the apical surface by direct interaction with ezrin 
[67]. My work suggests that these apical receptors are not actively targeted but randomly 
distributed.  When unable to bind to NHERF1 (due to either NHERF1 knockdown or 
mutations in the PDZ ligand), approximately 28% of PTH1R resides on the apical 
surface. Importantly, the apical membrane constitutes 25% of the total membrane 
surface of MDCK cells [69]. The similarity between these two numbers suggests that in 
the absence of NHERF1, PTH1R uniformly coats both the apical and basolateral 
membranes. This model does not explain the in vivo distribution of PTH1R in the distal 
convoluted tubule (DCT). In DCT cells, which do not express NHERF1, PTH1R is 
restricted to the basolateral membrane, and not uniformly distributed. One possible 
explanation is that DCT cells express basolaterally targeted PDZ proteins that can 
interact with PTH1R and polarize its distribution to the basolateral membrane. 
 
 Although not experimentally shown, it is likely that NHERF1 targets Frizzled 
receptors to the apical membrane. NHERF1’s ability to maintain proper apical 
distribution of Fzd receptors may be necessary for proper Wnt-Fzd signaling. In 
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Drosophila, both Frizzled receptor isoforms (fz and fz2 as designated in Drosophila) 
exist in polarized distributions and signal via different pathways (reviewed in [70]). Fz is 
apically localized and activates non-canonical/planar cell polarity (PCP) Wnt signaling, 
whereas fz2 is distributed along both the apical and basolateral membranes and 
mediates canonical Wnt signaling [71]. Interaction between the C-terminal tail of each 
receptor and polarized adaptor proteins (as of yet unidentified) mediates this polarized 
distribution. Drosophila express a NHERF1 analog (SIP-1), but its ability to interact with 
the fz receptors has not been tested [72]. Switching the distribution profiles of the two fz 
receptors (by switching the C-terminal portions of their tails) mildly inhibits PCP signaling 
but profoundly reduces canonical Wnt signaling [71]. Further investigation demonstrated 
that the decrease in canonical Wnt signaling was due to a redistribution of Dvl from the 
basolateral to apical surface [71]. Although Fzd distribution has not been linked to Wnt 
signaling in mammalian cells, these studies in Drosophila do raise the possibility that 
Fzd receptors may signal differently depending on which membrane they reside. Fzds 
on the apical membrane may preferentially signal through non-canonical pathways, 
while Fzds on the basolateral surface may preferentially activate -catenin. Expression 
of NHERF1 should then favor non-canonical signaling and reduce canonical signaling. 
Consistent with this model, the NHERF1-/- mice exhibit phenotypes of enhanced -
catenin activation (increased mammary proliferation) and impaired non-canonical 
signaling (misalignment of ependymal cilia). The tissue specificity of these phenotypes 
probably results from the unique tissue-specific expression pattern of Wnts, Fzds and 
PDZ adaptor proteins.  
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B. DYNAMIC SCAFFOLDING 
 
 The second major function of PDZ adaptor proteins is to scaffold protein 
complexes. While perceived as static structures, the protein complexes are highly 
dynamic and rapidly reorganize in response to ligand binding or changes in the local 
environment. At its core, dynamic scaffolding relies on competition between adaptor 
proteins for low affinity binding sites in close proximity.  
 
 PDZ domains interact with their target via the four C-terminal amino acids, the 
so-called PDZ ligand. While a single PDZ domain is able to interact with PDZ ligands of 
difference sequences, it is likely that different PDZ ligand sequences have different 
binding affinities. These small differences in affinity could produce a PDZ domain bias. 
For example, full length NHERF1 binds both the PDZ ligand of PTH1R (E-T-V-M) and 
the PDZ ligand of Fzd 4 (E-T-V-V).  The conservative substitution of methionine with 
valine should not dramatically alter the binding affinity. Yet, the PDZ ligand of PTH1R 
preferentially associates with PDZ1 of NHERF1 [73], but the PDZ ligand of Fzd 4 
interacts almost exclusively with PDZ2 [49]. The subtle difference in affinities afforded by 
the methionine to valine substitution is enough to direct the PDZ ligand of Fzd 4 to the 
second PDZ domain of NHERF1. In a cell that expresses a diverse set of PDZ ligands, 
these subtle differences in affinity may dictate which PDZ ligands interact with which 
PDZ domains. Experimentally, these subtle biases may be overlooked due to the fact 
that overexpression of a protein shifts the equilibrium to favor binding of the 
overexpressed protein. This may explain why PDZ proteins, like NHERF1, have 
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numerous binding partners in vitro yet a very select number of functionally relevant 
binding partners in vivo.  
 
 PDZ domains bind PDZ ligands with affinities around 100 nM [7, 74-76]. Prior 
kinetic studies demonstrate that this binding occurs without rate-limiting conformational 
changes [77], allowing us to estimate the half life of the complex to be on the order of 
seconds. These low affinity, short half-life interactions allow the complex to be highly 
dynamic. Addition of PTH rapidly induces the dissociation of NHERF1 from PTH1R [31]. 
Uncoupling from NHERF1 allows PTH1R to complex with a second adaptor protein, -
arrestin. Competition between adaptor proteins arises when the binding sites are in 
close proximity. For example, the short C-terminal tail of Fzd 4 contains binding sites for 
both NHERF1 and Dvl separated by only twenty residues. The proximity of these binding 
sites makes it unlikely that both proteins occupy the receptor simultaneously.  At rest, 
the majority of Fzd 4 is bound to NHERF1 and Dvl is diffusely distributed in the cytosol 
(Figure 16A). Binding of Wnt induces the rapid dissociation of NHERF1 from Fzd 4, 
which opens the Dvl binding site. Dvl is recruited to the C-terminus of Fzd 4 where it 
both transduces signals and internalizes the receptor (Figure 16B,C). This shift in 
binding partner can be observed by measuring Dvl recruitment to the membrane 
following the addition of Wnt. Within 6-8 half lives (~180 to 250 seconds) Fzd’s PDZ 
ligand dissociates from NHERF1 and binds Dvl, causing an increase in Dvl at the 
membrane (Figure 16B). 
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C. REGULATION OF GPCR SIGNALING 
 
 In addition to targeting and scaffolding, adaptor proteins also directly regulate 
GPCR signal transduction. By interacting with PTH1R, NHERF1 can alter the sensitivity 
for the ligand, alter which G-proteins couple to the receptor and change which effectors 
are activated by the second messenger.  
 
 I125-PTH binding experiments in CHO cells clearly demonstrate that PTH1R has 
decreased affinity for PTH when bound to NHERF1 (2.4 nM in control cells vs. 12.8 nM 
in NHERF1 expressing cells, Figure 22). This difference in Kd is also observed when 
comparing PTH1R on the apical and basolateral membranes of polarized MDCK cells 
(Figure 6A). The simplest explanation of this behavior is based on thermodynamic 
considerations. The complex of receptor, NHERF1 and PTH can be modeled as 
simultaneous binding of multiple ligands (NHERF1 and PTH). In a multi-ligand system, 
negative cooperativity occurs when the binding of one ligand decreases the affinity for 
the second. Because binding of PTH to the receptor induces the dissociation of NHERF1 
(i.e. lowers the affinity of PTH1R for NHERF1) [31], PTH and NHERF1 exhibit negative 
cooperativity. The converse must also be true; binding of NHERF1 to PTH1R must 
decrease its affinity for PTH. However, this simple thermodynamic model must be 
viewed with caution, as it assumes that the system is in equilibrium, a condition that 
might not be found in a live cell. Furthermore, there is abundant evidence of covalent 
modifications of both PTH1R and NHERF1 after the addition of PTH (i.e., 
phosphorylation [29, 78-80] and ubiquitination [81]). Thus, the magnitude of this 
cooperative effect may be small and masked by other biological processes. Finally, 
PTH-induced recruitment of additional intracellular partners of PTH1R, such as -
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arrestin, must be taken into account. My data show that expression of NHERF1 delays 
recruitment of -arrestin to the receptor [31, 82], demonstrating that NHERF1 and -
arrestin binding are not independent phenomena. Nevertheless, regardless of the exact 
mechanism, my experiments show that, at least in some cells, NHERF1 decreases the 
affinity of PTH1R for PTH. Under experimental conditions using saturating 
concentrations of PTH this decrease may be trivial, but in vivo, where circulating PTH 
concentrations range from 1-7 pM, this small decrease may have important 
consequences [83].  
 
 In addition to regulating ligand affinity, NHERF1 also regulates which G-proteins 
couple with PTH1R. In their initial description of this “signaling switch”, Mahon and 
colleagues demonstrated that expression of NHERF1 caused PTH signaling to switch 
from exclusively cAMP to cAMP and calcium. The PTH-induced NHERF1-dependent 
calcium transients were sensitive to both Pertussis toxin and pharmacologic 
phospholipase C inhibition, suggesting the involvement of Gi [23]. GTP--S binding 
experiments from our laboratory confirmed that NHERF1 expression causes PTH to 
activate G-proteins other than Gs [63]. Interestingly, expression of NHERF1 increases 
the amount of PTH-induced activation of Gq, not Gi, as hypothesized by Mahon and 
colleagues [23]. My work with MDCK cells supports a model where NHERF1 increases 
coupling of PTH1R and Pertussis toxin-sensitive Gi. One possible explanation for these 
discordant results is that the NHERF1-induced G-protein switch is cell-type specific. In 
proximal tubule-like MDCK and OK cells NHERF1 couples PTH1R and Gi, but in less 
differentiated HEK293 cells, NHERF1 couples PTH1R to Gq. In bone cells (UMR and 
ROS expressing NHERF1) this signaling switch does not occur [30].  
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Although the exact mechanism of the NHERF1-mediated G-protein switch is 
unknown, several models have been proposed. One possible mechanism is that Gi is 
enriched at the apical membrane [84, 85]. NHERF1 recruits PTH1R to the apical 
membrane, where it is exposed to high concentrations of Gi. When activated by PTH, a 
small subset of PTH1R would couple to Gi and produce a calcium transient. 
Consistent with this model, disruption of the apical targeting of PTH1R by 
depolymerizing the actin cytoskeleton with cytochalasin D inhibits PTH-induced calcium 
transients [23]. Coupling only a small percentage of receptor to Gi is also consistent with 
the observation that apical PTH stimulates a large amount of cAMP in polarized MDCK 
cells (Figure 8A). Furthermore, immunohistochemistry has shown that at least two 
isoforms (Gi1 and Gi2) localize to the apical membrane of renal tubular cells [86]. A 
second potential mechanism is that NHERF1 directly recruits Gq to the receptor. The 
second PDZ domain of NHERF1 binds PLC, which in turn interacts with Gq [67, 87]. 
Activated receptor couples to this vicinal Gq and produces a calcium transient. This 
model is supported by the observation that PLC strongly co-localizes with PTH1R and 
that NHERF1 expression increases PTH-induced GTP--S binding to Gq. However, it 
does not explain why the calcium transients are Pertussis toxin-sensitive, as Gq is 
unaffected by Pertussis toxin treatment.  These two models are not mutually exclusive 
and may occur to distinct degrees in different cell types. Experimentally, these two 
models can be differentiated based on the requirement for either the second PDZ 
domain or MERM binding domain. NHERF1 lacking the C-terminal MERM binding 
domain (NHERF1 ERM) should delocalize the receptor from the actin cytoskeleton but 
still allow PLC and Gq recruitment. NHERF1 containing a mutated PDZ2 domain 
(NHERF1 S2) would still properly localize the receptor but would be unable to scaffold 
the receptor-PLC-Gq complex. If the main function of NHERF1 is to localize PTH1R to 
25 
G-protein rich domains (i.e. model 1) then NHERF1 S2 should function identically to wild 
type while NHERF1 and ERM should abolish PTH-induced calcium transients. If 
NHERF1 is serving as a scaffold, then a NHERF1 ERM construct that contains both 
PDZ domains should permit PTH-induced calcium signaling while expression of 
NHERF1 S2 should not.  
 
 As mentioned above, the G-protein switch does not occur in cell lines derived 
from bone. This is likely due to differences in protein expression. While NHERF1 still 
localizes PTH1R to actin fibers, osteoblastic cells may not express the correct adapter 
protein or G-protein isoform to enrich these areas with Gi. Even if the cells express the 
correct G-protein / adapter protein pair, the expression may not be high enough to force 
coupling of a significant amount of PTH1R. In addition to not being able to create Gi-rich 
subcellular regions, bone cells may express different NHERF1 interaction proteins that 
prevent Gq recruitment. While all three PLC isoforms interact with NHERF1 in vitro, only 
PLC1 and 3 interact in vivo [23]. If bone cells predominantly express PLC2, then 
NHERF1 would be unable to scaffold the PTH1R-NHERF1-PLC1-Gq complex. 
Assuming bone cells express the correct PLC isoform, they may also express other 
NHERF1 binding proteins that compete for the second PDZ domain. As noted earlier, 
two isoforms of the L-type calcium channel (1D and 1C) terminate in PDZ ligands 
predicted to interact with NHERF1. It is possible that in bone cells NHERF1 clusters 
PTH1R and L-type calcium channels instead of scaffolding PTH1R with PLC and Gq. 
This would be consistent with our data that NHERF1 does not cause a G-protein switch 
in ROS cells but promotes PTH-induced activation of L-type calcium channels [30].  
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 The final way that NHERF1 alters PTH1R signaling is by altering which effectors 
are activated by second messenger signaling. Addition of 100 nM PTH to the apical or 
basolateral membrane stimulates almost identical cAMP responses (Figure 8A). 
However, only basolateral cAMP appears to induce transcription of the 1-OHase gene 
(Figure 12B). This suggests that cAMP generated on the apical membrane activates 
different effectors than cAMP generated from the basolateral surface. Specifically, 
basolateral cAMP activates the transcription factor CREB which enters the nucleus and 
increases transcription of 1-OHase. While controversial, generation of apical cAMP 
appears to be more important for internalizing the sodium phosphate transporter and 
regulating phosphate uptake (reviewed in [88]). Therefore, by determining the 
localization of the receptor, NHERF1 can influence what downstream effectors will be 
activated by the second messenger cascade.    
 
 
D. PUZZLING PHENOTYPES FOR MOUSE AND MAN 
  
In addition to the phenotypes already described, NHERF1-/- mice also exhibit a 
30% decrease in bone density and a 40% decrease in bone mineral content [27].  The 
majority of NHERF1-/- mice have evidence of bone fractures by X-ray [27]. 
Histologically, these mice exhibit irregular trabecular bone with large amount of 
unmineralized osteoid (unpublished observation). This pathology is very similar to that 
seen in the human disease rickets. Osteoblasts build bone by depositing collagen matrix 
(osteoid) that is then coated by calcium hydroxyapatite crystals (Ca10(PO4)6OH2). This 
calcium-phosphate lattice gives bones their rigidity and tensile strength. Rickets (also 
known as osteomalacia when it occurs in adults) is characterized by the inability to 
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deposit calcium and phosphate onto osteoid. Patients with rickets present with bowed 
legs, craniotabes (soft skull bones), and multiple bone fractures. The most common 
cause of rickets is nutritional vitamin D deficiency. Low levels of vitamin D prevent 
proper calcium absorption by the small intestine resulting in low serum calcium 
(hypocalcemia) and secondary elevation of PTH (secondary hyperparathyroidism). 
Calcium is not deposited onto osteoid causing weak bone. This pathophysiology is not 
consistent with the NHERF1-/- phenotype because the knockout mouse exhibits 
elevated levels of vitamin D (Figure 13B) and normal serum calcium values [27]. A 
second, rarer form of rickets, hypophosphatemic rickets, is caused by excessive 
phosphate wasting. The inability to retain phosphate leads to low serum phosphate 
levels and defective bone mineralization despite high levels of circulating vitamin D. 
Hereditary rickets with hypercalciuria (HHRH) is a genetic form of hypophosphatemic 
rickets caused by mutations in Npt2a (SLC34A3) [89]. HHRH patients present with low 
levels of serum phosphate (hypophosphatemia), increased excretion of phosphate 
(hyperphosphaturia) and calcium (hypercalciuria), normal PTH and elevated vitamin D 
levels. This presentation is consistent with the NHERF1-/- mice that exhibit decreased 
serum phosphate levels, increased urine phosphate levels, normal PTH levels and 
elevated vitamin D levels [27, 43]. Superficially, phosphate wasting due to loss of 
NHERF1 seems to explain the bone phenotype in NHERF1-/- mice. However, knockout 
of Npt2a, the alleged target of NHERF1 in the kidney, produces a more severe 
phosphate wasting but no rachitic phenotype [90, 91]. This suggests that phosphate 
wasting may not be the cause of the NHERF1-/- bone phenotype. To experimentally test 
this, NHERF1-/- mice should be supplemented with phosphate. If phosphate 
supplementation normalizes both the hypophosphatemia and bone phenotypes, then a 
causative relationship is correct. If supplementation does not correct the bone phenotype 
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that is strong evidence that the bone and kidney phenotypes of the NHERF1-/- mouse 
are independent. 
 
 If the bone phenotype is independent of mineral ion disturbances, then what is 
the molecular mechanism? One clue may be that the marrow cavity of NHERF1-/- mice 
is filled with adipose tissue. Progenitor cells in the marrow cavity proliferate and 
differentiate into either osteoblasts or adipocytes in response to paracrine and endocrine 
signals. In vitro and in vivo, transient PTH administration increases both proliferation and 
differentiation of osteoblasts [92-96]. These effects are thought to be mediated by 
changes in gene expression secondary to phosphorylation and activation of transcription 
factors AP-1, CREB and Runx2 (Figure 10). Consistent with this hypothesis, knockout of 
c-fos (a member of the AP-1 transcription factor family) and mutation of PKA-
phosphorylation sites on CREB and Runx2 inhibit PTH-induced osteoblastogenesis and 
bone formation [97-100]. Based on our studies in an osteosarcoma cell line, NHERF1 
knockout progenitor cells should not be able to generate a calcium transient in response 
to PTH [30]. Therefore, in the absence of NHERF1, PTH-induced PKC activation of AP-1 
would be impaired. Furthermore, PTH stimulates less cAMP in the absence of NHERF1 
[30]. Decreased cAMP will result in less PKA activation and decreased activation of 
CREB and Runx2. All together, the loss of NHERF1 should significantly diminish PTH-
induced gene expression. In the absence of pro-osteoblast signals, progenitor cells 
differentiate into adipocytes by default. Canonical Wnt signaling also contributes to the 
differentiation of osteoprogenitors and pre-osteoblasts to osteoblasts (reviewed in [101]). 
However, the majority of this signaling is mediated by Fzd 6 (which does not terminate in 
a PDZ ligand) and thus would be insensitive to NHERF1 [102].  
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NHERF1 interacts with Fzd receptors and inhibits Wnt-induced -catenin 
activation (Figure 19). One would expect the NHERF1-/- mouse to have deregulated 
Wnt signaling, resulting in developmental defects and neoplasia. However, the NHERF1 
knockout develops normally and does not develop spontaneous neoplasia within the first 
two years of life. How can we reconcile these two facts? Although we speculate that 
NHERF1 interacts with eight of the ten Fzd receptors due to the presence of canonical 
C-terminal PDZ ligands in their sequences, we have only experimentally proven this 
interaction for Fzd 1, 2, 4 and 7. Furthermore, we have proven that Fzd 3 does not 
interact with NHERF1. Therefore, it is possible that the majority of Wnt signaling is 
transduced by Fzds that do not interact with NHERF1. An alternative hypothesis would 
be that there are other PDZ proteins that can also regulate canonical Wnt signaling. 
Previous work demonstrates that several other PDZ proteins are capable of interacting 
with Fzd receptors. For example, MAGI-3, which has a similar expression pattern to 
NHERF1, binds Fzd 4 (and presumably other Fzds) with its second PDZ domain [47, 
103]. Interestingly, while other PDZ adaptor proteins have been found to interact with the 
Fzd receptor, they only appear to regulate non-canonical signaling. NHERF1 appears to 
be unique in its ability to regulate canonical signaling. However, future studies may 
reveal this is not the case.  
 
 The promoter of NHERF1 contains several estrogen response elements [58, 
104]. Consistent with this, NHERF1 expression is estrogen-dependent in a variety of 
tissues including mammary, colonic, biliary, and endometrial epithelia [58, 105-107]. 
Conversely, estrogen does not increase NHERF1 expression in renal proximal 
convoluted tubule or pituitary GH3 cells [108, 109]. These results indicate that regulation 
of NHERF1 by estrogen is cell-type specific. This cell-type specific signaling does not 
appear to be mediated by differential expression of estrogen receptor isoforms, as 
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several observations suggest that both ER and ER can stimulate NHERF1 expression 
[54, 105, 106, 110, 111]. Estrogen regulates NHERF1 expression in both the uterus, 
which predominantly expresses ER and the colon, which mainly utilizes ER[105, 
106, 110]. Estrogen up-regulated NHERF1 expression in human osteosarcoma cells 
stably expressing either ER or ER [111]. Finally, NHERF1 is expressed at high levels 
in breast cancer cells that express either ER or ER alone [54]. Assuming that both ER 
isoforms are capable of interacting with the ERE in NHERF1’s promoter, it may be 
differential expression of ER co-activators or co-repressors that mediate the cell-specific 
effects. 
 
 Not surprisingly, tamoxifen and other anti-estrogens can decrease NHERF1 
expression. As described above, treatment of MCF7 cells with tamoxifen results in 
decreased NHERF1 expression (Figure 20B). This also occurs in vivo; tumors recurring 
after tamoxifen treatment express less NHERF1 than the parental tumor (Figure 23). 
However, it is still unclear whether this tamoxifen-induced decrease in NHERF1 has 
functional or clinical relevance. Based on our in vitro studies, decreases in NHERF1 
expression should enhance Wnt signaling and induce a more aggressive tumor 
phenotype. While some tumors do become more aggressive following tamoxifen 
treatment, they comprise only a small minority [112, 113]. Clearly, there are other factors 
that determine if tamoxifen-induced NHERF1 suppression will correlate with poor 
treatment outcome. One such factor may be the initial level of NHERF1 expression.  A 
recent proteomic study of tamoxifen-sensitive and tamoxifen-resistant tumors found that 
NHERF1 expression was approximately 2.5-fold higher in tamoxifen-sensitive tumors 
[114]. This increased NHERF1 expression was independent of estrogen receptor levels 
and thus assumed to be partially mediated by estrogen-independent pathways. If a 
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tumor has high NHERF1 levels, tamoxifen treatment may not decrease NHERF1 
sufficiently to increase Wnt signaling. The tumor would be unable to respond to estrogen 
(due to tamoxifen) or Wnt (due to sufficient levels of NHERF1) and would remain in 
remission. In tumors with low initial levels of NHERF1, tamoxifen would decrease 
NHERF1 below a critical threshold, where Wnt signaling would be enhanced and the 
treatment would fail. Significantly, this model suggests that a pharmacological agent able 
to induce NHERF1 expression should significantly enhance tamoxifen treatment and 
decrease the occurrence of tamoxifen-resistant tumors.  
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V.  IMPLICATION FOR DISEASE 
 
 
Given the central role of PDZ-PDZ ligand interactions in proper cell function, it is 
not surprising that their disruption causes disease. Disruption of the multiple-PDZ 
containing protein harmonin (either by frameshift mutation [115], insertion [116], or point 
mutation within PDZ1[117]) results in Usher syndrome, a severe sensory disorder 
resulting in hearing loss and retinal degeneration. Similarly, frameshift [118, 119] and 
point mutations [120] in the PDZ protein periaxin causes Charcot-Marie-Tooth disease, 
an inherited neuropathy. Polymorphisms in the NHERF family of PDZ proteins contribute 
to the development of metabolic and mineral ion disorders. A single nucleotide 
polymorphism (SNP) in NHERF3 (PDZK1_i33968 C > T) is associated with elevated 
plasma triglycerides, abdominal obesity and metabolic syndrome [121]. In the related 
family member NHERF1, two polymorphisms (c.328C > T, c.458 G > A) and one 
mutation (c.673G > A) have been linked to nephrolithiasis and bone demineralization 
[122]. Still other mutations (c.516 A > G, c.537 C > T, c.902 A > T) have been found in 
breast cancer cells but not in normal controls [53]. The majority of these mutations are in 
the second PDZ domain, implying that PDZ2 is particularly important for proper NHERF1 
function. This is unexpected given that the majority of proteins interact with NHERF1 
through the first PDZ domain. As we understand more about how PDZ proteins regulate 
cellular signaling their role in disease is sure to expand. 
 
The emerging recognition of the role of PDZ proteins in disease makes them 
attractive targets for drug development. The first attempt at modulating PDZ-PDZ ligand 
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interactions came in the form of blocking peptides. The Glu2 subunit of AMPA receptors 
interacts with the PDZ proteins PICK1 and GRIP. Expression of a 10-amino acid peptide 
corresponding to the C-terminus of Glu2 blocked interaction between Glu2 and its PDZ 
partners, resulting in decreased surface expression and inhibition of long term 
depression (LTD) [123]. Despite the effectiveness of blocking peptides, they are of 
limited therapeutic use due to poor membrane permeability and rapid degradation. 
Although more difficult to create, small molecular inhibitors offer the best chance of 
being medically useful. Given the structural diversity and specificity of the binding pocket 
of PDZ domains, it should be possible to engineer class- and domain-specific inhibitors. 
Using indole-based chemistry, small-molecule antagonists have been developed for 
PDZ domains in MAGI3 [124, 125], Dvl [126] and NHERF1 [127]. When evaluated with 
purified PDZ domains and ligands, these molecules inhibited interactions with IC50s in 
the mid-micromolar range [127]. Recently, a second generation inhibitor for the PDZ 
domain of Dvl has been identified that blocks Wnt signaling both in vitro and in vivo at 
nanomolar concentrations [128]. With continued research, PDZ domain inhibitors will 
increase in number, diversity, specificity, and potency and will likely provide novel 
treatments for rare and common diseases.    
 
It is clear that there is still much to learn about the cell biology, physiology, 
pathology and pharmacology of PDZ adaptor proteins. The next steps in PDZ biology 
will be to fully characterize the ligand profile for all known PDZ proteins and decipher the 
role of these interactions in vitro and in vivo. With this knowledge, we will be able to 
understand better how mutations and dysregulation of PDZ proteins contribute to 
disease. Finally, discovery of specific PDZ protein inhibitors has the potential to make a 
profound impact in treating numerous metabolic and neoplastic disorders.  
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FIGURE LEGENDS 
 
 
Figure 1: Structural model of PDZ – PDZ ligand interaction. A model of the PTH1R PDZ 
ligand (ball and stick, CPK colored) docked in PDZ1 of NHERF1 (ribbon diagram, navy 
blue). Terminal Met593 occupies a hydrophobic pocket at the head of the groove. His72 
(yellow) and Arg40 (red) salt bridge with Thr591 and Glu590 providing specificity for the 
consensus sequence-E-S/T-x-V/L/M. 
 
Figure 2: Structure and phylogeny of NHERF family of PDZ proteins. 
 
Figure 3: Tissue distribution of NHERF1. Hemi-section of a mouse stained for NHERF1 
(A). NHERF1 is expressed in the proximal convoluted tubules of the kidney (B) the 
ependyma of the brain (C) and osteoblasts in bone (D).  
 
Figure 4: NHERF1 decreases the lateral mobility of PTH1R. CHO-N10 cells were 
transfected with PTH1R-eGFP or PTH1R M593A-eGFP and NHERF1 expression was 
induced with tetracycline for 24 hours. The diffusion coefficient of the fluorescent 
receptor was measured using image cross-correlation spectroscopy as described in [31]. 
  
Figure 5. Distribution of PTH1R in non-polarized cells. CHO-N10 cells expressing the 
indicated constructs were imaged using TIRF microscopy. The percentage of receptor 
was measured as described in [31] and is indicated above the scale bar. Scale bar 
represents 5 m.  
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Figure 6. Distribution of endogenous PTH1R in wild type and shNHERF1 polarized 
MDCK cells. (A) Wild type and shNHERF1 MDCK cells were grown to confluency on 
transwell filters. Cells were considered to be polarized when the transepithelial 
resistance was greater than 2,000 Ohms. Receptor numbers were calculated from 
radioligand binding experiments as previously described [30]. (B) Receptor density was 
calculated by dividing the receptor number by the membrane surface area as reported 
by [69].  
 
Figure 7. Distribution of PTH1R-eGFP in wild type and shNHERF1 polarized MDCK 
cells. (A) Sub-confluent wild type or shNHERF1 MDCK cells were transfected with 
PTH1R-eGFP and grown to confluency on transwell filters. Upon polarization of the 
MDCK cells, the filters were fixed, removed from the transwells, stained for E-cadherin, 
mounted on slides and imaged with confocal microscopy. A 15-20 image Z-stack was 
obtained for each cell. (B) The basolateral membrane was defined by presence of E-
cadherin staining (images not shown). The intensity of PTH1R on the apical and 
basolateral membranes was measured using ImageJ. The percentage of apical and 
basolateral PTH1R was calculated by dividing the individual intensities by the total sum.  
 
Figure 8. PTH-induced cAMP generation at the apical and basolateral membrane. (A) 
Various concentrations of PTH were added to the apical or basolateral membrane of 
polarized MDCK cells. cAMP was measured as previously described [30]. (B) NHERF1 
knockdown MDCK cells showed decreased apical and increased basolateral cAMP 
response.  
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Figure 9. Expression of NHERF1 causes apical PTH1R to couple to Gi and stimulate a 
calcium transient. (A) PTH-induces a rapid calcium transient when added to the apical 
membrane of polarized wild type MDCK cells. This calcium transient is not observed 
when PTH is added to the basolateral surface. (B) PTH-induced calcium transients are 
inhibited by pre-treatment with Pertussis toxin or gallein. (C) Knockdown of NHERF1 
prevents apical PTH1R from generating calcium transients.  
 
Figure 10. Model describing how NHERF1 directs PTH1R signaling in osteoblasts. 
NHERF1 binds the PDZ ligand of PTH1R and clusters it along actin fibers. Aggregated 
PTH1R produces high concentrations of cAMP, which activate PKA. PKA 
phosphorylates L-type calcium channels enhancing their activity and producing a 
calcium transient. This calcium transient activates PKC. PKA and PKC phosphorylate 
transcription factors (AP-1, CREB, and Runx2) that increase expression of genes 
necessary for proliferation and osteoblastic differentiation. 
 
Figure 11. NHERF1 regulates the distribution and signaling of PTH1R in polarized cells.  
 
Figure 12. Apical PTH1R regulates phosphate uptake, while basolateral PTH1R 
regulates 1-OHase expression. (A) Polarized MDCK cells were treated with vehicle, 
100 nM apical PTH or 100 nM basolateral PTH for 4 hours. Radioactive phosphate 
uptake in Na-replete or Na-free buffer was measured by liquid scintillation. Na-
dependent phosphate uptake was calculated by subtracting Na-free phosphate uptake 
from phosphate uptake in Na-replete buffer. (B) Polarized MDCK cells were treated with 
vehicle, 100 nM PTH on the apical surface, 100 nM PTH on the basolateral surface or 
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100 nM PTH on both surfaces for 8 hours. 1-OHase expression was quantified with 
qPCR using GAPDH as an endogenous control.  
 
Figure 13. NHERF1-/- mice have increased expression of 1-OHase and increased 
concentrations of 1,25(OH)2 vitamin D. (A) 1-OHase and VDR mRNA levels were 
measured in whole kidney lysates using qPCR (* p < 0.05, Students’ t-test). (B) Serum 
1,25(OH)2 vitamin D concentrations of NHERF1+/+ and NHERF1-/- littermates (* p < 
0.05, Students’ t-test).  
 
Figure 14.  Multiple sequence alignment of the terminal amino-acids of Fzd receptors.  
 
Figure 15. NHERF1 modulates the distribution and dynamics of Fzd 4. (A, B) CHO-N10 
cells were transfected with Fzd 4-eGFP or Fzd 4 V573A-eGFP and stained with 
phalloidin-Alexa 546. Scale bar represents 5 m. (C, D) Lateral mobility of Fzd 4 in 
control and NHERF1 expressing cells was measured by FRAP. (* p < 0.05, Students’ t-
test) 
 
Figure 16. NHERF1 inhibits Fzd-Dvl coupling. (A) In control CHO-N10 cells Dvl2-mRFP 
localizes to the plasma membrane. Expression of NHERF1 displaces Dvl2 from the 
membrane to the cytosol. (B) CHO-N10 cells expressing Fzd 4-eGFP and Dvl2-mRFP 
were rapidly imaged using TIRF microscopy. All intensities were normalized to Fzd 4-
eGFP to account for receptor internalization. Addition of Wnt5a is indicated by an arrow. 
(C) NHERF1 expression decreases the amount of Dvl2 that co-immunoprecipitates with 
Fzd 4. The amount of Dvl-Fzd complex after Wnt5a treatment was not affected by 
NHERF1 expression.   
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Figure 17. Enhanced Wnt signaling occurs in the absence of NHERF1. (A) CHO-N10 
cells were co-transfected with the indicated Fzd receptors and either TOP or FOP 
luciferase reporter plasmid. NHERF1 expression blunted Wnt-induced luciferase 
expression via Fzd 2, 4 and 7 but had no effect on Wnt signaling through Fzd3 (** p < 
0.01, * p < 0.05, Two-way ANOVA with Bonferroni post-hoc tests). (B) Mutational 
ablation of the Fzd 4 PDZ ligand (Fzd 4 V573A) rescues Wnt signaling from NHERF1 
inhibition. This mutation has no effect on Wnt signaling in the absence of NHERF1. (C) 
Wnt-induced β-catenin activation was blocked by wild type NHERF1 and NHERF1 
containing a mutated PDZ1 domain (S1). This inhibition was not generated by NHERF1 
containing a mutated PDZ2 domain (S2) or with both PDZ domains mutated (S1S2) (*** 
p < 0.001, One-way ANOVA with Tukey post-hoc tests). (D) Transfection of MCF7 cells 
with NHERF1-targeted shRNA reduced expression by 95%. (E) NHERF1 knockdown 
enhanced Wnt-induced -catenin activation in MCF7 cells (* p < 0.05, ** p < 0.01, Two-
way ANOVA with Bonferroni post-hoc tests).  (F) Following 8 hours of treatment with 
Wnt, NHERF1 knockdown cells shown increased levels of cyclin-D1. (*** p < 0.001, 
Two-way ANOVA with Bonferroni post-hoc tests). (G) Wnt-induced proliferation was 
measured using a 24 hour radiolabeled-thymidine incorporation assay. MCF7 cells 
lacking NHERF1 showed marked proliferative responses to both Wnt3a and Wnt5a 
compared to scrambled controls (** p < 0.01, *** p < 0.001, Two-way ANOVA with 
Bonferroni post-hoc tests). Adapted from [49]. 
 
Figure 18. Mammary glands of NHERF1-/- mice exhibit elevated duct density, increased 
proliferation and heightened -catenin activation. (A) The fourth and fifth mammary 
glands from virgin NHERF1+/+ and NHERF1-/- mice were removed and histologically 
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prepared. Ductal density was quantified from at least 10 high-power fields from three 
different animals (* p<0.05, Students’ t-test). (B) Breasts from NHERF1+/+ and 
NHERF1-/- mice injected with BrdU were removed, embedded in paraffin and sectioned. 
BrdU incorporation was visualized by immunofluorescence. Percentage of BrdU(+) cells 
was quantified from three independent animals (* p<0.05, Students’ t-test). (C) Individual 
ducts from NHERF1+/+ and NHERF1-/- mice stained with DAPI, anti--catenin and 
NHERF1. Scale bar 20 m.  
 
Figure 19. Model for NHERF1 regulation of distribution and signaling of Fzd receptors. 
PDZ2 of NHERF1 interacts with the C-terminal PDZ ligand of Fzd receptors, tethering 
them to the actin cytoskeleton. Addition of Wnt induces the dissociation of NHERF1, 
allowing Dvl to be recruited and activated. In the absence of NHERF1, Fzd-Dvl 
precoupling causes enhanced Wnt signaling and hyperproliferation.  
 
Figure 20. Tamoxifen treatment reduces NHERF1 expression and enhances Wnt 
signaling. (A) Schema for the regulation of NHERF1 expression and Wnt signaling by 
tamoxifen. (B) NHERF1 expression was measured by qPCR in MCF7 cells and MCF7 
cells chronically treated with tamoxifen (MCF7 LY2). (C) Wnt-induced -catenin in MCF7 
and MCF7 LY2 cells was measured using the TOP/FOP luciferase reporter assay.    
 
Figure 21. NHERF1 localizes to the apical membrane in polarized MDCK cells.  
 
Figure 22. NHERF1 expression right-shifts 125I-PTH binding curves in CHO-N10 cells.  
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Figure 23. Decreased NHERF1 expression and increased -catenin staining are 
observed in breast tumors that recur following tamoxifen treatment.  
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Internalization of the PTH type I receptor (PTH1R) is
regulated in a cell- and ligand-specific manner. We
previously demonstrated that the sodium/proton ex-
changer regulatory factor type 1 (NHERF1; EBP50) is
pivotal in determining the range of peptides that inter-
nalize the PTH1R. Antagonist PTH fragments can inter-
nalize the PTH1R in some kidney and bone cell models.
PTH(7-34), which binds to, but does not activate, the
PTH1R, internalizes the PTH1R in kidney distal tubule
(DT) cells, where NHERF1 is not expressed. The effect
of antagonist PTHrP peptides has not, to this point,
been assessed. PTH1R internalization was measured by
real-time confocal fluorescence microscopy of DT cells
stably expressing 105 EGFP-tagged PTH1R/cell (1).
PTHrP(7-34) internalized the PTH1R in a manner indis-
tinguishable from PTH(7-34). Introduction of NHERF1
into DT cells, however, blocked PTH(7-34)–, but not
PTHrP(7-34)–, induced PTH1R internalization. To delin-
eate the sequences within PTHrP that determine whether
PTH1R internalization is affected by NHERF1, chim-
eric PTH/PTHrP fragments were tested for their abil-
ity to induce PTH1R internalization. PTH(7-21)/PTHrP
(22-34), PTH(7-32)/PTHrP(33-34), and PTH(7-33)/
PTHrP(34) at 1 µM each internalized the PTH1R 50–
70% in a NHERF1-independent manner. When the C
terminus of PTHrP was replaced with homologous
amino acids from PTH, NHERF1 inhibited PTH1R in-
ternalization. It was determined that simply mutating
F34 to A in PTH induced PTH1R internalization in a
NHERF1-independent manner. None of the chimeric
peptides activated the PTH1R but all effectively com-
peted for 1 nM PTH(1-34) in cyclic AMP assays. In
addition, all chimeric peptides competed for radiola-
beled PTH(1-34) in binding assays in DT cells. PTH(1-
34) and PTHrP(7-34), but not PTH(7-34), efficiently
recruited β-arrestin1 to plasma membrane PTH1Rs. We,
therefore, conclude that PTH(1-34) and PTHrP(7-34)
induce a conformational change in the PTH1R that pro-
motes arrestin binding and dissociates NHERF1 from
PTH1R internalization.
Key Words: Hormones and receptors; PTH/PTHrP; sig-
naling.
Introduction
Parathyroid hormone (PTH) is an 84-amino-acid pep-
tide hormone that is secreted by the parathyroid glands in
response to low serum calcium levels. PTH binds to and
activates the PTH/PTHrP receptor, also known as the type
I PTH receptor (PTH1R). The first 34 amino acids of PTH
are sufficient to bind with high affinity and activate the
PTH1R. Positions 1–6 are important for adenylyl cyclase
stimulation by the PTH1R, the first two positions being
required for full activity (2–5). Positions 1 and 29–32 are
critical for stimulation of phosphoinositide turnover and
activation of protein kinase C (6,7). Sequences distal to
position 15 are thought to be important for binding of PTH
to the N terminal extracellular ligand-binding domain of
the PTH1R. The PTH-related protein (PTHrP) is synthe-
sized and released by many normal and malignant cell types.
It acts typically in an autocrine or paracrine fashion, in
contrast to the endocrine actions of PTH. In bone develop-
ment, PTHrP plays a pivotal role as a growth factor in bone
development, delaying chrondrocyte differentiation and
promoting bone growth (8). PTHrP is a 141-amino-acid
hormone that has high sequence identity to PTH at its N
terminus, sharing 8 of 13 amino acids. PTHrP also binds to
and activates the PTH1R. The first 34 amino acids of
PTHrP, like PTH, can fully activate the PTH1R. There are,
however, differences in the interactions between PTH and
PTHrP with the PTH1R, even in regions of high identity
between these two peptides (4).
The PTH1R belongs to Class B (also called Class II) of
the seven-transmembrane family of guanine nucleotide
binding protein (G protein)–coupled receptors (GPCRs)
(9). Receptors in this family bear some structural similarity
and exhibit a defining characteristic in that they activate
both adenylyl cyclase and phospholipase C (PLC) (10–12).
The responses of the PTH1R to agonists are regulated by
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multiple mechanisms. Upon activation, downstream second
messengers can feed back and attempt to shut off the signal
from the PTH1R. Typically, G protein–coupled receptor
kinase 2 (GRK2) phosphorylates the agonist-activated re-
ceptor (13,14). This promotes arrestin recruitment (15–17)
and uncoupling of the receptor from its cognate G proteins,
Gs and Gq. Following this desensitization, the PTH1R is
endocytosed into intracellular compartments after which it
can be recycled back to the plasma membrane (resensitiza-
tion) (18), or targeted for degradation, leading to receptor
downregulation (19,20). We have demonstrated that both
the synthetic PTH(7-34) and the secreted form of the peptide
PTH(7-84), which bind to but do not activate the PTH1R,
internalize the PTH1R very efficiently in kidney distal
tubule cells and rat osteosarcoma ROS 17/2.8 cells (1). In
contrast, neither PTH(7-34) nor PTH(7-84) internalizes
the PTH1R in kidney proximal tubule cells or the human
SaOS-2 osteosarcoma cell line. The cell-specific effects of
PTH(7-34) on PTH1R internalization depend of the expres-
sion of NHERF1 (1). NHERF1 is expressed in kidney prox-
imal tubule cells and SaOS cells but is absent in kidney dis-
tal tubule and ROS17/2.8 cells (1). Expression of NHERF1
inhibits PTH(7-34) induces PTH1R internalization in
kidney distal tubule cells (1). In contrast, expression of a
dominant negative NHERF1 promotes PTH(7-34)-induced
PTH1R internalization in proximal tubule cells where
NHERF1 is expressed at high levels. The synthetic peptide
PTHrP(7-34), like PTH(7-34), is a PTH1R antagonist. To
this point, it has not been compared with PTH for its ability
to induce PTH1R endocytosis.
Results
In previous studies, we demonstrated that PTH(7-34)
internalizes the PTH1R and that this internalization is regu-
lated by NHERF1. Because PTH and PTHrP both bind to
and activate the PTH1R, we sought to determine if PTHrP-
stimulated PTH1R internalization was similarly regulated.
PTH(1-34) and PTHrP(1-36), both PTH1R agonists, share
8 of 13 N terminal amino acids. PTH(7-34) and PTHrP(7-
34), by comparison, share four amino acids between posi-
tions 7 and 13. We, therefore, inquired whether these se-
quence disparities translated into differentially regulated
PTH1R internalization. PTH(1-34) and PTHrP(1-36) at 1
µM each internalized the PTH1R 50% after 15 min (Fig. 1)
in mouse kidney distal tubule cells that stably express 105
PTH1R/cell (D1 cells). These cells do not express NHERF1
(1). Expression of NHERF1 does not inhibit PTH1R inter-
nalization by these agonists (1) (data not shown). PTH(7-
34) and PTHrP(7-34) at 1 µM internalized the PTH1R 80%
after 15 min in D1 cells (Fig. 1). PTH(7-34)–induced PTH1R
internalization was blocked by expression of NHERF1
(Fig. 1) (1), PTHrP(7 34)–stimulated PTH1R internaliza-
tion was not inhibited by NHERF1 (Fig. 1).
In order to determine the sequences within PTHrP that
promote PTH1R internalization by a NHERF1-independent
mechanism, a series of chimeric PTH/PTHrP peptides were
Fig. 1. PTH(7-34) and PTHrP(7-34) both induce PTH1R endocytosis. The effect of 10−6 M of the indicated peptides on PTH1R
internalization in kidney distal tubule cells expressing 100,000 PTH1R/EGFP per cell (D1 cells). Receptor endocytosis was measured
by real-time quantitative confocal microscopy in D1 cells that had been transfected with empty pcDNA3 vector or NHERF1. The extent
of PTH1R internalization after a 15 min peptide exposure is presented. Results are the means ± SEM of triplicate determinations in three
independent experiments. *p < 0.01 for PTH(7-34) in the presence of NHERF1 vs the absence of NHERF1 as determined by a one-way
ANOVA with a post-hoc Bonferroni test for statistical significance.
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designed (Table 1). Previous work of Gardella indicated,
that the C terminus of PTH is incompatible with the N termi-
nus of PTHrP with respect to receptor binding (28). Posi-
tions 5, 19, and 21 were found to be critical to maintaining
binding activity of chimeric peptides. We, therefore, de-
cided that the dividing point for initial chimeric peptides
would be at position 21. PTH(7-21)PTHrP(22-34) inter-
nalized the PTH1R 55% after 15 min in D1 cells (Fig. 2).
This is somewhat less than PTH(7-34) and may reflect a
reduced efficiency of the chimeric peptides to induce a con-
formational change in the PTH1R that promotes receptor
internalization. Expression of NHERF1 had a minimal ef-
fect on PTH(7-21)PTHrP(22-34)–stimulated PTH1R endo-
cytosis. The reverse chimera, PTHrP(7-21)PTH(22-34),
internalized the PTH1R 40% after 15 min (Fig. 2) and expres-
sion of NHERF1 completely blocked this effect. These data
suggest that replacement of PTH sequences between posi-
tions 22 and 34 with homologous amino acids from PTHrP
dissociate NHERF1 and PTH1R internalization.
PTH(8-34) and PTH(9-34) internalized the PTH1R 45%
and 40%, respectively, and this endocytosis was blocked by
expression of NHERF1 (Fig. 3). In contrast, neither PTH
(10-34) nor PTH(7-31) internalized the PTH1R in D1 cells
(Fig. 3). This indicated that positions 7-9 and 32-34 might
be important for promoting PTH1R internalization by PTH.
We have also demonstrated that PTH(7-34)–induced PTH1R
internalization is PKC dependent (22). Positions 29–32 are
critical for activation of PKC by PTH (6,7). Taken together,
this suggested that positions 32–34 of PTH might be im-
portant amino acids for PTH1R endocytosis. Both PTH and
Table 1
PTH and PTHrP(7-34) and Chimeric Peptides were Designed to Identify
Sequences Within PTH That Confer NHERF1-Sensitivity to PTH1R Internalization
PTH(7-34) LMHN LGKHLNSMER VEWLRKKLQD VHNF
PTHrP(7-34) LLHD KGKSIQDLRR RFFLHHLIAE IHTA
PTH(7-21)PTHrP(22-34) LMHN LGKHLNSMER VFFLHHLIAE IHTA
PTHrP(7-21)PTH(22-34) LLHD KGKSIQDLRR REWLRKKLQD VHNF
PTH(7-32)PTHrP(33-34) LMHN LGKHLNSMER VEWLRKKLQD VHTA
PTHrP(7-32)PTH(33-34) LLHD KGKSIQDLRR RFFLHHLIAE IHNF
PTH(7-33)PTHrP(34) LMHN LGKHLNSMER VEWLRKKLQD VHNA
PTHrP(7-33)PTH(34) LLHD KGKSIQDLRR RFFLHHLIAE IHTF
Fig. 2. NHERF1 inhibition of PTH1R internalization is dependent on sequences in the C terminus of PTH(7-34). The effect of 10−6 M
of the indicated peptides on PTH1R internalization in D1 cells. Receptor endocytosis was measured as outlined in Fig. 1. The extent of
PTH1R internalization after a 15 min peptide exposure is presented. Results are the means ± SEM of triplicate determinations in four
independent experiments. *p < 0.01 in the presence of NHERF1 vs the absence of NHERF1 as determined by a one-way ANOVA with
a post-hoc Bonferroni test for statistical significance.
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PTHrP share a histidine at position 32. Therefore, chimeric
PTH/PTHrP peptides were designed where positions 33 and
34 were substituted. PTH(7-32)PTHrP(33-34) internalized
the PTH1R 50% in D1 cells and this process, as with PTHrP
(7-34), was not inhibited by NHERF1 expression (Fig. 2).
PTHrP(7-32)PTH(33-34) internalized the PTH1R 53%
and, like PTH(7-34), this action was completely inhibited
by NHERF1 expression (Fig. 2). These data clearly dem-
onstrate that mutation of N33 and F34 in PTH promotes
NHERF1-insensitive PTH1R internalization by PTH(7-34).
PTH and PTHrP have the amino acids NF and TA in
positions 33–34, respectively. Asparagine and threonine are
polar amino acids that constitute a relatively conservative
substitution at position 33. In contrast, phenylalanine 34 of
PTH has a large aromatic sidechain and is very different in
size from alanine 34 of PTHrP. We, therefore, focused our
attention on position 34. PTH(7-33)PTHrP(34) internal-
ized the PTH1R in a NHERF-insensitive manner, whereas
PTHrP(7-33)PTH(34) stimulated PTH1R internalization
with the same magnitude but in a NHERF-sensitive manner
(Fig. 2). A single mutation of F34 in PTH therefore alters
the pathway of PTH1R trafficking by PTH(7-34).
Peptide concentrations of 1 µM were employed for all of
the chimeric PTH/PTHrP PTH1R internalization experi-
ments. All of the peptides induced PTH1R internalization
at this concentration and we wanted to test their respective
antagonist properties in D1 cells. Therefore, we determined
the ability of each of these peptides to stimulate cyclic AMP
formation on their own in D1 cells and to inhibit cyclic
AMP formation by 1 nM PTH(1-34). As shown in Fig. 4,
only PTH(1-34) stimulated cyclic AMP formation in D1
cells (8.3-fold of control). Neither PTH(7-34), PTH(7-31),
nor any of the chimeric PTH/PTHrP peptides tested affected
cyclic AMP. In contrast, all of the peptides tested, with one
exception, inhibited cyclic AMP formation by 1 nM PTH(1-
34) with EC50s in the 200–2000 nM range and these values
were not affected by NHERF1 expression (Table 2). The nota-
ble exception to this was PTHrP(7-21)PTH(22-34), which
inhibited PTH(1-34)–stimulated cyclic AMP formation
with an EC50 of 0.2 nM in D1 cells. Expression of NHERF1
in D1 cells shifted the EC50 for this peptide to 200 nM.
We also performed binding studies using [125I]PTH(1-
34) as a tracer in D1 cells in the presence and absence of
NHERF1 (Table 3). Both PTH(7-34) and PTHrP(7-34)
inhibited radiolabeled PTHrP binding with IC50 values of
50 nM. Most of the chimeric peptides inhibited tracer bind-
ing with similar affinity. There were exceptions to this, how-
ever. Similar to its ability to inhibit cyclic AMP formation
by PTH(1-34), PTHrP(7-21)PTH(22-34) robustly inhibited
tracer binding in D1 cells with an IC50 of 3 pM. To our knowl-
Fig. 3. Induction of PTH1R internalization requires positions 7–
9 and 32–34 of PTH(7-34). The effect of 10−6 M of the indicated
peptides on PTH1R internalization in D1 cells is presented. Re-
ceptor endocytosis was measured by real-time quantitative con-
focal microscopy in D1 cells that had been transfected with empty
pcDNA3 vector or NHERF1. The extent of PTH1R internaliza-
tion after a 15 min peptide exposure is presented. Results are the
means ± SEM of triplicate determinations in four independent
experiments. *p < 0.01 in the presence of NHERF1 vs the absence
of NHERF1 as determined by a one-way ANOVA with a post-hoc
Bonferroni test for statistical significance.
Fig. 4. Stimulation of adenylyl cyclase by chimeric PTH/PTHrP
peptide fragments. D1 cells were exposed to 10–6 M of the indi-
cated peptide for 15 min at 37°C and cAMP accumulation was
measured. Data are the mean ± SEM normalized to unstimulated
controls (n = 3). *p < 0.01 vs control.
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edge, this is the highest affinity PTH1R ligand described
to date. This is a very exciting finding and is the focus of
ongoing investigations in our laboratory. The presence of
NHERF1 shifted the IC50 for this peptide to 400 pM. PTH
(7-32)PTHrP(33-34) and PTH(7-33)PTHrP(34) also inhib-
ited tracer binding with greater affinity than PTH(7-34),
with IC50s of 4 nM and 6 nM, respectively. The data indi-
cate that all of the chimeric PTH/PTHrP peptides tested in
the PTH1R internalization should be bound to the PTH1R
at maximal levels at a concentration of 1 µM and NHERF1
expression has a modest effect on the binding.
Based on photoaffinity crosslinking studies, PTH1R
antagonists such as PTH(7-34) are thought to primarily in-
teract with the extracellular N terminus of the PTH1R (the
N domain), with minimal contacts to the transmembrane
helix bundle and extracellular loops (the J domain) (2,29,
30). Recently, a new class of synthetic PTH1R antagonists
was characterized that bind to the J domain (31). We tested
two of these peptides for their ability to stimulate PTH1R
internalization in D1 cells. Neither peptide 807 ([Deg1,3,
Bpa2,Nle8,Q10,A12,W14,Y15]rPTH(1-15)NH2) nor peptide
827 ([Ac5c1,Bpa2,Aib3,Nle8,Q10,A12,W14,Y15]rPTH(1-15)
NH2) internalized the PTH1R (Fig. 5) as compared with
55% internalization by PTH(1-34). Both peptides were used
at 1 µM, well above the IC50 for competition with radiola-
beled PTH(1-15) of 100 nM (31). These data provide a clear
distinction between the classical N domain PTH1R antag-
onists that can internalize the receptor in the absence of
NHERF1 and the J domain antagonists that lack this ability.
There are conflicting reports on the importance of re-
ceptor phosphorylation in the induction of PTH1R inter-
nalization. We previously reported that both PTH(1-34) and
(7-34) induce PTH1R phosphorylation (22). We therefore
tested PTH(7-34), PTHrP(7-34), and the chimeric peptides
for their respective abilities to stimulate PTH1R phospho-
rylation in D1 cells in the presence or absence of NHERF1
(Fig. 6) using in vivo receptor phosphorylation as described
previously (22). All of the peptides induced PTH1R phos-
phorylation at 1 µM. There may have been a modest inhibi-
tory effect of NHERF1 on PTH1R phosphorylation by
PTH(7-32)PTHrP(33,34) and PTHrP(7 32)PTH(33-34).
This is not likely related to PTH1R internalization because,
despite inducing similar levels of receptor phosphoryla-
tion, only PTH(7-32)PTHrP(33,34) is able to internalize
the receptor in the presence of NHERF1. While all of the
peptides tested reproducibly induced PTH1R phosphory-
lation, the apparent enhanced ability of PTH(7-21)PTHrP
(22-34), PTH(7-32)PTHrP(33,34), and PTHrP(7-32)PTH
(33-34) to induce PTH1R was not reproducible.
Table 2
EC50 Values ± SEM for Inhibition by Chimeric
PTH/PTHrP Peptides of 1 nM PTH(1-34)–Stimulated
Cyclic AMP Formation in D1 Cellsa
EC50 (−NHERF), EC50 (+NHERF),
Peptide nM nM
PTH(7-21)PTHrP(22-34) 500 ± 10 700 ± 15
PTHrP(7-21)PTH(22-34) 0.2 ± 0.05 200 ± 10
PTH(7-32)PTHrP(33-34) 800 ± 10 1300 ± 10
PTHrP(7-32)PTH(33-34) 200 ± 5 300 ± 10
PTH(7-33)PTHrP(34) 200 ± 15 200 ± 10
PTHrP(7-33)PTH(34) 2000 ± 10 1500 ± 15
aData represent n = 3 performed in triplicate.
Table 3
IC50 Values ± SEM for Inhibition
of Radiolabeled PTH(1-34) Binding in D1 Cellsa
IC50 (-NHERF), IC50 (+NHERF),
Peptide nM nM
PTH(7-34) 50 ± 5 300 ± 10
PTHrP(7-34) 50 ± 5 20 ± 0.5
PTH(7-21)PTHrP(22-34) 50 ± 0.5 5 ± 0.5
PTHrP(7-21)PTH(22-34) 0.005 ± 0.001 0.4 ± 0.05
PTH(7-32)PTHrP(33-34) 4 ± 0.05 0.2 ± 0.05
PTHrP(7-32)PTH(33-34) 90 ± 5 400 ± 15
PTH(7-33)PTHrP(34) 6 ± 0.5 60 ± 15
PTHrP(7-33)PTH(34) 300 ± 15 40 ± 5
aData represent n = 3 performed in triplicate.
Fig. 5. J domain antagonists do not internalize the PTH1R . The
effect of 10−6 M of the indicated peptides on PTH1R internaliza-
tion in D1 cells. Receptor endocytosis was measured by real-time
quantitative confocal microscopy in D1 cells that had been trans-
fected with empty pcDNA3 vector or NHERF1. The extent of
PTH1R internalization after a 15 min peptide exposure is pre-
sented. Results are the means ± SEM of triplicate determinations
in three independent experiments. *p < 0.01 vs control as deter-
mined by a one-way ANOVA with a post-hoc Bonferroni test for
statistical significance.
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The β-arrestins play a key role in the internalization
of GPCRs. We sought to determine if NHERF1 regulates
PTH1R mobilization of β-arrestins or arrestin-dependent
receptor internalization. We hypothesized that differences
therein underlie the ability of some PTH1R ligands to disso-
ciate PTH1R internalization from NHERF1. The binding
of β-arrestin1 to PTH1R residing on the plasma membrane
of D1 cells was measured using image cross-correlation
spectroscopy (ICCS). The fraction of binding was mea-
sured in cells with and without NHERF1 (Fig. 7). Binding
of arrestin to PTH1R was negligible before the addition of
ligand, independent of NHERF1 expression. Addition of
PTH(1-34) promoted a dramatic increase in the binding of
β-arrestin1 to PTH1R. This increase was modestly but sig-
nificantly reduced by the expression of NHERF1 (p = 0.004).
Addition of PTH(7-34) did not induce any increase in β-
arrestin-1–bound receptor, independently of the expression
of NHERF1. In contrast, 100 nM PTHrP(7-34) caused a
robust increase in the binding of β-arrestin1 to PTH1R,
which was modestly but significantly (p = 0.04) decreased
by NHERF-1 expression.
Discussion
In our earlier work, we demonstrated that both the syn-
thetic PTH(7-34) and the secreted form of the peptide PTH
(7-84), which bind to but do not activate the PTH1R, inter-
nalize the PTH1R very efficiently in kidney distal tubule
cells and rat osteosarcoma ROS 17/2.8 cells (1). In fact,
PTH(7-34) is more efficacious than PTH(1-34) at inducing
PTH1R internalization in these cells. The mechanistic de-
tails that account for this difference are, at present, unknown.
In contrast, neither PTH(7-34) nor PTH(7-84) internalizes
the PTH1R in kidney proximal tubule cells or the human
Fig. 6. Chimeric PTH/PTHrP peptides all induce PTH1R phosphorylation. PTH1R phosphorylation was assessed in D1 cells in the
presence or absence of NHERF1 as described in Methods. pPTH1R represents the phosphorylated PTH1R. PTH1R represents the level
of PTH1R/EGFP as measured by Western blots using a polyclonal anti-EGFP antibody. D1 cells were exposed to 10−6 M of chimeric
peptides 1–6 or vehicle (C) as outlined in Methods. The data were reproduced three times. A representative experiment is presented.
Fig. 7. (A) The binding of β-arrestin1 to PTH1R residing on the
plasma membrane of D1 cells was measured using image cross-
correlation spectroscopy. The fraction of binding was measured
in cells with and without NHERF1. The following ligands were
used to promote arrestin binding: PTH(1-34) (100 nM), PTH(7-34)
(100 nM), and PTHrP(7-34) (100 nM). Data represent mean ±
SEM of four independent measurements. *p < 0.005, **p < 0.05 vs
empty vector as determined by a one-way ANOVA with a post-hoc
Bonferroni test for statistical significance. (B) D1 cells were con-
currently transfected as in A, lysates prepared, and HA–NHERF1
expression was confirmed in duplicate by immunoblot using a
monoclonal anti-HA antibody.
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SaOS-2 osteosarcoma cell line. The cell-specific effects of
PTH(7-34) on PTH1R internalization depend of the ex-
pression of NHERF1 (1). Expression of NHERF1 inhibits
PTH(7-34)-induced PTH1R internalization. In this article,
we demonstrate that PTHrP(7-34) also internalizes the
PTH1R but in a NHERF1-independent manner (Fig. 1).
We determined that mutation of phenylalanine 34 of PTH
induces PTH1R internalization by a NHERF1-indepen-
dent mechanism (Fig. 2). Conversely, F34–PTHrP(7-34)
(A34 replaced by the homologous amino acid from PTH)
fails to alter NHERF1-regulation of PTH1R internaliza-
tion. Photoaffinity crosslinking studies using photoreactive
L-p-benzoylphenylalanine (Bpa)–substituted PTH(1-34)
and PTHrP(1-34) peptides have identified interactions
between the C terminal of the peptide ligands and the extra-
cellular N terminal of the PTH1R. Alanine scanning muta-
genesis and crosslinking experiments identified position
23 in the C terminal of PTHrP as having important contacts
with the ligand-binding domain of the PTH1R. Bpa23–
PTHrP(1-36) binds to threonine-33 and glutamine-37 in
the N terminal extracellular domain (32). This interaction
is important for binding of the agonist, PTH(1-34), as well
as the antagonist, PTH(7-34). Furthermore, Bpa27–PTH(1-
34) has been shown to crosslink to leucine-261 in the first
extracellular loop (33). The distal portion of PTH(7-34) is
critical for induction of receptor internalization. Deletion
of positions 32–34 eliminates PTH1R sequestration (Fig. 3)
and also results in a reduction of the ability of N-terminally
truncated PTH peptides to bind the PTH1R (data not shown).
It is tempting to speculate that the large aromatic sidechain
of F34 in PTH and the small sidechain of A34 in PTHrP
have very different interactions with the ligand binding
domain of the PTH1R and that these interactions underlie
conformational changes in the PTH1R that could dissoci-
ate NHERF1 from the PTH1R.
The interactions of antagonists that bind to the N termi-
nal extracellular domain of the PTH1R are clearly different
from antagonists that interact with the transmembrane
bundle and the extracellular loops. We demonstrated that
the “J domain antagonists,” in contrast to the “N domain
antagonists” that we are focusing on, are unable to internal-
ize the PTH1R in the presence or absence of NHERF1 (Fig.
5). This is consistent with a role for peptide binding to the
N terminus of the PTH1R transducing a signal and altering
the receptor conformation that leads to internalization in
some cells. The J domain antagonists used in this study
were highly modified PTH(1-15) peptides that were opti-
mized for their ability to bind the PTH1R with high affinity
(31). In contrast, the native PTH(1-15) sequence only effi-
ciently binds and initiates conformational changes in the
receptor in the presence of additional sequences that pro-
mote peptide binding to the extracellular N terminus (34).
Receptor phosphorylation plays an important role in the
classical mechanism of GPCR internalization. Typically,
the agonist-activated receptor is phosphorylated by GRK2
(13,14). This promotes arrestin recruitment (15–17) and
uncoupling of the receptor from its cognate G proteins, Gs
and Gq. Following this desensitization, the PTH1R is endo-
cytosed into intracellular compartments after which it can
be recycled back to the plasma membrane (resensitization)
(18), or targeted for degradation, leading to receptor down-
regulation (19,20). The C terminal of the PTH1R contains
multiple sites for serine phosphorylation, but there are
conflicting data from different cell lines concerning the
role that phosphorylation plays in PTH1R internalization.
We presented data in this article (Fig. 6) that demonstrate
that PTH(7-34), PTHrP(7-34), and chimeric PTH/PTHrP
peptides of the same length all induce PTH1R phosphory-
lation in D1 cells in the presence or absence of NHERF1.
These data can be interpreted in a couple of different ways.
First, PTH1R phosphorylation by N terminally truncated
PTH/PTHrP peptides may be an epiphenomenon that is not
related to PTH1R internalization because it occurs even
in the presence of NHERF1-induced blockade of receptor
endocytosis. Alternatively, antagonist-induced PTH1R phos-
phorylation may be required for receptor internalization but,
in this instance, NHERF1-induced inhibition of PTH1R
internalization occurs downstream of PTH1R phosphory-
lation. This will have to be tested in future studies. PTH1R
phosphorylation and internalization has been examined in
other cell lines. In LLC–PK1 cells, mutation of seven C-
terminal serine residues to alanine markedly reduced ago-
nist induced PTH1R internalization (35). A murine model
with a genetic knock-in of this phosphorylation-deficient
receptor exhibited exaggerated cAMP and calcemic re-
sponses to administered PTH, likely as a result of a reduc-
tion in PTH1R desensitization and internalization (36). A
similarly substituted, phosphorylation-deficient PTH1R,
when expressed at high levels in HEK 293 cells, was inter-
nalized normally in response to agonist binding (24). In con-
trast, a similarly substituted phosphorylation-deficient opos-
sum PTH1R exhibited a 30% reduction in agonist-induced
receptor internalization in HEK293 cells (37). This under-
scores the cell-specific nature of the regulation of PTH1R
internalization.
We demonstrated that PTH(7-34) does not recruit β-
arrestin1 (Fig. 7) but is, nonetheless, able to robustly inter-
nalize the PTH1R (1). This is different from the findings of
the Lefkowitz laboratory (38), who determined that PTH(7-
34) promoted an interaction between the β-arrestins and
the PTH1R in transfected HEK293 cells. The discrepancy
likely reflects differences in methodology. The Lefkowitz
study examined co-immunoprecipitation of β-arrestins with
the PTH1R in whole cell lysates, whereas we were using
ICCS to examine only the PTH1R at the plasma membrane.
We determined that NHERF1 completely inhibits this β-
arrestin–independent PTH1R internalization induced by
PTH(7-34). In contrast, both PTH(1-34) and PTHrP(7-34)
recruit β-arrestin1 to the PTH1R and receptor internaliza-
tion is not inhibited by NHERF1. Romero and colleagues,
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using total internal reflection and confocal microscopy,
have determined that NHERF1 tethers the PTH1R to actin
filaments (G. G. Romero, personal communication). This
slows down receptor movement in and out of the mem-
brane and facilitates formation of complexes with other
cytoskeletal proteins. The PTH1R is concentrated in actin
stress fibers in the presence of NHERF. This does not pre-
vent internalization of the PTH1R by ligands that promote
β-arrestin recruitment, but it does slow down this process.
Tethering by NHERF, however, prevents arrestin-indepen-
dent internalization of the PTH1R by the antagonist PTH(7-
34). In the absence of NHERF1, the PTH1R moves much
more freely in the membrane and is more diffusely distrib-
uted within the cell and the plasma membrane. We propose
that this freedom of movement permits the PTH1R to be
internalized without antecedent β-arrestin binding. It is un-
clear why changing F34 to A in PTH(7-34) promotes PTH1R
internalization in the absence of NHERF1. Presumably this
alters the receptor conformation induced by ligand binding
such that β-arrestins are recruited and NHERF1 is no longer
able to tether the PTH1R to actin and it internalizes on
binding to A34-PTH(7-34) or PTHrP(7-34). We propose a
model in Fig. 8 to summarize these findings. We conclude
that NHERF1 blocks arrestin-independent but not arrestin-
dependent PTH1R internalization. Furthermore, the dif-
ferential ability to recruit β-arrestins between PTH(7-34)
and PTHrP(7-34) underlies their inability or ability, respec-
tively, to dissociate PTH1R internalization from NHERF1
regulation.
The ability of the synthetic PTHrP(7-34) fragment to
induce PTH1R internalization, while not physiological, is
informative in terms of how PTH1R levels can be exoge-
nously regulated. Under pathophysiological circumstances
such as renal failure, N-terminally truncated PTH peptides
are secreted by the parathyroid glands, the most predomi-
nant of these being PTH(7-84) (39). Levels of these peptides
are elevated and may contribute to PTH resistance by selec-
tively downregulating the PTH1R in specific tissues such
as renal distal tubules, where NHERF1 is absent. If a less
selective downregulation of the PTH1R is desirable, syn-
thetic peptides could be designed that break the NHERF1-
dependence of this process and promote PTH1R internal-
ization in a broader range of cells and tissues. Replacement
of F34 in PTH with alanine would likely accomplish this
goal. Very little is known about the role of PTH1R confor-
mational changes that occur on binding N-terminally trun-
cated PTH and PTHrP peptides and how this affects arrestin
recruitment. It is interesting that the two fragments, PTH(1-
34) and PTHrP(7-34), promote very different signaling cas-
cades (the former robustly stimulates cAMP formation,
while the latter does not) and yet they both efficiently recruit
β-arrestin1 to the PTH1R. Future studies in our laboratory
will focus on characterizing PTH1R receptor conforma-
tions that promote arrestin binding and how this dissociates
the PTH1R from NHERF1.
Methods
Peptides
The chimeric peptides used in the study are described in
Table 1. The University of Pittsburgh School of Medicine,
Department of Molecular Genetics and Biochemistry Pep-
tide Core Facility synthesized these peptides, and hPTH(7-
31), as free acid amides. Each lyophilized peptide was re-
constituted in 10 mM sodium acetate at a concentration of
100 mM and stored at −80°C. In addition, hPTH(8-34), (9-
34), and (10-34) were obtained as a gift from Harald Jupp-
ner at Massachusetts General Hospital in Boston, MA.
Cell Culture and DNA Transfection
The preparation, subcloning, characterization, and cul-
ture conditions of mouse kidney distal tubule cells have
been described (21). Cells were grown in a 50:50 mix of
DMEM/F12 (10–092-CV; Mediatech, Inc.), which was
supplemented with 5% heat-inactivated FCS (Invitrogen)
and 1% PS (5 mg penicillin, 5 mg streptomycin/mL; In-
vitrogen Life Technologies) in a humidified atmosphere of
95% air–5% CO2 at 37°C. The immortalized mouse DT cells
were stably transfected with human (hPTH1R)/enhanced
green fluorescent protein (EGFP) as described previously
(22). The EGFP moiety lies in frame at the C terminus of
the PTH1R. We have previously demonstrated that this does
not interfere with PTH1R signaling nor does it impair the
interaction between NHERF1 and the PTH1R (1). These
D1 cells were maintained in DMEM/F12 supplemented
with 5% FCS, 1% PS, and 1% G418 (50 mg/mL solution,
Invitrogen). D1 cells express 105 receptors/cell as determined
Fig. 8. A working model of NHERF1 regulation of PTH1R inter-
nalization. PTH(1-34) and PTHrP(7-34) each recruit β-arrestins to
the PTH1R and internalize the PTH1R in a NHERF1-independent
manner. PTH(7-34) does not recruit β-arrestins and internalizes
the PTH1R in a NHERF1-inhibitable manner. NHERF1 inhibits
β-arrestin-independent PTH1R internalization while only mod-
estly affecting β-arrestin binding to the PTH1R.
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by Scatchard analysis of radioreceptor binding assays using
[125I]hPTH(1-34) as the radioligand (23). D1 cells plated
on 25 mm glass coverslips, where indicated, were transiently
transfected with 1 µg mNHERF1 (a gift from Edward Wein-
man at the University of Maryland School of Medicine) or
empty pcDNA3.1 vector (Invitrogen), using Fugene 6
(Roche Applied Science). Fluorescent PTH1R internaliza-
tion studies were performed 48 hr post-transfection.
Quantitative, Real-Time Fluorescence
Measurement of PTH1R Internalization
PTH1R internalization was examined and quantified in
D1 cells as described previously (1). Receptor internaliza-
tion is measured as a loss of plasma membrane fluores-
cence after addition of PTH fragments and results are con-
sistent with internalization of radiolabeled PTH(1-34) (1).
Control experiments confirm that no photobleaching of EGFP
occurs when D1 cells are treated with vehicle.
Cyclic AMP Assays
Ligand-stimulated accumulation of cAMP was deter-
mined in the presence of 1 mM 3-isobutyl-1-methylxanthine.
cAMP was measured chromatographically as previously
described (5). Where activation properties of the chimeric
PTH/PTHrP peptides were being assessed, cAMP was mea-
sured in cells treated for 15 min with 1 µM of the indicated
peptide. In competition experiments, cells were incubated
with increasing concentrations of chimeric peptide concur-
rently with 1 nM hPTH(1-34). Competition curves were fit
and EC50 values calculated using a four-point logistic algo-
rithm (Prism, GraphPad Software).
Radioligand Binding
Confluent D1 cells on 24 well plates (100,000–200,000)
were incubated on ice for 2 h with 100,000 cpm of high-pres-
sure liquid chromatography–purified [125I][Nle8,18Tyr34]
hPTH(1-34)NH2 in 250 µL of Dulbecco’s modified Eagle’s
medium/F-12 medium containing 5% fetal bovine serum,
essentially as described (23,24). In brief, cells grown to con-
fluence in 24-well plates were incubated for 2 h on ice to
prevent internalization of the radioligand and to achieve
equilibrium binding. Under these conditions, the concentra-
tion of radioligand was 0.1 nM. Where indicated, the radio-
ligand was incubated concurrently with various concen-
trations of competitor peptides. Following incubation, the
cells were washed twice with ice-cold phosphate-buffered
saline and collected in 0.5 mL of 0.1 N NaOH, and bound
[125I]PTH was assessed using a Wallac Wizard 1470 Auto-
matic Gamma Counter. Specific binding competition curves
were fit and IC50 values calculated using a four-point logis-
tic algorithm (Prism).
In Vivo Receptor Phosphorylation
PTH1R phosphorylation by chimeric PTH/PTHrP pep-
tides in D1 cells was performed exactly as described pre-
viously (22). As a control, PTH1R levels were assessed
using Western blots as described (22) using a rabbit poly-
clonal anti-GFP antibody (Invitrogen).
Image Cross-Correlation Spectroscopy (ICCS)
These experiments were based on the experimental ap-
proach described by Wiseman et al. and Bacia and Schwille
(25,26). ICCS involves rapid (approx 60 ms/frame) two-
channel scanning of a small section of the plasma mem-
brane of cells containing two different protein-conjugated
dyes. Correlations between the fluctuations in the fluores-
cence intensity of the two channels are used to generate a
cross-correlation function, which can then be used to cal-
culate the fractional binding of one of the fluorescent spe-
cies to the other (27). For these experiments, D1 cells were
cultured in Mattek dishes and co-transfected with PTH1R/
EGFP and mRed (a monomeric variant of dsRed)–β-arres-
tin-1. Only cells that expressed comparable amounts of both
fluorescent proteins, as determined by confocal microscopy,
were used for these studies. All confocal microscopy studies
were conducted on an Olympus Fluoview 1000 equipped
with a SIM scanner using the photon counting option to
ensure accurate quantitation of the fluorescence fluctua-
tions. The 488 nm line of an argon laser and the 543 nm line
of a HeNe laser were used to excite eGFP and mRed, respec-
tively. Emission bandpasses were optimized to eliminate
bleedthrough using the spectral detection system of the
instrument. Images were collected at 50–60 ms intervals.
Up to 300 images per experiment were collected. The cells
were kept at 37°C using an open perfusion incubator (Har-
vard Apparatus, Inc). The data collected were exported to
ImageJ and analyzed using a plug-in specifically written to
calculate image autocorrelation and image cross-correla-
tion. This plug-in was based on code originally developed
by Tully (Compix, Inc). The fractional degree of binding of
PTH1R to arrestin was calculated from the ratio of the
amplitudes of the cross-correlation function and the PTH1R
and β-arrestin1 autocorrelation functions, as described by
Kim et al. (27).
Statistical Analyses
Where indicated, a one way analysis of variance (ANOVA)
was performed, followed by post-hoc Bonferroni analysis
using Prism software.
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NHERF-1 and the Cytoskeleton Regulate the Traffic and
Membrane Dynamics of G Protein-coupled Receptors*
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The sodium-hydrogen exchange regulatory factor 1 (NHERF-
1/EBP50) interacts with the C terminus of several G protein-
coupled receptors (GPCRs). We examined the role of NHERF-1
and the cytoskeletonon thedistribution, dynamics, and traffick-
ing of the !2-adrenergic receptor (!2AR; a type A receptor), the
parathyroid hormone receptor (PTH1R; type B), and the calci-
um-sensing receptor (CaSR; typeC) using fluorescence recovery
after photobleaching, total internal reflection fluorescence, and
image correlation spectroscopy. !2AR bundles were observed
only in cells that expressed NHERF-1, whereas the PTH1R was
localized to bundles that parallel stress fibers independently of
NHERF-1. The CaSR was never observed in bundles. NHERF-1
reduced the diffusion of the!2AR and the PTH1R. The addition
of ligand increased the diffusion coefficient and themobile frac-
tion of the PTH1R. Isoproterenol decreased the immobile frac-
tion but did not affect the diffusion coefficient of the!2AR. The
diffusion of the CaSR was unaffected by NHERF-1 or the addi-
tion of calcium. NHERF-1 reduced the rate of ligand-induced
internalization of the PTH1R. This phenomenon was accompa-
nied by a reduction of the rate of arrestin binding to PTH1R in
ligand-exposed cells. We conclude that some GPCRs, such as
the !2AR, are attached to the cytoskeleton primarily via the
binding of NHERF-1. Others, such as the PTH1R, bind the
cytoskeleton via several interacting proteins, one of which is
NHERF-1. Finally, receptors such as the CaSR do not interact
with the cytoskeleton in any significant manner. These interac-
tions, or the lack thereof, govern the dynamics and trafficking of
the receptor.
Cell membranes are highly heterogeneous structures con-
sisting of an ensemble of fluctuating microdomains with dis-
tinct lipid and protein compositions. Thesemicrodomains play
important functions in signal transduction processes by
increasing the rate and efficiency of coupling of key intermo-
lecular interactions involved in specific signaling processes
(1–3). The cytoskeleton has also been implicated in the regula-
tion of signal transduction processes by serving as a substrate
for the anchoring of specific proteins (4), regulating traffic (5),
and partitioning the cell membrane into microdomains
through the formation of effective barriers to the diffusion of
lipids and proteins present in the bulk of the plasmamembrane
(6, 7). However, this general model of the cytoskeleton’s role in
the regulation of signaling processes depicts a somewhat pas-
sive picture. Most studies of the relationships among cytoskel-
etal structures and signaling processes focused on the effects of
extracellular signals on cytoskeletal reorganization rather than
on the effects of the cytoskeleton upon signaling pathways. This
viewhas been recently challenged by the discovery of a family of
proteins containing N-terminal postsynaptic density protein
(PSD95)/Drosophila disc large tumor suppressor (DlgA)/Zo-1
protein (PDZ)2 domains (which interact with a variety of sig-
naling molecules) and a C-terminal Ezrin-Radixin-Moesin
(ERM)-binding domain (that enables these proteins to interact
with cytoskeletal structures) (8–10). Two of the members of
this family, the Na!/H! exchange regulatory factors 1 and 2
(NHERF-1 and -2), interact with and modulate the function of
several G protein-coupled receptors (10–13). However,
although the data show unequivocally that NHERF-1 and
NHERF-2modulate the function of GPCR, a unified hypothesis
to explain the multiple roles of these scaffolding molecules is
lacking.
Here, we examined the effects of the expression of NHERF-
1/EBP50 in the dynamics of three GPCRs: the !2-adrenergic
receptor (!2AR), the parathyroid hormone receptor (PTH1R),
and the calcium-sensing receptor (CaSR). The !2AR and the
PTH1R are type A and B receptors, respectively, and were cho-
sen because of their well documented interactions with
NHERF-1 (10, 12, 14–18). The CaSR is a type C receptor that
does not interact with NHERF-1, thus serving as an important
control. The data show that the !2AR and the PTH1R are
closely associated to actin stress fibers by a mechanism that is
modulated by their interactions with NHERF-1. NHERF-1
expression was not required for the cytoskeletal association of
the PTH1R; however, the !2AR was found in bundles only in
cells expressing NHERF-1. The CaSR was not associated with
the cytoskeleton independently of NHERF-1 expression. The
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diffusion of the PTH1R and the
!2ARwas strongly influenced by the
expression of NHERF-1. Finally, we
show that the effects of NHERF-1
on PTH1R traffic are consistent
with a novel model in which
NHERF-1 interferes with the bind-
ing of arrestin to the activated
PTH1R.
EXPERIMENTAL PROCEDURES
Materials and Constructs—Anti-
NHERF-1 antibody was purchased
from Upstate Biotechnology, Inc.
Anti-FLAG (M1) was from Sigma,
and anti-hemagglutinin (HA11)was
purchased from Covance. Anti-rab-
bit IgG antibody conjugated to
TRITC was obtained from Jackson
ImmunoResearch. All other materi-
als were purchased from Sigma
unless otherwise noted. A pEGFP-
N2 plasmid encoding a full-length
human PTH1R carboxyl-terminal
eGFP fusion protein (PTH1R-
eGFP) was kindly provided byC. Silve (INSERM, Paris, France).
Similar plasmids coding for the!2-adrenergic receptor (!2-AR-
eGFP) and the calcium-sensing receptor (CaSR-eGFP) were
kindly supplied by Dr. Jeffrey Benovic (Thomas Jefferson Uni-
versity) and Dr. Gerda Breitwieser (Geisinger Medical Center),
respectively.
Cell Culture—Chinese hamster ovary N10 cells (CHO-N10)
were cultured in Ham’s F-12medium (Mediatech, Inc.) supple-
mented with 10% fetal bovine serum (Invitrogen) and 1% pen-
icillin/streptomycin solution at 37 °C/5% CO2. All live cell
imaging experiments were done in Mattek dishes in complete
medium. Lipofectamine 2000 (Invitrogen) or FuGENE 6
(Roche Applied Science) were used for transient transfections.
Confocal Microscopy—An Olympus Fluoview 1000 confocal
microscope equipped with a SIM scanner was used for all
experiments unless otherwise indicated. For live cell imaging
experiments, the cells were kept at 37 °C using an open perfu-
sion microincubator (Harvard Apparatus Inc.).
Immunocytochemistry—Cells were cultured on glass cover-
slips, transfected with the desired plasmids, and allowed to
grow until 80% confluent. The coverslips were washed in phos-
phate-buffered saline and fixed for 20 min in 4% paraformalde-
hyde in phosphate-buffered saline at 4 °C. Cells were permeabi-
lized with 5% nonfat milk, 0.1% Triton X-100 for 1 h at 4 °C and
then stained with either phalloidin-TRITC (3 nM) or anti-
NHERF-1 antibody (1 "g/ml) overnight at 4 °C. Phalloidin-
stained cells were washed four times with phosphate-buffered
saline and mounted using gelvatol. Anti-NHERF-1-stained
cells were further treated with anti-rabbit IgG conjugated with
TRITC (1:1000) in 5% nonfat milk for an additional 2 h at room
temperature. The cells were then washed four times with phos-
phate-buffered saline, mounted with gelvatol, and examined by
confocal microscopy.
FIGURE 1. Expression of NHERF-1/EBP50 by CHO-N10 cells. CHO-N10 cells were cultured as described.
NHERF-1 expression was induced by the addition of tetracycline at the indicated doses. NHERF-1 expression
was determined 24 h after the addition of tetracycline.
FIGURE 2. Distribution of !2AR-eGFP, PTH1R-eGFP, and CaSR-eGFP on
the surface of CHO-N10 cells.CHO-N10 cells were transfected with!2AR-
eGFP (A and B), PTH1R-eGFP (C and D), and CaSR-eGFP (E and F). Where
indicated (NHERF(!) in B, D, and E), the cells were induced with tetracy-
cline (50 ng/ml; 24 h) prior to transfection. The cells were examined with
TIRF microscopy 24 h after transfection with the receptor-GFP chimeras.
Scale bars, 10 "m.
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Fluorescence Recovery after Pho-
tobleaching (FRAP)—All FRAP
measurements were done focusing
the microscope onto the plasma
membrane adjacent to the cover-
slip. This region of the cell was cho-
sen for two main reasons: 1) it pro-
vides a large surface, and 2) many
supplemental studies were done
using total internal reflection fluo-
rescence (TIRF), a technique that is
limited to the observation of the cell
membranes adjacent to the cover-
slip. The plasma membrane was
located using a Z-stack scanning
procedure (20). Circular regions of
interest (between 90 and 200 "m2)
were selected and bleached with a
1-s pulse from a 405-nm laser line
using the Fluoview 1000 SIM scan-
ner, whereas recovery data were
acquired using the instrument’s
main scanner and the 488-nm line
of an argon gas laser. This short
pulse was selected to ensure a Gaus-
sian bleaching spot. To maximize
reproducibility of the experimental
conditions, all data were acquired in
the photon-counting mode of the
instrument. Sixty images were then
collected at intervals of 1–1.6 s. The
images were exported to Meta-
Morph (Universal Imaging, Inc.),
and the average fluorescence inten-
sities of the bleached regions and
control regions in other cells or far
removed regions of the same cell
were obtained. The data were fitted
to a single exponential decay and
plotted using GraphPad Prism. The
diffusion coefficient was calculated
using the Stokes-Einstein equation
FIGURE 3. PTH1R distribution on the plasma membrane of CHO-N10 cells. A, TIRF images of the plasma
membrane of CHO-N10 cells transfected with PTH1R-eGFP. The cells shown in this image were not induced
with tetracycline and therefore did not express NHERF-1. B, the addition of latrunculin A (200 ng/ml; 15 min
prior to observation) induced the redistribution of the PTH1R from bundles to the bulk membrane. C, co-
localization of PTH1R (green) with F-actin (phalloidin stain; red, left) and co-localization of PTH1R (green) with
NHERF-1 (red, right) in CHO-N10 cells induced with tetracycline. D, a mutation of the PDZ domain binding
motif of the PTH1R (590ETVM5933 590ETVA593) reduces the interactions of the receptor with cytoskeletal
fibers. E, overexpression of a truncated NHERF-1 mutant that does not contain the ERM-binding domain
significantly reduces the binding of PTH1R to cytoskeleton fibers. Scale bars, 10 "m.
TABLE 1
Effects of NHERF-1 expression on receptor distribution
CHO-N10 cells expressing the indicated constructswere imaged byTIRF. The distribution of fluorescent receptorswas determined using a threshholding procedure to determine
“bundle” and “bulk” fluorescence in regions of interest that comprised most of the surface of each examined cell. The percentage of receptors bound to cytoskeletal bundles was
measured fromthe ratioof the integrated fluorescenceof identifiedbundles to the total integrated fluorescenceof the regionsof interest.At least six independentMattekplateswere
examined for each condition. The number n denotes the total number of cells examined for each condition. The statistical analyses were done by ANOVA followed by Tukey’s
multiple comparison tests.
NHERF-1(") NHERF-1(#)
Percentage fluorescence
in bundles
Fraction of cells with
visible bundles
Percentage fluorescence
in bundles
Fraction of cells with
visible bundles
% %
!2AR 1.2" 0.6 (n# 38) 1/38 19.4" 2.7 (n# 27)a 21/27
PTH1R 34.4" 3.0 (n# 22) 21/22 57.4" 2.8 (n# 34)a,b 34/34
M593A-PTH1R 17.4" 2.9 (n# 16) 12/16 17.69" 3.0 (n# 12) 9/12
PTH1R! $ERM-NHERF-1 14.5" 1.3 (n# 15) 8/15 12.1" 1.4 (n# 39) 12/39
CaSR NDc 0/22 ND 0/19
a Different from NHERF-1(%) cells (p& 0.001).
b Different from cells expressing M593A-PTH1R or $ERM-NHERF-1 (p& 0.001).
c ND, none detected.
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for two-dimensional diffusion (D#
r2/(4#d), where r is the radius of the
bleached spot, and #d is the half-life
of fluorescence recovery).
Image Correlation Spectroscopy
(ICS) and Image Cross-correlation
Spectroscopy (ICCS)—These studies
were based on the experimental
techniques described by Wiseman
et al. (21–23) and recently reviewed
by Bacia and Schwille (24) and Kim
et al. (25). The technique measures
the correlation of an image with
itself after a defined latency time #.
This correlation is a function of the
mobility of the fluorescent mole-
cules. The experimental design is, in
principle, identical to that used for
fluorescence correlation spectros-
copy, except that in ICS a larger
region of the cell is imaged. This
allows the acquisition of spatial
information that is not available in
typical fluorescence correlation
spectroscopy experiments. Two dif-
ferent experimental designs were
used for these studies. In some
cases, the data were collected with a
Fluoview 1000 confocal microscope
focused onto the plasma membrane
of the cell adjacent to the coverslip.
In others, the data were obtained
using an Olympus-based TIRF sys-
tem (see below). For confocal
microscopy experiments, a small
section of the plasma membrane
(&50 "m2) was rapidly scanned
(50–60 ms/frame) under low laser
power, and up to 300 images were
collected. For the TIRF experi-
ments, up to 200 images were
obtained consecutively using a
500-ms exposure time. With either
experimental set-up, fluorescence
loss due to photobleaching of the
sample was almost negligible. The
image data were exported to ImageJ
and analyzed using a plug-in specif-
ically written to calculate the auto-
correlation function of the data.
This plug-in was based on code
developed byA. Tully and E. Levitan
(University of Pittsburgh). The
resulting autocorrelation data were
exported to GraphPad Prism and fit
to a single species two-dimensional
diffusion model (G(#) # K(1 !
#/#d)%1!G0 where #d is the charac-
FIGURE 4. Dynamics of the PTH1R on the plasma membrane of CHO-N10 cells. A, fluorescence recovery
after photobleaching. CHO-N10 cells not induced with tetracycline were imaged at 1-s intervals with a Fluo-
view 1000 confocal microscope. At time 0, several circular spots were bleached (using a 405-nm laser line at
99% power applied for 1 s) where indicated using the SIM scanner of the confocal microscope without inter-
rupting image acquisition. B, summary of the diffusion data. NHERF-1(%), CHO-N10 cells not induced with
tetracycline to express NHERF-1; cells in which the expression of NHERF-1 had been induced are denoted with
NHERF-1(!). The data represent averages of 5–16 plates of cells. Statistical analysis was done by ANOVA
followed by Tukey’s post hoc tests to determine the statistical significance of the differences between tetracy-
cline-treated and untreated cells. a, a statistically significant difference with regard to the NHERF-1(!) state
(p& 0.025 in all cases).C, effects of variousmutations on the diffusion of PTH1R. ThemutantM593A-PTH1Rhas
a defective PDZ domain binding motif that does not bind PDZ domains efficiently. S1S2, cells that were co-
transfected with a NHERF-1 mutant in which the sequences of the core binding motifs of both PDZ domains
had been mutated to eliminate PTH1R binding.$ERM, cells co-transfected with PTH1R-eGFP and a C-terminal
truncation mutant of NHERF-1 that does not possess an ERM binding motif. Diffusion coefficients were deter-
mined from ICS data. The data represent a summary of 5–8 cells of at least five independent plates for each
condition. Only data from cells treated with tetracycline to induce NHERF-1 expression are presented. Statis-
tical analysis was done by ANOVA followed by Tukey’s post hoc tests. b, statistically significant differences with
both basal (NHERF-1(%)) and tetracycline-treated (NHERF-1(!)) cells (p & 0.01 for all cases). D, the effects of
latrunculin A on the dynamics of PTH1R. CHO-N10 cells were treated with 200 ng/ml latrunculin A 1 h before
imaging. Diffusion coefficients were determined from ICS data. The graph summarizes results obtained with
5–10 cells from at least five different plates per condition. c, statistically significant differences with cells that
had not been treated with latrunculin (p & 0.002); d, significant differences with cells that do not express
NHERF-1 (p& 0.01).
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teristic time constant, K is a proportionality factor, and G0 is a
term that accounts for spatial autocorrelation) as described by
Hebert et al. (21). The data were also fit to a two-state diffusion
model without any significant improvement in the quality of
the fit. Therefore, all analyses reported in this paper were done
using the single-species diffusion model. For calibration pur-
poses, the diffusion of free intracellular GFP was determined
using ICS and FRAP. The values for the diffusion coefficient of
GFP obtained by both methods were comparable. ICCS exper-
iments were conducted essentially using the same design,
except that images were collected from both green (eGFP) and
red (monomeric dsRed) channels. The cross-correlation calcu-
lation was performed using an ICCS plug-in for ImageJ devel-
oped for this purpose. Fractional binding was calculated from
the ratio of the amplitude of the cross-correlation function to
the amplitude of the autocorrelation function for PTH1R.
These calculations are based on the method described by
Kim et al. (25).
Total Internal Reflection Microscopy—TIRF microscopy
studies were conducted using an Olympus 1X71 equipped with
a 150-milliwatt argon laser, an Olympus'60 TIRF objective, a
Princeton CCD camera, and Sutter filter wheels. The imaging
work station was controlled with SimplePCI software (Compix,
Inc.). Typical exposure times of 500 ms were used for most
experiments. For ICS measurements, up to 200 images were
collected continuously. For endocytosis experiments, images
were taken once every 30 s for up to 20 min. The data collected
were exported to ImageJ and analyzed using the appropriate
plug-ins.
Endocytosis Studies—These experiments were done using
TIRFmicroscopy. Cells with or withoutNHERF-1were imaged
at 37 °C at 30-s intervals for 1–2 min before the addition of the
ligand. The microscope was refocused after stimulation of the
cells, and image acquisition was continued for an additional 20
min at 30-s intervals. Fluorescence intensity data of the whole
cell or of specific regions of interest were exported toGraphPad
Prism and analyzed by fitting to a single exponential decay.
Statistical Analysis—All multiple comparisons were done
using ANOVA followed by Tukey’s post-test pairwise compar-
isons using the analysis routines built in GraphPad Prism.
Plates from a minimum of five independent experiments were
used for every procedure. Most of the experiments described
here were repeated 12 times or more. ICS and ICCS studies
were done using ImageJ plug-ins developed in house. These are
available upon request.
RESULTS
Expression of NHERF-1 in CHO-N10 Cells—These studies
were done using a new cell line, derived from Chinese hamster
ovary cells. These cells, termedCHO-N10, expressNHERF-1 in
a tetracycline-inducible manner. We chose CHO cells as a
model system for these studies, because they do not express
detectable levels of NHERF-1 (Fig. 1). Fig. 1 also shows the
induction of NHERF-1 expression 24 h after the addition of
various doses of tetracycline. As shown, the expression of
NHERF-1 by CHO-N10 cells is exquisitely sensitive to tetracy-
cline. Therefore, CHO-N10 cells appear to be an ideal system to
examine the effects of NHERF-1 expression on the dynamics
and biochemistry of its interacting proteins. All experiments
reported below were done inducing NHERF-1 expression with
50 ng/ml tetracycline for 24 h.
GPCRs That Contain C-terminal PDZ Binding Motifs Are
Tethered to Actin Stress Fibers—Since NHERF-1 binds GPCR
and the cytoskeleton, we first examined the effects of NHERF-
1/EBP50 on the distribution of GPCR in live cells transfected
with !2AR-eGFP, PTH1R-eGFP, or CaSR-eGFP. TIRF micros-
copy revealed that the !2AR-eGFP construct aggregated on
puncta and bundle-like structures that closely resembled
cytoskeletal stress fibers only in cells expressing NHERF-1/
EBP50 (Fig. 2,A andB). In contrast, PTH1R-eGFP accumulated
in bundles even in the absence of NHERF-1 expression (Figs. 2,
C and D, and 3A). The CaSR chimeras were never observed in
bundles (Fig. 2, D and E). Several lines of evidence suggested
that these bundle structures were linked to the cytoskeleton.
For instance, prolonged serum starvation of the cells reduced
significantly the prevalence of receptor bundles. Furthermore,
the addition of latrunculin A to disrupt the cytoskeleton rapidly
dissipated most of the PTH1R bundles (see, for instance, Fig.
3B), such that 15 min after the addition of latrunculin, no bun-
dles were visible. The relative distribution of the receptors in
bundles was determined by morphometric analyses. The
results of these measurements are summarized in Table 1.
FIGURE 5. Effects of NHERF-1 expression on the diffusion of !2AR and
CaSR in the plasma membrane of CHO-N10 cells. CHO-N10 cells were
transfected with !2AR-eGFP or CaSR-eGFP, and NHERF-1 expression was
induced with 50 ng/ml tetracycline for 24 h. The diffusion of the fluorescent
receptorswas examinedby TIRF-ICS. Onehundred imageswere collectedper
set at a rate of 3 images/s. The measured total intensities were corrected for
photobleaching using a normalization plug-in for ImageJ. The corrected
intensities were fit to a single-component two-dimensional diffusion model
to determine the diffusion coefficient and the immobile fraction of the recep-
tor. Statistically significant differences (p& 0.01) between basal and tetracy-
cline-induced, NHERF-1-expressing cells are denoted by the asterisks (n # 6
for all experiments).
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These results illustrate the significant effects of the expression
of NHERF-1 on the subcellular distribution of the !2AR. The
effects of NHERF-1 on the distribution of the PTH1R were
much less dramatic although significant. In contrast, NHERF-1
expression had no detectable effects on the distribution of the
CaSR. Finally, to demonstrate that these distributions were not
peculiar toCHOcells, the distribution of the PTH1Rwas exam-
ined inHEK293, rat osteosarcoma (ROS), and human osteosar-
coma (SaOS2) cells. In all cases, a significant fraction of the
PTH1R was found in bundle-like structures (data not shown).
To determine the relationship between the receptor bundles
and the cytoskeleton, CHO-N10 cells expressing PTH1R-eGFP
were fixed and stained with TRITC-conjugated phalloidin. Fig.
3C shows clearly that the bundles
parallel actin fibers. As expected,
NHERF-1 co-localized with these
fibers.
The data shown in Fig. 1 clearly
suggested a major difference in the
subcellular distributions of the
CaSR on one side and the !2AR and
the PTH1R on the other. We
hypothesized that the differences in
the distribution of these receptors
were a consequence of the fact that
the !2AR and the PTH1R contain a
PDZ binding motif at their C termi-
nus, whereas the CaSR does not.
Since the PDZ binding motifs of the
!2AR and the PTH1R interact with
NHERF-1, we proceeded to exam-
ine the relevance of these interac-
tions for the stability of the receptor
bundles using the PTH1R as a
model. CHO-N10 cells were trans-
fected with 1) M593A-PTH1R-
eGFP (a PTH1R-eGFP in which the
C-terminal methionine has been
mutated to alanine, which results in
a dramatic reduction of the affinity
of the receptor for NHERF-1 (26))
or 2) wt-PTH1R-eGFP co-trans-
fected with a deletion mutant of
NHERF-1 that does not contain the
ERM-binding domain ($ERM-
NHERF-1, which has intact PDZ
domains and acts as a dominant
negative regarding most of the
effects of NHERF-1, primarily
because it does not interact with the
cytoskeleton (18)). In both cases, the
PTH1R bundles were still present,
albeit much less so than in the cells
that expressed wt-PTH1R-eGFP
alone (Table 1 and Fig. 3, D and E).
Thus, the binding of the PTH1R to
cytoskeletal fibers is mediated to a
significant extent by the interaction
of the C terminus of the receptor with specific PDZ domain-
containing proteins.
NHERF-1 Expression Modulates Receptor Diffusion—We
next studied the effects of the cytoskeleton and NHERF-1
expression on PTH1R mobility. Diffusion coefficients were
measured using a confocal microscope focused at the plasma
membrane closest to the coverslip using FRAP and ICS tech-
niques (Fig. 4). Fig. 4A shows a representative FRAPexperiment
carried out with cells that do not express NHERF-1. The diffu-
sion coefficients and immobile fractions were calculated for
several cells from 5–16 plates for each condition. These results
are summarized in Fig. 4B. The diffusion of the PTH1R was
significantly slower, and the fraction of immobile receptors was
FIGURE 6. Topological analysis of the diffusion of PTH1R. CHO-N10 cells were examined using TIRF micros-
copy. Images (100–300)were collectedat 500-ms intervals. The cellswere thenexamined todetectbundle-rich
and bulk plasma membrane regions. Small circular sections were selected in these regions (&10-"m diameter;
as seen in A), and the data were fit to one-species autocorrelation functions. B, the first 30 s of the autocorre-
lation curves calculated for the regions of interest shown in A. These results were used to calculate diffusion
coefficients (shown in C) and immobile fractions (D). Six cell plates for each experimental condition were
examined. The distribution among “bundle” and “bulk” regions was done based primarily on the local density
of bundles on the cell surfacewithin the selected regionof interest. Bundle-rich andbulk regionswere selected
using thresholding algorithms, and the analysis was limited to well defined bundle and bulk regions. Because
of these limitations, roughly 30% of the surface of each cell examined was covered. The data were analyzed by
ANOVA followed by post-test Tukey’s comparisons between the NHERF-1(!) and NHERF-1(%) groups. Rele-
vant significant differences are noted in the graph as asterisks (*, p & 0.001; **, p & 0.05). These data were
collected from six independent coverslips for each condition (1–3 cells were examined in each).
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significantly greater in cells that expressed NHERF-1. The
results obtained with FRAP and ICS were internally consistent;
both methods demonstrated that NHERF-1 significantly
decreased the diffusion coefficient and mobile fraction of
PTH1R (Fig. 4B). It should be noted that the numbers obtained
with ICS and FRAP were not identical. These differences are
not unusual and have been attributed to the existence of con-
finement zones that have a much greater relative influence in
the data collected by ICS, because the region imaged is signifi-
cantly smaller (27).
To demonstrate that the effects of NHERF-1 on receptor
mobility were primarily due to the interaction of PTH1R with
NHERF-1, we examined the diffusion of M593A-PTH1R.
M593A-PTH1R diffused very rapidly in comparison with
wt-PTH1R in the presence of NHERF-1 (Fig. 4C). Likewise,
wt-PTH1R diffused very rapidly when co-expressed with
NHERF-1 mutants that do not bind the receptor (such as S1S2,
in which the core binding sequences of the PDZ domains have
been scrambled) or that fail to interact with the cytoskeleton
(such as $ERM-NHERF-1) (Fig. 4C).
Finally, we examined the role of the cytoskeleton in the lat-
eral mobility of PTH1R (Fig. 4D). Blocking actin polymeriza-
tion with latrunculin A increased dramatically the diffusion
coefficient while decreasing the immobile fraction of
wt-PTH1R-eGFP. Interestingly, NHERF-1 decreased the diffu-
sion coefficient of PTH1R in latrunculin A-treated cells, sug-
gesting the presence of a macromolecular complex that
includes NHERF-1, PTH1R, and other proteins that may inter-
act with the second PDZ domain or with the ERM binding
motif of NHERF-1. These observations demonstrate that the
restricted mobility of the PTH1R observed in cells that express
NHERF-1 is a consequence of two concomitant phenomena: 1)
the interactions of the receptor withNHERF-1 and 2) the inter-
actions of NHERF-1 with the cytoskeleton.
Since NHERF-1 also interacts with the !2AR with high affin-
ity, we predicted that NHERF-1 expression should have similar
effects on !2AR diffusion. The results are shown in Fig. 5.
NHERF-1 dramatically reduced the mobility of the !2AR.
Importantly, NHERF-1 had no discernible effects on the diffu-
sion of the CaSR, which was included as a negative control.
Therefore, the effects of NHERF-1 are specific and not due to
generalized changes in the structure of the cytoskeleton in the
vicinity of the plasma membrane. Interestingly, the effects of
NHERF-1 on !2AR mobility were independent of the presence
of ligand, thus suggesting that the interactions between the
!2AR and NHERF-1 do not require ligand binding.
Local Effects of NHERF-1 on Receptor Lateral Diffusion—Be-
cause the distribution of the PTH1R on the cell surface was not
homogeneous, we examined the dynamics of the receptor in
different subregions of the cell using TIRF microscopy. “Bun-
dle” and “bulk” regionswithin each cell were identified based on
the concentration of observable bundles within the region of
interest (ROI) (Fig. 6A). Small (&2.5 "m in diameter) circular
ROI were selected within these regions, and the diffusion coef-
ficient of the receptor was measured by ICS. As shown in Fig.
6B, the autocorrelation functions of the PTH1R within “bulk”
and “bundle” regionswere very different.Within the bundles, in
the absence of NHERF-1, about 60% of the receptor molecules
diffusedwith a coefficient of 0.1"m2/s (Fig. 6C). In contrast, the
receptor diffused very slowly (D # 0.019 "m2/s) in the bulk
region of the cell. This finding strongly suggests that the recep-
tor diffuses along the bundles. However, this diffusion was still
very slow when compared with that observed in the presence
of latrunculin A; thus, we conclude that the motion of the
receptors along the bundles is limited by the binding of the
receptor to the cytoskeleton. NHERF-1 expression drasti-
cally reduced the diffusion coefficient of the fast moving
component within the bundles without exerting a statisti-
cally significant effect on the diffusion coefficient of PTH1R
molecules within the bulk membrane (Fig. 6C). Conversely,
the expression of NHERF-1 increased significantly the immo-
bile fraction of the PTH1Rwithin the bundles. Because the data
show that PTH1R bundles coincide with actin stress fibers (Fig.
3C), these results suggest that the effects of NHERF-1 on the
lateral diffusion of the PTH1R are effectively limited to the pop-
ulation of receptors located in very close proximity to actin
fibers.
Perturbation of the Effects of NHERF-1 Expression by the
Addition of Ligand—The diffusion data shown in Figs. 4 and 5
suggest that NHERF-1 effectively tethers PTH1R and !2AR to
the cytoskeleton. Inasmuch as the interactions of some GPCR
withNHERF-1 appear to be ligand-dependent (28), we hypoth-
FIGURE 7. Effects of the addition of ligand on the lateral mobility of cell
surface receptors. CHO-N10 cells were transfected with PTH1R-eGFP, !2AR-
eGFP, or CaSR-eGFP, and NHERF-1 expression was induced with 50 ng/ml
tetracycline for 24 h. The diffusion of the fluorescent receptors was examined
by TIRF-ICS immediately before and 5 min after the addition of saturating
concentrations of ligand (100 nM PTH-(1–34) for the PTH1R, 10 "M isoproter-
enol for the !2AR, and 5 mM Ca
2! for the CaSR). One hundred images were
collected per set at a rate of 3 images/s. The measured total intensities were
corrected for photobleaching and receptor endocytosis using a normaliza-
tion plug-in for ImageJ. The corrected intensities were fit to a single compo-
nent two-dimensional diffusion model to determine the diffusion coefficient
and the immobile fractionof the receptor. The statistical analysiswasdoneby
ANOVA followed by post-test Tukey’s comparisons. Statistically significant
differences between basal and post-ligand were noted (p& 0.01, n# 6 inde-
pendent coverslips (1–6 cells examined/coverslip) for each experiment).
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esized that the addition of ligand would result in changes of the
diffusion properties of these receptors. Since its diffusion was
insensitive to the expression of NHERF-1, once again we used
the CaSR for control purposes. TIRF experiments were done
using CHO-N10 cells transiently expressing PTH1R-eGFP,
!2AR-eGFP, or CaSR-eGFP. The results are shown in Fig. 7.
The addition of 5mM calcium did not influence the diffusion of
the CaSR. In contrast, the diffusion of the PTH1R was very
sensitive to the addition of ligand; the diffusion coefficient of
the PTH1R increased almost 4-foldwithin 5min of the addition
of PTH-(1–34), whereas the immobile fraction was reduced to
about half of its original value. The results obtained with the
!2AR were somewhat different. Prior to the addition of ligand,
about 95% of the surface !2AR was essentially immobile. The
addition of isoproterenol did not
alter the diffusion coefficient of the
!2AR; however, the immobile frac-
tion of the receptor was reduced
substantially. These results suggest
that ligand induces the dissociation
of the !2AR!NHERF-1 complexes
from the cytoskeleton without
affecting the binding of NHERF-1
to the receptor.
NHERF-1 Expression Modulates
PTH1R Internalization—To inves-
tigate the effects of NHERF-1 on
receptor traffic, we examined the
effects of the addition of ligand on
the surface distribution of the
PTH1R using TIRF microscopy. In
these experiments, images were col-
lected at 30-s intervals after the
addition of ligand. PTH-(1–34), a
well characterized PTH agonist (18,
26), induced the disappearance of
these receptor bundles (Fig. 8A).
Fig. 8B shows a kymograph of the xy
projections of the cells shown in Fig.
8A. Interestingly, the PTH1R inter-
nalized significantly more slowly at
the edges of the cell. Collected
intensity data were fit to a single
exponential to estimate an apparent
first order rate of internalization.
The plateau values from these fits
were used to calculate the fraction
of internalized receptor. In the pres-
ence of PTH-(1–34), 70–80% of the
receptors internalized. Strikingly,
NHERF-1 expression reduced the
rate of internalization of the recep-
tor by about 50% without affecting
significantly the fraction of internal-
ized receptors. In contrast, the
antagonist PTH-(7–34) induced
slower receptor internalization,
which was abrogated by the expres-
sion of NHERF-1. We conclude that NHERF-1 expression
affected differentially receptor internalization, depending on
the nature of the ligand used to induce endocytosis.
Effects of NHERF-1 Expression on the Binding of !-Arrestin to
the PTH1R—To gain some insight into the mechanisms by
which NHERF-1 modulates PTH1R dynamics and internaliza-
tion, CHO-N10 cells were transfected with PTH1R-eGFP and
!-arrestin-1 fused to mRFP (a monomeric variant of theDisco-
soma protein dsRed). These cells were then studied using ICCS
analysis, a technique developed to study protein-protein inter-
actions in live cells. This method is based on a time-dependent
analysis of the cross-correlation between the fluorescence
intensities of two targets labeled with distinct fluorophores
(24): proteins that are associated with a commonmacromolec-
FIGURE 8. Effects of the expression of NHERF-1 on the internalization of PTH1R. A, CHO-N10 cells treated
withvehicle (NHERF%) or tetracycline (NHERF!)wereexaminedbyTIRFmicroscopyafter theadditionof 100nM
PTH-(1–34). Images were collected at 30-s intervals. The figure shows representative images obtained at the
indicated times. B, kymograph of the cells shown in A. The image data were processed as follows. After correc-
tion for photobleaching, a y axis maximal projection of the cell was obtained. A pseudocolor look up table was
applied to the projection. As shown, the intensity decayed significantly more rapidly in the NHERF% cell shown
in A. Furthermore, receptor internalization was somewhat slower at the edges of both cells. C, summary of the
PTH1R endocytosis data. The data show the summary of 12–18 cells (12 separate coverslips) per condition.
The internalization rate constant was calculated fitting the intensity data to a single exponential, whereas
the fraction of surface receptors internalized was calculated from the span of the decay function obtained
from these fits. ANOVA analyses followed by Tukey’s post-test comparisons revealed that NHERF-1 expres-
sion had a significant effect on the rate of endocytosis of the PTH1R, independently of the ligand used to
induce internalization. Moreover, PTH-(7–34)-induced internalization of the receptor was almost com-
pletely blocked by NHERF-1 (p & 0.001, n # 12).
PTH1R Dynamics and Traffic
AUGUST 24, 2007•VOLUME 282•NUMBER 34 JOURNAL OF BIOLOGICAL CHEMISTRY 25083
 at University of Pittsburgh, on January 15, 2010
www.jbc.org
Downloaded from
 
ular complex diffuse together, whereas those that are not dif-
fuse in random directions with respect to one another. This
approach has been previously used to measure dynamic pro-
tein-protein association (24, 25).
In order to eliminate experimental artifacts due to signal
saturation, we selected cells in which the fluorescence inten-
sities of PTH1R-eGFP and mRFP-!-arrestin-1 were compa-
rable. In all cases, we calculated the cross-correlation func-
tion of the same cells, immediately before and at various
times after the addition of the ligand. The fractional degree of
binding was experimentally determined by measuring the ratio
of the amplitudes of the PTH1R autocorrelation curve and the
PTH1R-!Arrestin cross-correlation curve, as described by
Bacia et al. (24). The addition of
PTH-(1–34) increased substantially
the binding of PTH1R to arrestin in
a time-dependent manner from a
low basal value to almost 100%
(Fig. 9A), indicative of the forma-
tion of a complex that included
arrestin and the receptor. NHERF-1
reduced the rate of formation of this
complex 3-fold, suggesting that
NHERF-1 binding interferes with
arrestin recruitment to the recep-
tor. This observation also indicates
that NHERF-1 dissociation proba-
bly precedes arrestin binding.
Since PTH1R internalization in-
duced by PTH-(7–34) was signifi-
cantly slower, we examined the
interactions of the receptor with
!-arrestin-1 after the addition of
this ligand. PTH-(7–34) did not
increase the cross-correlation be-
tween PTH1R and!-arrestin-1 (Fig.
9B). To confirm that the ICCS data
reported in Fig. 9B reflected
PTH1R-arrestin interactions, CHO-
N10 cells were co-transfected with
FLAG-tagged !-arrestin-1 and hem-
agglutinin-tagged PTH1R. The cells
were treated with PTH-(1–34) or
PTH-(7–34) for 15min, and thebind-
ing of PTH1R to arrestin was deter-
mined by co-immunoprecipitation
methods (Fig. 9C). As shown, PTH-
(1–34) induced the formation of
complexes with !-arrestin, whereas
PTH-(7–34) did not. This suggests
that PTH-(7–34)-induced internal-
ization is arrestin-independent.
Because NHERF-1 expression com-
pletely blocked PTH-(7–34)-in-
duced PTH1R internalization, we
also conclude that NHERF-1 affects
PTH1R endocytosis by a dualmech-
anism: 1) reducing the rate of arres-
tin binding to the receptor, and 2) blocking arrestin-independ-
ent endocytic processes.
DISCUSSION
Direct, functional interactions of GPCRs with the cytoskele-
ton were initially suggested several years ago (29). We describe
here three different modes of interaction of GPCR with the
cytoskeleton: 1) some GPCR, such as the !2AR, are linked to
the cytoskeleton via their interactions with NHERF-1; 2)
some GPCRs, such as the PTH1R, interact with the cytoskel-
eton through their interactions with other proteins in addi-
tion to NHERF-1; and 3) some GPCRs, such as the CaSR, do
not appear to interact with the cytoskeleton at all.
FIGURE 9. Effects of PTH analogs and NHERF-1 expression on the binding of !-arrestin-1 to PTH1R.
CHO-N10 cells were transfected with PTH1R-eGFP and selected for 20 days with G418. These cells were further
transfected with a !-arrestin-1-mRFP construct and treated with vehicle (NHERF%) or with tetracycline
(NHERF!) as described under “Experimental Procedures.” The cells were then examined with a confocal micro-
scope focused on the plasma membrane.A, kinetics of binding of!-arrestin-1 to PTH1R. The fractional binding
was calculated from the autocorrelation and cross-correlation curves as described under “Experimental Pro-
cedures.” The solid lines were obtained by fitting the data to a single exponential. The rate constants obtained
were0.12and0.037min%1 for theNHERF%andNHERF! conditions, respectively. Thedifferencebetween these
rate constants is statistically significant (p # 0.002, n # 5). B, the fractional binding of PTH1R to arrestin was
determined by image cross-correlation spectroscopy 10 min after the addition of the various ligands. The
autocorrelation function for PTH1R-eGFP and the cross-correlation function were determined as described
under “Experimental Procedures.” The fractional binding of PTH1R to arrestin was calculated from the ratio of
the amplitudes of the cross-correlation and autocorrelation functions as described by Kim et al. (25). The
differences among groups were examined by ANOVA followed by pairwise Tukey’s test comparisons. a, differ-
ent from preligand basal (p & 0.05); b, different from NHERF% (p & 0.05). Five independent coverslips were
examined for each condition.C, CHO-N10 cellswere transfectedwith hemagglutinin-taggedPTH1R and FLAG-
tagged !-arrestin-1. Cells were treated with PTH-(1–34) (100 nM) or PTH-(7–34) (1 "M) where stated. Fifteen
minutes after the addition of ligand, the cells were lysed, and !-arrestin-1 was immunoprecipitated (IP) using
agarose-conjugated anti-FLAG antibodies. IB, immunoblot.
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The interactions of the !2AR with the cytoskeleton
appeared to be mediated almost exclusively by NHERF-1, as
there was no evidence of cytoskeletal localization of the
!2AR in cells that did not express NHERF-1. However, sur-
prisingly, the association of PTH1R to cytoskeletal struc-
tures was not strictly dependent on the expression of
NHERF-1, suggesting that NHERF-1 is only one of several
cellular components mediating the interactions of PTH1R
with the actin cytoskeleton. Consistent with this, at least two
other cytoskeleton-related proteins have been reported to
interact with PTH1R: Tctex-1, a dynein light chain (30),
reportedly linked to the actin cytoskeleton (31), and 4.1G, a
protein directly associated with actin (32). The binding sites
for these two proteins are located near the C terminus of
PTH1R, upstream of the PDZ domain binding motif
(ETVM), which appears to be excluded (30, 32). These inter-
actions may be sufficient to promote partial binding of
PTH1R to the cytoskeleton. However, interference with the
C-terminal PDZ domain binding motif significantly
decreased the accumulation of PTH1R in bundles, suggest-
ing that other PDZ domain-containing proteins may partic-
ipate in the linkage of the PTH1R to the cytoskeleton. Nev-
ertheless, our data strongly suggest strong interactions
between the PTH1R and NHERF-1 in live cells; the PTH1R
becomes effectively immobilized by its interactions with
NHERF-1 and the underlying cytoskeletal fibers. The func-
tional consequences of these interactions are probably mul-
tiple. The activation of phospholipase C-dependent path-
ways by PTH1R appears to be regulated by binding to
NHERF and the cytoskeleton (16, 33).
Much less is known about the functional consequences of
tethering the !2AR to NHERF-1 and the cytoskeleton, and
most of what we know about these is limited to the effects of
NHERF-1 on !2AR traffic. It is clear that !2AR recycling is
tightly regulated by NHERF-1 expression, since disruption
of the cytoskeleton impairs !2AR recycling and increases
receptor degradation (34). More
recently, it has been reported that
the ability of isoproterenol to acti-
vate cAMP production is in-
creased by disruption of the
cytoskeleton (35), but this obser-
vation has not been linked to
NHERF-1 expression or function.
The diffusion of the!2AR and the
PTH1R but not the CaSR was
strongly influenced by NHERF-1.
The expression of NHERF-1 re-
duced the diffusion coefficient of
the !2AR and the PTH1R while
increasing significantly the immo-
bile fraction of these receptors.
These results are consistent with
the report of Bates et al. (27), who
showed that the diffusion of the
CFTR was also strongly influenced
by NHERF-1 binding. These results
prove that NHERF-1 immobilizes
its targets by linking them to the cytoskeleton.
Our diffusion studies also shed important light on the
influence of ligand binding on interactions of GPCR with
NHERF-1. We hypothesized that ligands that reduce the
affinity for NHERF-1 should increase the lateral mobility of
the receptor. That seems to be the case for the PTH1R; ligand
binding induced a significant increase of the diffusion coef-
ficient and the mobile fraction of PTH1R in cells that
expressed NHERF-1, whereas it was without significant
effects in cells that did not. This indicates that, after ligand
binding, 1) the interactions of the PTH1R with NHERF-1
and other partners have been altered, and 2) the association
of PTH1R with the cytoskeleton has been impaired by either
releasing NHERF-1 from the cytoskeleton or by direct dis-
ruption of the cytoskeleton. However, the case of the !2AR is
somewhat different. NHERF-1 expression immobilizes non-
stimulated !2AR, strongly suggesting that !2AR!NHERF-1
complexes exist in the absence of ligand. Five minutes after
the addition of ligand, the mobile fraction of the !2AR was
significantly increased without changing its diffusion coeffi-
cient. This strongly suggests that the binding of the !2AR to
NHERF-1 is not significantly altered by the addition of
ligand, although the association of !2AR!NHERF-1 com-
plexes to the cytoskeleton probably is. The permanence of
!2AR!NHERF-1 complexes after the addition of ligand is
consistent with previously published data. In fact, it was sug-
gested that the interactions of the !2AR and NHERF-1 were
induced by ligand (28). However, more recent work by Cao et
al. (34) established that GRK5-dependent phosphorylation
of Ser411 impaired NHERF-1 binding to the !2AR, suggesting
that ligand binding might negatively influence the binding of
NHERF-1 to the !2AR. Thus, the binding of NHERF-1 to the
!2AR appears to be temporally and dynamically regulated by
signaling cascades downstream the activation of the recep-
tor. Our results suggest that, at least within 5min after ligand
addition, the !2AR remains associated to NHERF-1, but the
FIGURE 10.Model describing the interactions of PTH1Rwith ligand, NHERF-1, the actin cytoskeleton,
and arrestin. The PTH1R is anchored to the actin cytoskeleton by multiple interacting proteins, one of
which is NHERF-1. In the absence of NHERF-1, the PTH1R moves rapidly along actin fibers by a mechanism
that may involve dissociation from the cytoskeleton. The interaction of NHERF-1 with the ETVM C-terminal
sequence immobilizes the PTH1R and tethers it to actin fibers. The addition of ligand to the PTH1R induces
the dissociation of NHERF-1 and the binding of !-arrestin. Ligand-induced arrestin binding is significantly
slower in the presence of NHERF-1, probably because NHERF-1 dissociation must precede arrestin
binding.
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interactions of NHERF-1 with the cytoskeleton or the integ-
rity of the cytoskeleton itself are altered as a consequence of
the treatment. It should be noted that several effects of
cAMP and protein kinase A on the disruption of the
cytoskeleton have been documented (36–39).
The reduced lateral mobility of membrane proteins induced
by NHERF-1 is likely to result in the accumulation of receptors
in NHERF-1-enriched regions. Furthermore, the reduced
mobility of the receptors should have significant modulatory
effects on the traffic of these receptors. It was recently shown
that, in HEK293 cells (which express NHERF-1 at very high
levels), the interactions of PDZ domain-containing proteins
with the C terminus of GPCRs regulate the dynamics of the
endocytosis of these receptors by delaying the recruitment of
dynamin, inducing abortive events that reduce the efficiency of
endocytosis, or selecting subpopulations of clathrin-coated pits
(40). Here we show that the interactions with NHERF-1 govern
the overall dynamics of receptors that contain C-terminal PDZ
binding motifs. We propose that, since endocytic events are
initiated randomly on the cell surface and have a finite duration
(19), a significant reduction of the lateral mobility of the cargo
molecules will probably reduce the probability of accumulation
of cargo in clathrin-coated pits, thus reducing the net rate of
endocytosis. Furthermore, at least in the case of the PTH1R, the
interaction of the receptor with NHERF-1 delays the binding of
!-arrestin. Delayed !-arrestin recruitment implies delayed
recruitment of AP-2 and clathrin and, as a consequence,
delayed recruitment of dynamin to complete the endocytic
process. Thus, our findings provide a simple, self-consistent
explanation for the reduced rate of endocytosis of GPCR con-
taining C-terminal PDZ binding motifs observed in the pres-
ence of NHERF-1. Furthermore, we show that different ligands
can induce selective, alternative pathways of GPCR internaliza-
tion via mechanisms that may or may not involve arrestin and
that are tightly regulated by NHERF-1. The general model we
propose is shown in Fig. 10. GPCRs that contain a C-terminal
PDZ binding motif are tethered to the cytoskeleton via direct
interactions withNHERF-1. Some of these, such as the PTH1R,
may bind the cytoskeleton via multiple additional interactions
thatmay include other PDZdomain-containing targets. In gen-
eral, NHERF-1 binding plays a major role in anchoring these
receptors to the cytoskeleton, reducing receptor mobility, and
dynamically interfering with the binding of arrestin after ligand
stimulation. Furthermore, the binding of NHERF-1 to some of
these receptors blocks completely arrestin-independent recep-
tor internalization processes, such as PTH-(7–34)-induced
PTH1R endocytosis. These data, in conjunction with those of
Puthenveedu and von Zastrow (40), suggest that this may be a
very general mechanism for the regulation of GPCR trafficking.
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The effects of the expression of the Na!/H! ex-
changer regulatory factor-1 (NHERF1) on the dis-
tribution, dynamics, and signaling properties of the
PTH type 1 receptor (PTH1R) were studied in rat
osteosarcoma cells ROS 17/2.8. NHERF1 had a
dramatic effect on the subcellular distribution of
PTH1R, promoting a substantial relocation of the
receptor to regions of the plasma membrane lo-
cated in very close proximity to cytoskeletal fibers.
Direct interactions of NHERF1 with the PTH1R and
the cytoskeleton were required for these effects,
because they were abolished by 1) PTH1R muta-
tions that impair NHERF1 binding, and 2) NHERF1
mutations that impair binding to the PTH1R or the
cytoskeleton. NHERF1 reduced significantly the
diffusion of the PTH1R by a mechanism that was
also dependent on a direct association of NHERF1
with the PTH1R and the cytoskeleton. NHERF1 in-
creased ligand-dependent production of cAMP
and induced ligand-dependent rises in intracellular
calcium. These effects on calcium were due to
increased calcium uptake, as they were blocked by
calcium channel inhibitors and by the addition of
EGTA to the medium. These calcium effects were
abolished by protein kinase A inhibition but phos-
pholipase C inhibition was without effect. Based on
these analyses, we propose that, in ROS cells, the
presence of NHERF1 induces PTH-dependent cal-
cium signaling by a cAMP-mediated mechanism
that involves local protein kinase A-dependent ac-
tivation of calcium channels. (Molecular Endocrin-
ology 22: 1163–1170, 2008)
THE TYPE 1 PTH receptor (PTH1R) is a G protein-coupled receptor that signals primarily through the
activation of adenylyl cyclase and the production of
cAMP. However, PTH exhibits remarkable cell- and
tissue-specific signaling. In most cells and tissues, the
PTH1R signals via the activation of cAMP and intra-
cellular Ca2! release (1, 2). In some cells and heterol-
ogous expression systems, for instance, the PTH1R
activates both adenylyl cyclase and phospholipase C
(PLC). In certain instances, however, the PTH1R cou-
ples only to a single pathway and does so in a cell-
specific manner. For example, in vascular smooth
muscle cells, PTH stimulates adenylyl cyclase but not
PLC (3, 4), whereas in keratinocytes (5–7), cardiac
myocytes (8, 9), and lymphocytes (10–12), PLC, but
not adenylyl cyclase, is activated. The PTH1R may be
influenced by the relative levels of expression of spe-
cific G proteins (13). Likewise, N-truncated PTH an-
tagonists, whereas failing to elicit detectable down-
stream signaling, promote PTH1R internalization in
some cell types, but not in others (14, 15). Based on
the observation that the PTH1R interacts with the
Na!/H! exchanger regulatory factor proteins,
NHERF1 and NHERF2 (16, 17), a unified model to
explain these diverse findings was developed.
NHERF1 and NHERF2 are characterized by two tan-
dem N-terminal post-synaptic 95, PSD95 (PDZ) do-
mains that interact primarily with the C-terminal end of
many targets, including the PTH1R, regulating their
traffic, dynamics, and signaling properties (18–20).
NHERF1 and NHERF2 also contain an ezrin-radixin-
moesin (ERM) binding motif at the C terminus (20).
Because of the multivalent nature of NHERF1 and
NHERF2, it has been proposed that these proteins act
as scaffolds, bringing together specific target mole-
cules, and mediating the interactions of specific pro-
teins with the cytoskeleton (16, 17).
Previous work established that NHERF1 expression
has dramatic effects on the modulation of the re-
sponses of PTH1R to various ligands. Some of these
are: 1) reduction of the rate of ligand-induced PTH1R
endocytosis (21); 2) reduced production of cAMP (16,
First Published Online January 17, 2008
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17); 3) induction of calcium responses (16, 17); and 4)
blockade of the receptor internalization effects of N-
truncated PTH analogs (14, 15). Because calcium re-
sponses and cAMP production appear to be inversely
correlated, it has been suggested that NHERF1 in-
duces a signaling switch, impairing the coupling of
PTH1R with Gs and promoting the activation of PLC by
mechanisms linked to the activation of Gi/Go (16, 17)
or Gq/G11 (13, 22). The molecular mechanisms under-
lying the signaling switch have not been characterized.
Relatively little is known about the mechanisms by
which NHERF1 regulates PTH responses in bone cells.
NHERF1 is not expressed in rat osteosarcoma ROS
17/2.8 (ROS) cells (16), and in these cells PTH neither
activates PLC nor induces calcium-dependent signals.
However, PTH(1–34) increased the activity of an acti-
vating protein 1-responsive luciferase reporter in ROS
cells transfected with NHERF2, suggesting that ex-
pression of NHERF2 suffices to induce PKC-depen-
dent responses (16). There is limited additional evi-
dence for a NHERF1 or NHERF2-dependent signaling
switch in bone cells. In fact, PLC-independent activa-
tion of PKC has been described in bone (23). In this
paper we examine the influence of NHERF1 expres-
sion on the distribution, dynamics, and signaling
events downstream of the PTH1R in ROS cells. Our
data show that stable expression of NHERF1 alters
significantly the distribution and diffusion of PTH1R,
concomitantly inducing the appearance of calcium re-
sponses to stimulation with PTH. However, in contrast
with the observations made in other cell systems, the
induction of calcium responses by NHERF1 in ROS
cells is not due to the activation of PLC. We show here
that the elevation of intracellular calcium is a conse-
quence of the activation of calcium channels by a
mechanism mediated by protein kinase A (PKA) and
requiring NHERF1. A novel model for the physiological
role of NHERF1 in PTH1R signaling is proposed.
RESULTS
NHERF1 Regulates the Distribution of the PTH1R
Examination of a PTH1R-enhanced green fluorescent
protein (EGFP) construct by confocal microscopy re-
vealed a uniform surface distribution of the receptor on
the surface of ROS cells (Fig. 1A). Actin fibers were
Fig. 1. NHERF1 Regulates the Distribution of the PTH1R
ROS and ROS-NHERF1 cells were transfected with PTH1R-EGFP and examined by confocal microscopy. The images shown were
obtaining by focusing the microscope onto the plasma membrane adjacent to the coverslip. PTH1R-EGFP (wild-type and the ETVA
mutant) images are shown in panels A, D, G, and J. Actin fibers stainedwith TRITC-phalloidin are shown in panels B, E, H, and K. Panels
C, F, I, and L show the merged images. Colocalization of the green and red labels is shown in yellow. wt, Wild type.
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stained with phalloidin-tetramethylrhodamine isothio-
cyanate (TRITC) (Fig. 1B) to investigate the colocaliza-
tion of the PTH1R and the cytoskeleton. As shown in
Fig. 1C, there was no colocalization of the receptor
with actin fibers in the parental ROS cells. To examine
the effects of NHERF1 expression on the distribution
of the PTH1R, ROS cells were transfected with human
NHERF1. NHERF1 expression was verified by Western
blotting and immunocytochemistry (data not shown).
Stably transfected cells were selected (ROS-NHERF1
cells) and further transfected with PTH1R-EGFP, and
the distribution of the receptor was examined. In
marked contrast with the results obtained with ROS
cells, PTH1R-EGFP was organized around actin fibers
(Fig. 1, D"F). To confirm that the interactions of
PTH1R and NHERF1 were responsible for the reorga-
nization of the receptor and its colocalization with the
actin cytoskeleton, ROS and ROS-NHERF1 cells were
transfected with M593A-PTH1R-EGFP (ETVA-
PTH1R). This mutated receptor has a defective PDZ-
binding motif and does not bind NHERF1 (15). As
shown (Fig. 1, G–L), the distribution of ETVA-PTH1R
was identical in ROS and ROS-NHERF1 cells. Further-
more, the colocalization with actin fibers was lost in
the mutant receptor. Thus, binding of the PTH1R to the
actin cytoskeleton requires an intact PDZ-recognition
domain and the presence of NHERF1. To confirm that
these results were not a consequence of the overex-
pression of the receptor, the experiments were repro-
duced by immunocytochemistry using antibodies
against the PTH1R. The results shown in Fig S2 (pub-
lished as supplemental data on The Endocrine Soci-
ety’s Online web site at http://mend.endojournals.org),
demonstrate that the endogenous receptor is also or-
ganized around actin fibers in ROS-NHERF1 cells.
NHERF1 Reduces the Mobility of the PTH1R
The diffusion of PTH1R-EGFP was studied in ROS and
ROS-NHERF1 cells by image correlation spectroscopy.
As shown in Fig. 2, in ROS cells 80% of the PTH1R was
readily mobile and diffused with a diffusion coefficient of
about 0.15 !m2/sec. In contrast, in ROS-NHERF1 cells,
most of the receptor molecules (80%) were immobile,
and those receptors that diffused did so with a diffusion
coefficient of 0.045!m2/sec. Importantly, the expression
of NHERF1 mutants that do not bind the PTH1R (S1S2,
in which the core of the PDZ domains 1 and 2 has been
scrambled), or that bind the receptor but fail to attach to
the cytoskeleton (#ERM, where the ERM-binding do-
main of NHERF1 has been deleted) had no detectable
effects on the mobility of the receptor. These data dem-
onstrate that immobilization of the PTH1R by NHERF1 is
the result of specific tethering of the receptor to the actin
cytoskeleton.
NHERF1 Regulates PTH1R Signaling
It has been proposed that NHERF1 induces a signaling
switch in the responses of the PTH1R to hormone (16,
17). According to the signaling switch hypothesis,
NHERF1 promotes the coupling of the PTH1R to per-
tussis toxin-sensitive PLC activity with a concomitant
reduction in the production of hormone-dependent
cAMP. To test this model, we examined the produc-
tion of cAMP and changes in the intracellular concen-
tration of Ca2! in ROS and ROS-NHERF1 cells. Figure
3 shows a comparison of the cAMP responses in-
duced by 100 nM PTH(1–34) and forskolin (100 !M) in
ROS and ROS-NHERF1 cells. The data demonstrate
clearly that NHERF1 expression increased rather than
diminished cAMP production. These differences are
not due to different levels of adenylyl cyclase expres-
sion, because both cell types exhibited comparable
responses to forskolin. Radioligand binding studies
using the PTH analog [125I][Nle8, 18,Tyr34]PTH(1–
34)NH2 demonstrated that ROS and ROS-NHERF1
cells expressed comparable numbers of receptors on
the surface (ROS: 10.8 $ 1.6 nmol/mg protein; ROS-
Fig. 2. NHERF1 Regulates the Diffusion of the PTH1R
ROS and ROS-NHERF1 cells were transfected with
PTH1R-EGFP and the diffusion of the PTH1R was examined
by image correlation spectroscopy as described in the text.
Autocorrelation data were fit to a model assuming a single
mobile species. A, The diffusion coefficient was calculated
from the autocorrelation data. B, The immobile fraction was
calculated from the autocorrelation function fitted to the im-
aging data. *, Statistically significant differences with all other
samples in the data set (P % 0.01; n & 6).
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NHERF1: 13.6 $ 2.2 nmol/mg protein) (Fig. S1, pub-
lished as supplemental data).
Because the increased cAMP production observed
in the ROS-NHERF1 cells was inconsistent with the
predictions of the signaling switch model, we also
examined PTH(1–34)-induced changes of intracellular
Ca2!. The data shown in Fig. 4 demonstrate robust
Ca2! responses to 100 nM PTH(1–34) but only in the
ROS-NHERF1 cells (Fig. 4, A and B). These Ca2!
responses were remarkable on two accounts. First,
they appeared to be relatively slow in comparison with
typical PLC-mediated responses (see Fig. 6B); sec-
ond, the Ca2! response was biphasic, with a slow
increase in Ca2! after the initial spike (Fig. 4A). The
secondary rise in Ca2! was not a consequence of
reduced cell integrity because it was absent in the
parental ROS cells. The Ca2! responses depicted in
Fig. 4A were due to the entry of extracellular Ca2!, as
they were blocked by addition of 5 mM EGTA to the
extracellular medium 5 min before the addition of
PTH(1–34) (Fig. 4C). Furthermore, the voltage-depen-
dent Ca2!-channel blockers nifedipine and verapamil
abolished the Ca2! responses induced by PTH (Fig. 4,
D and E).
To further define the mechanism of PTH-induced
Ca2! entry, PLC activity was inhibited with U73122 (24).
Fig. 3. NHERF1 Modulates PTH-Induced cAMP Production
ROS and ROS-NHERF1 cells were prelabeled with tritiated adenine and treated with PTH(1–34) in the presence or absence of IBMX.
* and ** denote statistically significant differences with the control and control ! IBMX samples (*, P % 0.001; **, P % 0.01; n & 3).
Fig. 4. NHERF1 Modulates PTH-Regulated Intracellular Ca2! by a Mechanism Mediated by Voltage-Dependent Ca2! Channels
ROS-NHERF1 (A) and ROS (B) cells were preloaded with Fluo4 AM. Cells were treated with 100 nM PTH(1–34), and changes
in the intracellular Ca2! concentration were recorded from the changes in fluorescence at 1-sec intervals for up to 20 min. Actual
[Ca2!] concentrations were determined as described in Materials and Methods. C, ROS-NHERF1 cells were pretreated with 5 mM
EGTA 5 min before stimulation with PTH (1–34). D, ROS-NHERF1 cells were pretreated with 5 !M nifedipine 15 min before the
experiment. E, ROS-NHERF1 cells were pretreated with 10 !M verapamil 15 min before the experiment. The figure shows
representative traces of experiments that were reproduced at least three times. Calcium traces from 8–12 cells were recorded
simultaneously in each experiment.
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Even at rather high concentrations (10 !M), U73122 had
only minor effects on the PTH-induced entry of Ca2! in
ROS-NHERF1 cells (Fig. 5A). At these concentrations,
U73122 completely blocked carbachol-induced Ca2!
responses (Fig. 5B). These studies strongly suggest that
PLC activation was not involved in PTH-stimulated Ca2!
entry. To test the involvement of a classical cAMP-PKA-
dependent mechanism, the cells were pretreated with
the PKA inhibitor H89 (10 !M, 10 min) before exposure to
the ligand. As shown in Fig. 5C, H89 abolished PTH-
induced Ca2! entry. Consistent with this, treatment of
the cells with forskolin elicited a transient Ca2! response
in ROS-NHERF1 cells (Fig. 5D). Remarkably, ROS cells
did not display an equivalent response to forskolin, indi-
cating that NHERF1 is required for cAMP-dependent
Ca2! entry. These data strongly suggest that PKA acti-
vation is necessary, but not sufficient, for the activation
of Ca2! entry.
The actual role of NHERF1 in the generation of the
Ca2! responses observed in ROS-NHERF1 cells was
further explored using a C-terminal NHERF1 truncation
mutant missing most of the ERM-binding motif (#ERM).
As shown in Fig. 6A, #ERM did not elicit any Ca2!
responses, unlike full-length NHERF1. Furthermore,
transfection of ROS-NHERF1 cells with the #ERM mu-
tant blocked the Ca2! responses induced by PTH treat-
ment. We conclude from these results that the binding of
PTH1R to the cytoskeleton is required for the observed
NHERF1 effects on Ca2! entry.
DISCUSSION
There are multiple signaling pathways downstream
of the PTH1R. Abundant evidence shows the acti-
vation of cAMP- and Ca2!-mediated responses, and
the nature and magnitude of these responses are
cell and tissue dependent (2, 13, 14, 16, 17, 22, 25).
These remarkable variations in the signals triggered
by PTH have received substantial attention in the
last few years. Some insight as to the origins of
these variations emerged from the discovery of the
NHERF1/EBP50 family of scaffolding proteins. Ma-
hon et al. (16) reported that NHERF2, a protein very
closely related to NHERF1, reduced cAMP re-
sponses to PTH and promoted the activation of PLC
by a Pertussis toxin-sensitive mechanism. These
observations were extended to NHERF1 (17). Thus,
a signaling switch mechanism was proposed. Ac-
cording to this model, the two PDZ domains of
NHERF1/2 interact with the C terminus of the
PTH1R and PLC", while tethering this complex to
the cytoskeleton. The formation of this complex pre-
sumably switches the signaling mode of the PTH1R
from a Gs-based activation of adenylyl cyclase to a
Gi-dependent inhibition of cAMP production and ac-
tivation of PLC". Thus, the PTH1R, in the presence
of NHERF1, would signal via the activation of Ca2!-
dependent processes.
Fig. 5. PTH-Dependent Ca2! Entry Is Mediated by PKA Activation and Independent of PLC Activity
Calcium entry experiments were performed as described for Fig. 4. A, Cells were preincubated with 10 !M U73122 15 min
before the addition of PTH. B, Cells were preincubated with 15 !M U73122 15 min before treatment with carbachol. C, H89 (15
!M) was added to the cells 20 min before stimulation with PTH(1–34). D, Cells were stimulated with forskolin (20 !M) after
preincubation with 250 !M IBMX for 20 min.
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The generality of the signaling switch model has not
been well established. In fact, several lines of evidence
suggest that the proposed NHERF1-dependent Gs-
to-Gi coupling change is not necessary for the stimu-
lation of substantial Ca2!-dependent responses to
PTH. For instance, some cells that express NHERF1 at
very high levels, such as osteoblast-like UMR-106
cells (our unpublished observations), produce large
amounts of cAMP in response to PTH (26). Further-
more, several G protein-coupled receptors primarily
linked to Gs and cAMP production elicit Ca
2! entry via
the activation of voltage-dependent Ca2! channels
(27). Finally, work with signaling-selective PTH ana-
logs demonstrated that PKC-dependent pathways
may be activated by the PTH1R without concomitant
activation of PLC-dependent phosphatidylinositol hy-
drolysis (23), suggesting PLC-independent Ca2!-de-
pendent responses. In this study we address the
mechanism by which NHERF1 induces PTH-depen-
dent Ca2! signaling in a well-established bone cell
model, the rat osteosarcoma ROS 17/2.8 cell line.
Remarkably, the present results diverge substan-
tially from those reported for other cell systems (13,
16, 22, 25). Our data indicate that NHERF1 increases
PTH-dependent cAMP accumulation, and that this ef-
fect is accompanied by Ca2! entry. Importantly,
NHERF1 is absolutely required for PTH-induced Ca2!
entry in ROS cells. However, the entry of Ca2! into
ROS-NHERF1 cells is qualitatively different from the
responses reported in opossum kidney (OK) cells (17).
Whereas the response to PTH appears as a single
Ca2! spike that has a duration of less than 50 sec in
OK cells, the PTH response in ROS-NHERF1 cells is
biphasic, with an initial spike that has a duration of
200–250 sec and a second, sustained phase that ap-
pears to plateau after 15 min (Figs. 4A and Fig. 5A).
Furthermore, the mechanisms by which PTH induces
Ca2! entry in the ROS-NHERF1 cells differs from that
in OK cells. In OK cells, Gi-dependent activation of
PLC appears to be involved in the pathway, whereas in
ROS-NHERF1 cells the mechanism is PKA mediated.
An important question is: because PTH increases
cAMP levels in both ROS and ROS-NHERF1 cells, why
is Ca2! entry observed exclusively in the latter? We
propose that the answer to this question lies in the
subcellular distribution and membrane dynamics of
the PTH1R and its signaling targets in cells that ex-
press NHERF1. First, NHERF1 is not serving a simple
scaffolding role by bringing together proteins targeted
by NHERF1’s PDZ domains. This is evident from the
fact that #ERM-NHERF1 fails to transduce Ca2! sig-
nals (Fig. 6A). These data clearly demonstrate that the
attachment of NHERF1 to the cytoskeleton is abso-
lutely required for its role in the promotion of Ca2!
entry in ROS-NHERF1 cells. This conclusion is further
strengthened by the fact that #ERM-NHERF1 inhibits
the effects of the expression of the full-length
NHERF1, acting as a dominant-negative mutant (Fig.
6B). Second, in the absence of IBMX (i.e. under phys-
iological conditions) very little cAMP accumulates in
ROS cells. In fact, the data shown in Fig. 3 suggest
that, 20 min after the addition of PTH, the levels of
cAMP are indistinguishable from the basal state in the
parental ROS cells. In contrast, even in the absence of
IBMX, PTH elicits cAMP production to some detect-
able degree in ROS-NHERF1 cells. Third, the PTH1R
distribution and diffusion data shown in Figs. 1 and 2
demonstrate clearly that NHERF1 tethers the PTH1R
to the cytoskeleton, promoting the accumulation of
the receptor in the vicinity of actin fibers, where the
PTH1R is immobilized. Therefore, even though the
average intracellular concentration of cAMP may not
substantially increase after stimulation, the local con-
centration of cAMP may rise dramatically in the vicinity
of the cytoskeletal fibers. And finally, as shown in Fig.
5D, forskolin cannot induce Ca2! entry in the absence
of NHERF1. Taken together, these data clearly sug-
gest that the scaffolding function of NHERF1 is an
absolute requirement for the cAMP-dependent entry
of Ca2! in ROS cells. Furthermore, several known A
kinase-anchoring proteins link PKA to the cytoskele-
ton, such as ezrin (28), which also interacts with
NHERF1 via the C-terminal ERM-binding motif of
NHERF1. We propose an alternative model for PTH-
dependent activation of Ca2! entry in cells that ex-
press NHERF1/2. According to this model, NHERF1
Fig. 6. PTH-Induced, NHERF1-Dependent Ca2! Entry Requires the Binding of PTH1R and NHERF1 to the Cytoskeleton
ROS and ROS-NHERF1 cells were transiently transfected with #ERM-NHERF1 24 h before the experiments. The cells were
stimulated with 100 nM PTH(1–34), and the intracellular [Ca2!] was monitored as described in Fig. 4.
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forms a scaffolding complex with the PTH1R and ERM
proteins, such as ezrin or radixin. This complex accu-
mulates along actin fibers running parallel to the sur-
face of the cell. Upon the activation of the receptor,
Gs-dependent adenylyl cyclase produces high local
concentrations of cAMP, which, in turn, activate PKA
locally, inducing the phosphorylation of voltage-de-
pendent Ca2! channels, thus allowing Ca2! entry.
PTH-dependent PLC activation may occur or not, but
our data suggest that PLC activity is not required for
the Ca2! entry process.
MATERIALS AND METHODS
ROS and ROS-NHERF1 Cells
ROS 17/2.8 cells were grown in DMEM/F12 medium supple-
mented with 10% fetal calf serum. ROS-NHERF1 cells were
generated by transfection of the parental cell line with human
NHERF1 subcloned in the multiple cloning site of the plasmid
pCDNA3.1/Hygro (Stratagene, La Jolla, CA). Stable transfec-
tants were selected with hygromycin (up to 150 !g/ml) over
a period of 4 wk. The expression of NHERF1 was determined
by Western blotting using a specific anti-NHERF1 antibody
(Upstate Biotechnology, Inc., Lake Placid, NY). ROS-
NHERF1 cells were further characterized by measuring the
levels of expression of PTH1R and the dissociation constant
(Kd) for PTH(1–34). Both cell lines expressed similar levels of
PTH1R (ROS: 10.8 $ 1.6 nmol/mg protein; ROS-NHERF1:
13.6 $ 2.2 nmol/mg protein). Likewise, the Kd of PTH(1–34)
was the same in both cell lines (see Fig S1).
Immunocytochemistry
Cells were cultured on glass coverslips, transfected with
wild-type PTH1R-EGFP or ETVA-PTH1R-EGFP, and allowed
to grow until 80% confluence. The coverslips were washed in
PBS and fixed for 20 min in 4% paraformaldehyde in PBS at
4 C. Cells were permeabilized with 5% nonfat milk, 0.1%
Triton X-100 for 1 h at 4 C and then stained with phalloidin-
TRITC (3 nM) overnight at 4 C. For the detection of endoge-
nous receptors, untransfected cells were simultaneously in-
cubated with anti-PTH1R antibody E-17 (Santa Cruz
Biotechnology, Inc., Santa Cruz, CA) and a dilution of 1:100.
Bound antibody was detected with an Alexa488-conjugated
antigoat IgG. The cells were then washed four times with
PBS, mounted with gelvatol, and examined by confocal mi-
croscopy using an Olympus Fluoview 1000 instrument (Olym-
pus Corp., Lake Success, NY). Colocalization was measured
using the image correlation plug-ins of Image J.
Adenylate Cyclase Activity
cAMP accumulation was determined as described previously
(14). Briefly, cells cultured in 24-well plates were labeled with 0.5
!Ci of [3H]adenine for 2 h. The cells were then treated with
vehicle or 100 nM PTH(1–34) for 5 min. IBMX (250 !M) was
included where indicated. The reaction was terminated by ad-
dition of 1 M trichloroacetic acid followed by neutralization with
KOH. cAMP was isolated by the two-column method (29).
Measurement of the Diffusion Coefficient of the PTH1R
These studies were done by total internal reflection-image
correlation spectroscopy as described previously (21). The
technique is based on the analysis of the correlation of an
image with itself after a certain lag time #. This correlation is
a function of the mobility of the fluorescent molecules (30,
31). Cells were transfected with PTH1R-EGFP and examined
24 h after transfection. Cell images were collected by total
internal reflection microscopy at 200-msec intervals. Up to
300 images were obtained for each experiment. Fluores-
cence loss due to photobleaching of the sample was almost
negligible. The image data were exported to ImageJ and
analyzed using a plug-in specifically written to calculate the
autocorrelation function of the data (21). The resulting auto-
correlation data were exported into GraphPad Prism and fit to
a single species two-dimensional diffusion model [G(#) & K(1
! #/#d)
"1! G0 where #d is the characteristic time constant, K
is a proportionality factor, and GD is a term that accounts for
spatial autocorrelation]. The diffusion coefficient was calcu-
lated from the Stokes-Einstein equation [D & r2/(4#d)].
Determination of Intracellular Ca2!
ROS and ROS-NHERF1 cells cultured in Mattek dishes were
loaded with the calcium-sensitive dye Fluo4 AM in serum-free
medium for 20–30 min. The final loading concentration of the
dye was 4 !M. All calcium measurements were done using
DMEM/F12 containing 20 mM HEPES (pH 7.4) at 37 C in an
Olympus IX70 inverted microscope equipped with a tempera-
ture-controlled chamber (Harvard Apparatus, Inc., South
Natick, MA) and a Orca ER camera (Hamamatsu Photonic Sys-
tems Corp., Bridgewater, NJ). The intracellular Ca2! concen-
tration was determined using the expression F & [Fmax "
Fmin)/(1 ! ([Ca
2!]/Kd)] where F is the measured fluorescence
intensity, Fmax is the fluorescence measured after addition of
ionomycin (which equilibrates the interior of the cell with the
extracellular medium), Fmin is the fluorescence measured after
addition of 10 mM EGTA, and Kd is the dissociation equilibrium
constant of the dye-Ca2! complex (0.19 !M) (32).
Statistical Analysis
All curve-fittinganalysesweredoneusingGraphPadPrism (Graph-
Pad Software, Inc., San Diego, CA). All experiments reported were
reproduced at least three times anddoneby triplicate. The calcium
concentration traces shown in Figs. 4–6 are representative, and
somecell-to-cell variationswereobserved.Statistical comparisons
of multiple samples were done by ANOVA followed by posttest
comparisons using Tukey’s method. Pairs of samples were com-
pared using Student’s t tests.
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Calcium/Calmodulin-Dependent Protein Kinase (CaMK) IV
Mediates Nucleocytoplasmic Shuttling and Release of HMGB1
during Lipopolysaccharide Stimulation of Macrophages1
Xianghong Zhang,2* David Wheeler,2* Ying Tang,* Lanping Guo,* Richard A. Shapiro,*
Thomas J. Ribar,† Anthony R. Means,† Timothy R. Billiar,* Derek C. Angus,‡
and Matthew R. Rosengart3*‡
The chromatin-binding factor high-mobility group box 1 (HMGB1) functions as a proinflammatory cytokine and late mediator of
mortality in murine endotoxemia. Although serine phosphorylation of HMGB1 is necessary for nucleocytoplasmic shuttling before
its cellular release, the protein kinases involved have not been identified. To investigate if calcium/calmodulin-dependent protein
kinase (CaMK) IV serine phosphorylates and mediates the release of HMGB1 from macrophages (M) stimulated with LPS,
RAW 264.7 cells or murine primary peritoneal M were incubated with either STO609 (a CaMKIV kinase inhibitor), KN93 (a
CaMKIV inhibitor), or we utilized cells from which CaMKIV was depleted by RNA interference (RNAi) before stimulation with
LPS. We also compared the LPS response of primary M isolated from CaMKIV/ and CaMKIV/ mice. In both cell types
LPS induced activation and nuclear translocation of CaMKIV, which preceded HMGB1 nucleocytoplasmic shuttling. However,
M treated with KN93, STO609, or CaMKIV RNAi before LPS showed reduced nucleocytoplasmic shuttling of HMGB1 and
release of HMGB1 into the supernatant. Additionally, LPS induced serine phosphorylation of HMGB1, which correlated with an
interaction between CaMKIV and HMGB1 and with CaMKIV phosphorylation of HMGB1 in vitro. In cells, both HMGB1
phosphorylation and interaction with CaMKIV were inhibited by STO609 or CaMKIV RNAi. Similarly, whereas CaMKIV/
M showed serine phosphorylation of HMGB1 in response to LPS, this phosphorylation was attenuated in CaMKIV/ M.
Collectively, our results demonstrate that CaMKIV promotes the nucleocytoplasmic shuttling of HMGB1 and suggest that the
process may be mediated through CaMKIV-dependent serine phosphorylation of HMGB1. The Journal of Immunology, 2008,
181: 5015–5023.
H igh-mobility group box 1 (HMGB1)4 was initially iden-tified as an architectural chromatin-binding factor thatbends DNA and directs protein assembly on specific
DNA targets. Recently it has been demonstrated to function as a
proinflammatory cytokine and late mediator of mortality in murine
endotoxemia and sepsis (1–3). HMGB1 appeared 8 h poststimu-
lation and plateaued at 16–32 h, a time course very distinct from
the acute rise and fall of early mediators of severe sepsis and septic
shock (TNF-, IL-1) (3). Recombinant HMGB1 mimicked the
lethality of high-dose LPS and induced the release of TNF- by
macrophages (M) (3). Anti-HMGB1 Abs conferred a dose-de-
pendent protection in animal models of endotoxemia, even when
the first dose of anti-HMGB1 Abs was delayed for at least 2 h (2,
3). Human studies have revealed that systemic HMGB1 levels are
markedly elevated in patients that die of sepsis and during hem-
orrhagic shock (4, 5).
In the context of sepsis, current data indicate that HMGB1 is
released by activated monocytes and M via an active process
that involves shuttling the protein from nucleus to cytoplasm (3,
6, 7). Acetylation of HMGB1 and of the histones to which it
binds appears to be essential for its release (8). HMGB1 con-
tains two nuclear localization signals (NLS) and two putative
nuclear export signals, suggesting that HMGB1 shuttles be-
tween the nucleus and cytoplasm through a tightly controlled
mechanism (6). Recently, serine phosphorylation has been dem-
onstrated to be a requisite step for this process, although neither
the kinase nor the mechanisms controlling nucleocytoplasmic
shuttling have been identified (9). Considering the data suggest-
ing that HMGB1 may serve as a target to reduce mortality from
sepsis, identifying the mechanisms responsible for inducing and
controlling its release is important.
We have recently demonstrated the integral role for members of
the family of multifunctional calcium/calmodulin-dependent pro-
tein kinases (CaMKI, II, IV) in the release of HMGB1 by hepa-
tocytes subjected to oxidant stress and hepatocellular injury in an
in vivo model of hepatic ischemia/reperfusion, although we have
yet to identify the specific members involved (10). The multifunc-
tional CaMKs are serine/threonine kinases sensitive to changes in
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intracellular [Ca2] that coordinate a variety of cellular functions,
including gene expression, cell cycle progression, apoptosis,
differentiation, and ischemic tolerance (11, 12). Whereas isoforms
of CaMKI and CaMKII are expressed in all mammalian cells,
CaMKIV is present in only selective tissues, which include the
bone marrow (13). CaMKIV is activated and translocates into
the nucleus upon its phosphorylation by an upstream CaMKK in
the cytoplasm (14, 15). The nuclear, autonomously active form
of CaMKIV phosphorylates a number of proteins involved in
the regulation of transcription (16). Additionally, it has recently
been shown that CaMKIV is a component of a signaling cas-
cade initiated by LPS activation of TLR4 that facilitates sur-
vival of dendritic cells by phosphorylating CREB and regulat-
ing expression of the Bcl-2 gene (17). These observations
suggested to us that CaMKIV would be an attractive candidate
kinase to phosphorylate HMGB1 in macrophages and facilitate
its translocation from nucleus to cytoplasm in response to LPS.
Materials and Methods
Reagents
Escherichia coli 0111:B4 LPS was obtained from Sigma-Aldrich. KN93,
obtained from Calbiochem, was dissolved in sterile DMSO at a concen-
tration of 10 mM. STO690 was obtained from Calbiochem. STO609 is
selective for CaMKK: it has an in vitro IC50 of 0.13–0.38 M for CaMKK
and 32 M for CaMKII with little or no inhibition of CaMKI, CaMKIV,
protein kinase A, protein kinase C, ERK, or myosin light chain kinase (18).
mAb against autonomously active, Thr196-phosphorylated CaMKIV (anti-
p-Thr196-CaMKIV) was the generous gift of Dr. Naohito Nozaki (Kana-
gawa, Japan). Abs against total CaMKIV and HMGB1 were obtained from
Abcam. Ab against phosphoserine was obtained from Promega. Ab against
FLAG epitope was obtained from Sigma-Aldrich. DAPI was obtained from
Molecular Probes.
Cell isolation and treatment
Murine monocyte/macrophage-like cells (RAW 264.7, American Type
Culture Collection) were grown in DMEM (BioWhittaker) supplemented
with 10% FCS (Sigma-Aldrich), 50 U/ml penicillin, and 50 g/ml strep-
tomycin (Cellgro/Mediatech). Primary murine peritoneal M were isolated
by lavaging the peritoneal cavity with five 3-ml aliquots of sterile PBS.
After centrifugation at 300  g for 10 min, the M were resuspended in
RPMI 1640 with 10% FCS, 50 U/ml penicillin, and 50 g/ml streptomycin.
Selected cells were pretreated with varying concentrations of KN93 (5, 10,
20 M) or STO609 (1, 2, 5, 10, 20 M) for 1 h or subjected to RNA
interference (RNAi) using nontarget or CaMKIV small interfering RNA
(siRNA) (see below). Selected cells were then treated with increasing doses
of LPS (1, 10, 100 ng/ml).
Transfection of fluorescein-labeled cyclophilin, nontarget, and
CaMKIV siRNA
RAW 264.7 cells (2 104) or murine peritoneal M (1 105) were plated
in 0.5 ml of growth medium (without antibiotics) in each well of a 24-well
FIGURE 1. LPS activates CaMKIV.
A, RAW 264.7 cells were treated with
LPS (10 ng/ml) for the durations of 15,
30, 60, and 120 min, at which time total
cell lysate was harvested, subjected to
immunoblot analysis, and probed for
p-Thr196-CaMKIV. Parallel popula-
tions were treated with STO609 (5
M) for 1 h before LPS stimulation
and subjected to similar immunoblot
analysis. Each blot was stripped and re-
probed with anti-CaMKIV Ab to con-
firm equal loading. Representative blot
of three individual experiments. B,
Densitometry represents means 
SEM OD of individual p-Thr196-
CaMKIV immunoblots (n 3); , p
0.05 vs control, unstimulated cells. C,
Murine peritoneal M were exposed to
similar experimental conditions, and
p-Thr196-CaMKIV and total CaMKIV
were assessed by SDS-PAGE as previ-
ously described. Representative blot of
three individual experiments. D, Densi-
tometry represents means  SEM OD
of individual p-Thr196-CaMKIV immu-
noblots (n 3); , p 0.05 vs control,
unstimulated cells.
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plate, resulting in 30% or 80% confluence, respectively. Fluorescein-la-
beled cyclophilin control siRNA, nontarget siRNA, and CaMKIV siRNA
obtained from Dharmacon were added to 50 l serum-free DMEM in a
final concentration of 25 nM. We utilized the SMARTpool siRNA from
Dharmacon that incorporates four separate siRNA sequences for CaMKIV:
5-GAGAUCCUCUGGGCGAUUUUU3-, 5-UCAAGGAAAUAUUC-
GAAACUU3-, 5-GGUGCUACAUCCAUUGUGUUU3-, and 5-GG-
GAUGAAGUGUCUUUAAAUU3-. In a separate tube, 3 l HiPerFect
was diluted in 50 l serum-free DMEM and incubated at room temperature
for 5 min. These two solutions were combined, and the final transfection
mixture was incubated for 20 min at room temperature. This transfection
mixture was applied to each well and incubated for 6 h, after which it was
replaced by 500 l of cell medium and incubated for 72 h. Transfection
efficiency was determined at 24 h by fluorescence microscopy. For each
experiment at least three microscopic visual fields (200 magnification)
were counted to facilitate calculation of the ratio of fluorescent cyclophilin-
expressing cells to nonfluorescent cells. Inhibition of each targeted protein
was determined by immunoblot or RT-PCR. All experiments and cell num-
ber determinations were performed in triplicate.
Plasmid construction and transfection
Plasmids encoding a constitutively active CaMKIV (CaMKIV-dCT) or a
kinase-inactive CaMKIV-dCTK75E mutant were the generous gifts of
Dr. Douglas Black (19). CaMKIV-dCT contains a C-terminally trun-
cated version of the human CaMKIV-encoding gene, truncated to
Leu317, and an N-terminal FLAG epitope (19, 20). CaMKIV-dCTK75E
was constructed by changing Lys75 to glutamate in CaMKIV-dCT,
which negatively affects ATP binding at the catalytic site (19, 20). For
transient transfection, RAW 264.7 cells were seeded in a 24-well plate
at 3  105 cells/well. After 2 h of adhesion, M were transfected with
1 g of plasmid CaMKIV-dCT or CaMKIV-dCTK75E using the Lipo-
fectamine 2000 reagent according to the instructions specified by the
manufacturer (Invitrogen). Following transfection, cells were handled
as detailed in the figure legends.
Cellular protein extraction
Total cellular protein was extracted at 4°C in 500 l of lysis buffer (20 mM
Tris, 137 mM NaCl, 2 mM EDTA, 10% glycerol, 1% Triton X-100, 1 M
sodium orthovanadate, 100 M DTT, 200 M PMSF, 10 g/ml leupeptin,
0.15 U/ml aprotinin, 50 mM sodium fluoride, 10 mM sodium pyrophos-
phate, 2.5 g/ml pepstatin A, 1 mM benzamidine, and 40 mM -glycer-
ophosphate). Protein concentration was determined using a bicinchoninic
acid protein assay (Pierce).
Nuclear and cytoplasmic protein isolation
Cells were harvested and washed with PBS, followed by centrifugation at
300  g for 10 min. The cell pellet was lysed with NE-PER nuclear and
cytoplasmic extraction reagent according to the instructions specified by
the manufacturer (Thermo Scientific).
Immunoprecipitation
Equal amounts of cellular protein obtained from each experimental condition
were used for immunoprecipitation. Five microliters of Ab was added to 500
FIGURE 2. CaMK kinase cascade mediates LPS-induced HMGB1 re-
lease. A, RAW 264.7 cells were treated with LPS (100 ng/ml) for 16 h, at
which time cellular supernatant was harvested, subjected to immunoblot
analysis, and probed for HMGB1. Parallel populations were pretreated
with STO609 (5 M) for 1 h before LPS stimulation and subjected to
similar immunoblot analysis. Representative blot of three individual ex-
periments. B, RAW 264.7 cells were subjected to similar conditions as
described above. Cell viability was evaluated by MTT assay and is shown
as means  SEM fold change relative to control, untreated cell population
(n  4). C, Murine peritoneal M were isolated and treated with LPS and
STO609 as previously described. The supernatant was harvested, subjected
to Western blot analysis, and probed for HMGB1. Representative blot of
three individual experiments.
FIGURE 3. CaMKIV mediates LPS-induced
HMGB1 release. A, RAW 264.7 cells were
transfected with fluorescent cyclophilin B
siRNA for 24 h and imaged by confocal micros-
copy. Transfection efficiency was determined by
determining the ratio of fluorescent cells to total
number of cells. B, RAW 264.7 cells were trans-
fected with either nontarget (NT) or CaMKIV
siRNA for 72 h, at which time total cell lysate
was harvested, subjected to immunoblot analysis,
and probed for CaMKIV. Representative blots of
three individual experiments. C, RAW 264.7 cells
were transfected with either NT or CaMKIV
siRNA for 72 h and then stimulated with LPS (100
ng/ml) for 16 h. The supernatant was harvested,
subjected to immunoblot analysis, and probed for
HMGB1. Representative blots of three individual
experiments. D, RAW 264.7 cells were subjected
to similar conditions as described above. Cell via-
bility was evaluated by MTT assay and is shown as
means  SEM fold change relative to control, un-
treated NT cell population (n  4).
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g of isolated cellular protein within lysis buffer and incubated at 4°C over-
night on a rotator. Fifty microliters of 50% slurry of prewashed protein G-
agarose beads (Abcam) were then added to each sample, followed by incuba-
tion for an additional 2 h at 4°C. The samples were spun briefly in a
microcentrifuge at 14,000 rpm and washed four times in lysis buffer. Samples
were then resuspended in 30 l of lysis buffer for future analysis.
FIGURE 4. Spatial and temporal
relationship of LPS-induced CaMKIV
Thr196 phosphorylation and HMGB1
nucleocytoplasmic shuttling. A, RAW
264.7 cells were stimulated with LPS
(100 ng/ml) for 15 min and 1, 2, and
8 h, at which time they were fixed,
permeabilized, stained for HMGB1
(green) or p-Thr196-CaMKIV (red),
and imaged by confocal microscopy
at 630. Green, HMGB1; red,
p-Thr196-CaMKIV; blue, DAPI. Rep-
resentative image of three individual
experiments. B, RAW 264.7 cells
were subjected to similar conditions
as described above, stained for total
CaMKIV, and imaged by confocal
microscopy at 630. Red, CaMKIV;
blue, DAPI. Representative image of
three individual experiments.
FIGURE 5. CaMKIV mediates
HMGB1 nucleocytoplasmic shuttling.
A, RAW 264.7 cells underwent RNAi
using nontarget (NT) siRNA or
CaMKIV siRNA. Cells were stimu-
lated with LPS (100 ng/ml) for 8 h
and then fixed, permeabilized, stained
for HMGB1 (green), and imaged by
confocal microscopy at 630. Green,
HMGB1; blue, DAPI. Representative
image of three individual experi-
ments. B, RAW 264.7 cells were sub-
jected to STO609 (5 M) or KN93
(10 M) or underwent NT or
CaMKIV RNAi before stimulation
with LPS (100 ng/ml) as detailed
above. Nuclear and cytoplasmic pro-
tein were isolated, subjected to immu-
noblot analysis, and probed for
HMGB1. Representative blots of
three separate experiments.
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Immunoblots
Total cellular protein was electrophoresed in a 10% SDS-PAGE gel and
transferred to a Hybond ECL nitrocellulose membrane (Amersham Phar-
macia Biotech). The membrane was blocked for 1 h at room temperature
with 5% milk and was then incubated with primary Ab for 12 h at 4°C.
Blots were then incubated in a HRP-conjugated secondary Ab against the
primary Ab at room temperature for 1 h. The blot was developed using the
SuperSignal chemiluminescent substrate (Pierce) and exposed on KAR-5
film (Eastman Kodak). In addition to utilizing the primary anti-threonine
phosphorylated (Thr196) CaMKIV Ab, the active threonine phosphorylated
form of CaMKIV was determined using CaMK-immunoprecipitated pro-
tein. Densitometry was performed by the National Institutes of Health (Be-
thesda, MD) image program to quantify OD.
Immunocytochemistry and confocal microscopy
Cells were cultured on glass coverslips until 80% confluent. The coverslips
were washed in PBS and fixed for 20 min in 4% paraformaldehyde in PBS
at 4°C. Cells were permeabilized with 5% BSA, 0.1% Triton X-100 for 1 h
at 4°C and then stained with the appropriate Ab (1 g/ml) overnight at 4°C.
Cells were further treated with anti-rabbit IgG conjugated with FITC (1/
1000), anti-mouse IgG conjugated with tetramethylrhodamine isothiocya-
nate (1/1000), and DAPI (5 mg/ml) in 5% nonfat milk for an additional 2 h
at room temperature. The cells were then washed four times with PBS,
mounted with Gel/Mount (Biomeda) and examined by confocal
microscopy.
In vitro kinase assay
Recombinant HMGB1 (1 g) was incubated in the presence or absence of
activated p-Thr196-CaMKIV (25 ng) for 10 min at 30°C with the following
additions: 10 mM MgCl2, 0.2 mM ATP, 1 mM CaCl2, and 1 M CaM.
Reactions were terminated by boiling in SDS-2-ME dissociation solution,
subjected to 10% SDS-PAGE, and probed with anti-phosphoserine, anti-
CaMKIV, or anti-HMGB1 Ab.
Cell viability and morphologic features
Representative cell populations from each condition were examined under
light microscopy. Cell viability was also confirmed by MTT assay. Cells
were incubated in 96-well plates (Costar). After a 24-h incubation in 100
l RPMI 1640 medium containing the stimulus, 50 l of a 5 mg/ml MTT
(Sigma-Aldrich) solution in PBS was added, and cells were incubated at
37°C for 2 h. The cells were then lysed by addition of 100 l per well
extraction buffer (20% (w/v) SDS, 50% (v/v) N,N-dimethyl formamide, 2%
(v/v) acetic acid (pH 4.7)). After overnight incubation with extraction
buffer, the OD at 562 nm was measured.
Statistic analysis
Values are expressed as means  SEM. Groups are compared by Mann-
Whitney. A p value of 0.05 was considered statistically significant.
FIGURE 6. CaMKIV mediates serine phorpho-
rylation of HMGB1. A, RAW 264.7 cells were stim-
ulated with LPS (100 ng/ml) for 15 min and 1, 2,
and 4 h, at which point total cell lysate was har-
vested, immunoprecipitated for HMGB1, subjected
to immunoblot analysis, and probed for phosphory-
lated serine residues. Each membrane was stripped
and probed with anti-HMGB1 Ab to confirm equal
loading. B, Murine peritoneal M were stimulated
with LPS (100 ng/ml) for 2 h either in the presence
or absence of STO609 (5 M) or after CaMKIV
RNAi. Total cell lysate was harvested, immunopre-
cipitated for HMGB1, subjected to immunoblot
analysis, and probed for phosphorylated serine res-
idues. Each membrane was stripped and probed with
anti-HMGB1 Ab to confirm equal loading. C, Den-
sitometry represents means  SEM OD of individ-
ual phosphoserine HMGB1 immunoblots (n 4); ,
p 0.05 vs LPS stimulated M; #, p 0.05 vs LPS
stimulated nontarget RNAi M. D, Peritoneal M,
isolated from CaMKIV/ or CaMKIV/ mice,
were exposed to LPS 100 ng/ml for 2 h, at which
point total cell lysate was harvested, immunopre-
cipitated for phosphoserine, subjected to immuno-
blot analysis, and probed for HMGB1.
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Results
LPS activates CaMKIV
The phosphorylation of CaMKIV on Thr196 generates an autono-
mously active p-CaMKIV (11). We first established the time
course for CaMKIV activation in RAW 264.7 cells following LPS
stimulation. LPS activated CaMKIV, with Thr196 phosphorylation
occurring at 15 min and returning toward baseline by 60 min after
stimulation (Fig. 1A). Upstream inhibition of CaMKIV kinase with
STO609 prevented CaMKIV phosphorylation (Fig. 1A). We did
observe two bands in our assessment of CaMKIV phosphorylation,
and two CaMKIV isoforms have been described (21). This time
course of CaMKIV phosphorylation was consistent across all in-
dependent experiments, yielding a mean CaMKIV activation time
course that peaked 15–30 min after LPS (Fig. 1B). We repeated
these experiments with primary peritoneal M. LPS induced
Thr196 phosphorylation of CaMKIV within 15–30 min (Fig. 1C).
However, even at 60 min after LPS exposure, CaMKIV remained
phosphorylated (Fig.1, C and D). Again, CaMKIV activation was
dependent upon CaMKIV kinase, as inhibition with STO609
markedly reduced the LPS-induced increase in p-Thr196-CaMKIV
(data not shown).
The CaM kinase cascade mediates LPS-induced HMGB1
release
Consistent with previous studies, we found that LPS induced the
release of HMGB1 by RAW 264.7 cells, with detectable concen-
trations of supernatant HMGB1 occurring as early as 8 h (data not
shown) and peaking at 16 h after LPS stimulation as shown (Fig.
2A, lanes 1 and 2). Incubation with STO609 markedly reduced
supernatant HMGB1 concentration (Fig. 2A, lane 3). As shown in
Fig. 2B, the HMGB1 release was not due to differential cell death
since similar cell viability was observed for treated cell populations.
We confirmed that the CaM kinase cascade also mediated LPS-
induced HMGB1 release in primary peritoneal M. Similar to
RAW 264.7 cells, LPS induced HMGB1 release by peritoneal M
that was inhibited by upstream CaM kinase inhibition with
STO609 (Fig. 2C).
CaMKIV mediates LPS-induced HMGB1 release
The previous observations suggested that the CaM kinase cascade
is integral to LPS-induced M HMGB1 release. We utilized RNAi
to study the individual role of downstream CaMKIV in these
events. As determined by fluorescent microscopy, cell transfection
with fluorescent cyclophilin B siRNA was efficacious (Fig. 3A)
and, as determined by SDS-PAGE, CaMKIV RNAi markedly re-
duced CaMKIV expression (Fig. 3B). Control, nontarget RNAi-
treated cells released HMGB1 in response to LPS similar to un-
treated RAW 264.7 cells and peritoneal M (Fig. 3C, lanes 1 and
2). By contrast, CaMKIV RNAi almost completely inhibited LPS-
induced HMGB1 release (Fig. 3C, lanes 3 and 4). The effects of
CaMKIV RNAi were not related to cell death, as the MTT assay
demonstrated similar viability for all cells regardless of how they
were treated (Fig. 3D).
CaMKIV mediates nuclear export of HMGB1 after LPS
stimulation
HMGB1 release is an active process by which HMGB1 is shuttled
from nucleus to cytoplasm and then out of the cell. Because most
FIGURE 7. CaMKIV directly
serine phosphorylates HMGB1. A,
RAW 264.7 cells were stimulated
with LPS (100 ng/ml) either in the
presence or absence of STO609 (5
M) for 1, 2, and 4 h, at which point
total cell lysate was harvested, immu-
noprecipitated for HMGB1, subjected
to immunoblot analysis, and probed
for CaMKIV. Representative blots of
three separate experiments. B, Re-
combinant HMGB1 (1 g) was incu-
bated in the presence or absence of
activated p-Thr196-CaMKIV (25 ng)
for 10 min at 30°C with the following
additions: 10 mM MgCl2, 0.2 mM
ATP, 1 mM CaCl2, and 1 M CaM.
Reactions were terminated by boiling
in SDS-2-ME dissociation solution,
subjected to 10% SDS-PAGE, and
probed with anti-phosphoserine Ab.
Representative blots of three separate
experiments.
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of the identified functions of CaMKIV occur within the nucleus,
we hypothesized that CaMKIV plays an integral role in the trans-
location of HMGB1 from nucleus to cytoplasm. We initially ex-
plored the spatial and temporal relationships of CaMKIV phos-
phorylation and HMGB1 release. As shown in Fig. 4A, HMGB1
(green) is predominantly intranuclear under basal, unstimulated
conditions (Fig. 4A, top row). Within 120 min of LPS stimulation,
HMGB1 is observed within the cytoplasm and continues to in-
crease within the cytoplasm over the ensuing 8 h (Fig. 4A, top
row). Unstimulated RAW 264.7 cells demonstrate minimal
CaMKIV Thr196 phosphorylation (red), but within 15 min of LPS
stimulation, phosphorylation increases and continues to increase
with time, peaking at 120 min after LPS stimulation (Fig. 4A,
middle row). Although some active CaMKIV is apparent within
the cytoplasm, most of this p-Thr196-CaMKIV seems to be con-
centrated within the nucleus. This localization appears to result
from translocation of active CaMKIV to the nucleus as demon-
strated by the increased fluorescence of both p-Thr196-CaMKIV
(Fig. 4A, middle row) and total CaMKIV (Fig. 4B, top row) within
the nucleus after LPS stimulation. Inhibition of CaMKIV kinase
with STO609 inhibits the Thr196 phosphorylation of CaMKIV and
the translocation of HMGB1 to the cytoplasm (Fig. 4A, last
column).
To confirm that this translocation process was CaMKIV depen-
dent, we conducted similar experiments using cells treated with
CaMKIV RNAi. RAW 264.7 cells transfected with control, non-
target siRNA demonstrated nucleocytoplasmic shuttling of
HMGB1 (green) at 8 h after LPS stimulation (Fig. 5A, left). On the
other hand, CaMKIV RNAi inhibited LPS-induced HMGB1 trans-
location with strong nuclear and minimal cytoplasmic staining of
HMGB1 at 8 h after LPS stimulation (Fig. 5A, right). This inhi-
bition was similar to that induced by pretreatment with the
CaMKIV kinase inhibitor STO609 (Fig. 4A, last column).
We confirmed these immunofluorescent microscopic observa-
tions by analyzing the HMGB1 concentration of nuclear and cy-
toplasmic protein isolated from M subjected to similar conditions
as detailed above. As shown in Fig. 5B, LPS induced the translo-
cation of HMGB1 from the nucleus to the cytoplasm. By compar-
ison to LPS-stimulated M, there was a significant reduction in
HMGB1 translocation to the cytoplasm in response to either KN93
(which inhibits CaMKIV) or STO609 (which inhibits CaMKIV
kinase) (Fig. 5B). Similarly, by comparison to control, nontarget
RNAi, CaMKIV RNAi reduced the LPS-induced nucleocytoplas-
mic shuttling of HMGB1 (Fig. 5B). These results confirm our idea
that a CaMKK/CaMKIV cascade regulates LPS-induced nuclear-
to-cytoplasmic translocation of HMGB1.
CaMKIV directly serine phosphorylates HMGB1 after LPS
stimulation
Our results demonstrate that CaMKIV mediates LPS-induced
HMGB1 release, in part, through processes guiding the nuclear
exportation of HMGB1. Recently, HMGB1 translocation to the
cytoplasm has been demonstrated to require serine phosphoryla-
tion within its NLSs (9). We first confirmed that LPS induced
serine phosphorylation of HMGB1. As shown in Fig. 6A, stimu-
lation of RAW 264.7 cells with LPS results in serine phosphory-
lation of HMGB1 within 2 h. Additionally, this phosphorylation
event may require CaMKIV, as preincubation of primary perito-
neal M with STO609 inhibited LPS-induced serine phosphory-
lation of HMGB1 (Fig. 6B). Similarly, CaMKIV RNAi treatment
of M also reduced LPS-induced HMGB1 serine phosphorylation
(Fig. 6B), and the mean degree of inhibition determined by den-
sitometry is illustrated in Fig. 6C. Finally, we compared the degree
of serine phosphorylated HMGB1 in peritoneal M isolated from
either CaMKIV/ or CaMKIV/ mice. As shown in Fig. 6D,
control CaMKIV/ M show serine phosphorylation of HMGB1
after LPS stimulation, whereas the extent of this induced HMGB1
phosphorylation is reduced in CaMKIV/ M.
Our immunocytochemistry data suggest colocalization of
CaMKIV and HMGB1 after LPS stimulation, and thus we inves-
tigated whether CaMKIV interacts with HMGB1. As shown in
Fig. 7A, LPS stimulation markedly increased the degree to which
HMGB1 coimmunoprecipitated with CaMKIV. One hour after
stimulation with LPS, CaMKIV and HMGB1 coimmunoprecipi-
tation was markedly increased and peaked by 2 h. Reciprocal co-
immunoprecipitation experiments yielded similar results (data not
shown). These LPS-stimulated interactions likely require the phos-
phorylation and activation of CaMKIV, as preincubation of cells
with STO609 before addition of LPS inhibited the coimmunopre-
cipitation of HMGB1 with CaMKIV (Fig. 7A).
To determine whether CaMKIV could directly serine phosphor-
ylate HMGB1 we conducted in vitro kinase assays. Active
p-Thr196-CaMKIV was unable to phosphorylate HMGB1 in the
absence of Mg2/ATP (Fig. 7B, lane 1). Similarly, in the absence
of p-Thr196-CaMKIV, there was minimal serine phosphorylation
of HMGB1 (Fig. 7B, lane 2). However, activated p-Thr196-
CaMKIV, in combination with Mg2/ATP, was able to serine
phosphorylate HMGB1 (Fig. 7B, lane 4).
FIGURE 8. Active CaMKIV is sufficient for HMGB1 release. A, RAW
264.7 cells were transfected with either a constitutively active CaMKIV-
dCT or a kinase-dead mutant CaMKIV-dCTK75E. Eight hours later, total
cell lysate or nuclear protein was isolated, resolved by SDS-PAGE, and
probed for kinase expression using an anti-FLAG Ab. Representative blots
of three separate experiments. B, RAW 264.7 cells were transfected with
the indicated kinase construct as detailed above. After 24 h, the supernatant
was harvested, resolved by SDS-PAGE, and probed with an anti-HMGB1
Ab. Representative blots of three separate experiments. C, Densitometry
represents means  SEM OD of individual supernatant HMGB1 immu-
noblots (n  3); , p  0.03 vs CaMKIV-dCTK75E.
5021The Journal of Immunology
Active CaMKIV is sufficient for HMGB1 release
To assess whether active CaMKIV is sufficient for HMGB1 re-
lease, we transfected RAW 264.7 cells with plasmids expressing
either a truncated, constitutively active form of CaMKIV
(CaMKIV-dCT) or a similarly truncated kinase-inactive mutant of
CaMKIV (CaMKIV-dCTK75E). Both plasmids were successfully
transfected and expressed, although expression of the active
CaMKIV-dCT was greater than that of CaMKIV-dCTK75E (Fig.
8A), confirming previously published observations that substitu-
tions that disrupt kinase activity, including K75E, result in less
protein expression in mammalian cells compared with wild-type
CaMKIV-dCT (Fig. 8A) (20). As shown in Fig. 8B, expression of
the active CaMKIV-dCT induced the secretion of HMGB1 from
the cells, whereas CaMKIV-dCTK75E failed to do so (Fig. 8B).
This 6-fold induction of HMGB1 release in response to CaMKIV-
dCT was highly reproducible in three independent experiments
(Fig. 8C).
Discussion
During sepsis, perturbations in cellular calcium homeostasis are
postulated to mediate the aberrant inflammation underlying organ
dysfunction and death (22, 23). Recently, HMGB1, an architec-
tural chromatin-binding factor that bends DNA and directs protein
assembly on specific DNA targets, has been demonstrated to func-
tion as a late mediator of mortality in murine endotoxemia and
sepsis (1–3). Monocytes and M have been demonstrated to be a
primary source of HMGB1, and evidence is accumulating that pro-
duction of this inflammatory mediator is Ca2 dependent. Herein,
we characterize that LPS-induced HMGB1 release is mediated by
a Ca2-dependent signaling cascade involving a CaMKIV kinase
and CaMKIV. Our data suggest that this series of reactions may
terminate in the nucleus where CaMKIV phosphorylates HMGB1,
an event that is required to facilitate the translocation of HMGB1
from nucleus to cytoplasm (24).
Substantial work has been conducted to elucidate the mecha-
nisms by which HMGB1 is released, in part, because interventions
that inhibit systemic HMGB1 concentrations reduce mortality in
murine models of sepsis (2). Current data support an active process
initiated by HMGB1-histone disengagement, HMGB1 hyperacety-
lation, and shuttling of the protein from nucleus to cytoplasm (6).
Recently, serine phosphorylation of HMGB1 has been demon-
strated to be essential for this translocation event, although the
kinase responsible had not been identified (9). We hypothesized
that CaMKIV mediates this process, in part, because this enzyme
has been shown to function downstream of TLR4 in the pathway
by which LPS induces the Ca2-dependent survival of dendritic
cells (17). Additionally, prior studies demonstrated that activation
of CaMKIV by Ca2/CaM and threonine phosphorylation (Thr196
in mice, Thr200 in humans) by an upstream CaMK kinase generates
increased and autonomous CaMKIV activity that enables the ki-
nase to translocate to the nucleus where it modulates gene expres-
sion (11, 25, 26).
Indeed, our data demonstrate that LPS induces this Thr196-phos-
phorylated and autonomous species of CaMKIV in M, which
then enters the nucleus where it interacts with and phosphorylates
HMGB1. The evidence to support this contention is as follows: 1)
CaMKIV translocation to the nucleus preceded HMGB1 translo-
cation to the cytoplasm; 2) CaMKIV RNAi reduced cytoplasmic
HMGB1 concentration by retaining HMGB1 in the nucleus; 3)
CaMKIV coimmunoprecipitated with HMGB1 in response to LPS;
and 4) activated CaMKIV directly phosphorylated HMGB1 in in
vitro kinase assays. The modest degree of HMGB1 phosphoryla-
tion observed in our in vitro kinase assay suggests that, perhaps,
additional protein components may be necessary to assemble a
signaling complex that facilitates CaMKIV phosphorylation of
HMGB1. The minimum consensus CaMKIV substrate recognition
sequence Hyd-X-R-X-X-(S/T) provides only a rough template for
CaMKIV-mediated phosphorylation. In HMGB1 only Ser39 and
Ser46 in NLS1 meet the hydrophobic requirement at the 5 posi-
tion amino acid, and Ser46 carries a lysine substitution at 3,
which is also present in the well-characterized substrate oncopro-
tein 18 (27).
Interestingly, HMGB1 has two NLS sequences, and current ev-
idence suggests that phosphorylation of both sequences is impor-
tant for the cytoplasmic localization of HMGB1 (9). Our data sup-
port a role for CaMKIV in the mechanism that controls the nuclear
export of HMGB1 (9). Regarding this mechanism, Bianchi et al.
contend that the strength of HMGB1-histone binding is inversely
related to the histone acetylation status, and that increased histone
acetylation may enable HMGB1-histone disengagement and sub-
sequent cellular release of HMGB1 (6, 8). The CaMKs have been
demonstrated to modulate the nuclear export of various class II
histone deacetylases HDAC4 and HDAC5, a process that could
favor histone acetylation (28–31). Additionally, HMGB1 requires
direct hyperacetylation before export from the nucleus (8). Further
investigation of how CaMKIV activation and histone and HMGB1
acetylation are related will be an important aspect of future studies
on HMGB1 nuclear export.
Although LPS stimulation of TLR4 can clearly activate
CaMKIV, as shown here and in a prior study, the signaling events
that occur between receptor ligation and CaMKIV activation have
yet to be determined (17). Prior studies have established the de-
pendency of monocyte/M function on Ca2 transients and CaM
activation, and although it remains unclear precisely how the Ca2
transients are generated, the multifunctional CaMKs respond to
relatively small changes in intracellular [Ca2] (32). Regarding
CaMKIV activation and generation of autonomous activity, pub-
lished data have established a requirement for binding of the Ca2/
CaM complex to both CaMKK and CaMKIV (11, 12, 25). We note
the presence of nuclear and cytoplasmic activated CaMKIV in
resting cells and an increasing concentration of activated and total
CaMKIV within the nucleus after LPS stimulation. These obser-
vations support a LPS-mediated increase in the cytoplasmic Ca2
signal that is sufficient to activate CaMKIV and induce its nuclear
translocation. Alternatively, it is possible that CaMK may be ac-
tivated by reactive oxygen species in the absence of a Ca2 rise.
For example, Howe et al. suggested that IB phosphorylation in
lymphocytes in response to hydrogen peroxide is mediated by
Ca2-independent activation of CaMKs (33, 34). Hence, addi-
tional studies are necessary to determine the spatiotemporal pat-
terns of Ca2 signaling and CaMKIV activation following LPS
stimulation as well as the TLR4 dependence of such events.
In summary, CaMKIV kinase/CaMKIV mediates M LPS-in-
duced HMGB1 production by translocating to the nucleus after
activation and phosphorylating HMGB1 in a manner that enables
nuclear export of HMGB1 that must occur in order for the protein
to be secreted from the cell. The combined observations of inves-
tigations conducted by our laboratories and those of others are
beginning to highlight the integral role of the CaMK transduction
cascade in M function and cytokine production and inflamma-
tion. Future studies will elucidate the sites on both proteins that
participate in the CaMKIV-HMGB1 interaction and serine phos-
phorylation of HMGB1. Interestingly, precedent exists for
CaMKIV forming a stable complex with PP2A that is competitive
with Ca2/CaM and CaMKK, one of the two CaMKKs that has
been shown to form stable complexes with CaMKIV and PP2A or
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AMPK (15, 35). In the latter but not the former case, the interac-
tion requires the “RP” domain of CaMKK (35). Perhaps,
HMGB1 will also utilize a unique sequence of CaMKK to form
a complex. At any rate, these combined observations suggest that
modulation of CaMKK and/or CaMKIV activity may be of poten-
tial utility in diseases characterized by heightened and aberrant
inflammation.
Acknowledgments
Special thanks to Dr. Naohito Nozaki, who provided the monoclonal anti-
p-Thr196-CaMKIV Abs, and Dr. Douglas Black, who provided the
CaMKIV-dCT and CaMKIV-dCTK75E plasmids. Without the gracious
assistance of these individuals, a considerable portion of this work would
not be possible.
Disclosures
The authors have no financial conflicts of interest.
References
1. Wang, H., H. Yang, C. J. Czura, A. E. Sama, and K. J. Tracey. 2001. HMGB1
as a late mediator of lethal systemic inflammation. Am. J. Respir. Crit. Care Med.
164: 1768–1773.
2. Yang, H., M. Ochani, J. Li, X. Qiang, M. Tanovic, H. E. Harris, S. M. Susarla,
L. Ulloa, H. Wang, R. DiRaimo, et al. 2004. Reversing established sepsis with
antagonists of endogenous high-mobility group box 1. Proc. Natl. Acad. Sci. USA
101: 296–301.
3. Wang, H., O. Bloom, M. Zhang, J. M. Vishnubhakat, M. Ombrellino, J. Che,
A. Frazier, H. Yang, S. Ivanova, L. Borovikova, et al. 1999. HMG-1 as a late
mediator of endotoxin lethality in mice. Science 285: 248–251.
4. Angus, D. C., L. Yang, L. Kong, J. A. Kellum, R. L. Delude, K. J. Tracey, and
L. Weissfeld. 2007. Circulating high-mobility group box 1 (HMGB1) concen-
trations are elevated in both uncomplicated pneumonia and pneumonia with se-
vere sepsis. Crit. Care Med. 35: 1061–1067.
5. Ombrellino, M., H. Wang, M. S. Ajemian, A. Talhouk, L. A. Scher,
S. G. Friedman, and K. J. Tracey. 1999. Increased serum concentrations of high-
mobility-group protein 1 in haemorrhagic shock. Lancet 354: 1446–1447.
6. Bonaldi, T., F. Talamo, P. Scaffidi, D. Ferrera, A. Porto, A. Bachi, A. Rubartelli,
A. Agresti, and M. E. Bianchi. 2003. Monocytic cells hyperacetylate chromatin
protein HMGB1 to redirect it towards secretion. EMBO J. 22: 5551–5560.
7. Gardella, S., C. Andrei, D. Ferrera, L. V. Lotti, M. R. Torrisi, M. E. Bianchi, and
A. Rubartelli. 2002. The nuclear protein HMGB1 is secreted by monocytes via a
non-classical, vesicle-mediated secretory pathway. EMBO Rep. 3: 995–1001.
8. Scaffidi, P., T. Misteli, and M. E. Bianchi. 2002. Release of chromatin protein
HMGB1 by necrotic cells triggers inflammation. Nature 418: 191–195.
9. Youn, J. H., and J. S. Shin. 2006. Nucleocytoplasmic shuttling of HMGB1 is
regulated by phosphorylation that redirects it toward secretion. J. Immunol. 177:
7889–7897.
10. Tsung, A., J. R. Klune, X. Zhang, G. Jeyabalan, Z. Cao, X. Peng, D. B. Stolz,
D. A. Geller, M. R. Rosengart, and T. R. Billiar. 2007. HMGB1 release induced
by liver ischemia involves Toll-like receptor 4 dependent reactive oxygen species
production and calcium-mediated signaling. J. Exp. Med. 204: 2913–2923.
11. Soderling, T. R. 1999. The Ca-calmodulin-dependent protein kinase cascade.
Trends Biochem. Sci. 24: 232–236.
12. Braun, A. P., and H. Schulman. 1995. The multifunctional calcium/calmodulin-
dependent protein kinase: from form to function. Annu. Rev. Physiol. 57:
417–445.
13. Kitsos, C. M., U. Sankar, M. Illario, J. M. Colomer-Font, A. W. Duncan,
T. J. Ribar, T. Reya, and A. R. Means. 2005. Calmodulin-dependent protein
kinase IV regulates hematopoietic stem cell maintenance. J. Biol. Chem. 280:
33101–33108.
14. Lemrow, S. M., K. A. Anderson, J. D. Joseph, T. J. Ribar, P. K. Noeldner, and
A. R. Means. 2004. Catalytic activity is required for calcium/calmodulin-depen-
dent protein kinase IV to enter the nucleus. J. Biol. Chem. 279: 11664–11671.
15. Anderson, K. A., P. K. Noeldner, K. Reece, B. E. Wadzinski, and A. R. Means.
2004. Regulation and function of the calcium/calmodulin-dependent protein ki-
nase IV/protein serine/threonine phosphatase 2A signaling complex. J. Biol.
Chem. 279: 31708–31716.
16. Chow, F. A., K. A. Anderson, P. K. Noeldner, and A. R. Means. 2005. The
autonomous activity of calcium/calmodulin-dependent protein kinase IV is re-
quired for its role in transcription. J. Biol. Chem. 280: 20530–20538.
17. Illario, M., M. L. Giardino-Torchia, U. Sankar, T. J. Ribar, M. Galgani,
L. Vitiello, A. M. Masci, F. R. Bertani, E. Ciaglia, et al. 2008. Calmodulin-
dependent kinase IV links Toll-like receptor 4 signaling with survival pathway of
activated dendritic cells. Blood 111: 723–731.
18. Tokumitsu, H., H. Inuzuka, Y. Ishikawa, M. Ikeda, I. Saji, and R. Kobayashi.
2002. STO-609, a specific inhibitor of the Ca2/calmodulin-dependent protein
kinase kinase. J. Biol. Chem. 277: 15813–15818.
19. Xie, J., and D. L. Black. 2001. A CaMK IV responsive RNA element mediates
depolarization-induced alternative splicing of ion channels. Nature 410:
936–939.
20. Chatila, T., K. A. Anderson, N. Ho, and A. R. Means. 1996. A unique phospho-
rylation-dependent mechanism for the activation of Ca2/calmodulin-dependent
protein kinase type IV/GR. J. Biol. Chem. 271: 21542–21548.
21. Sun, Z., R. L. Means, B. LeMagueresse, and A. R. Means. 1995. Organization
and analysis of the complete rat calmodulin-dependent protein kinase IV gene.
J. Biol. Chem. 270: 29507–29514.
22. Zaloga, G. P., and B. Chernow. 1987. The multifactorial basis for hypocalcemia
during sepsis: studies of the parathyroid hormone-vitamin D axis. Ann. Intern.
Med. 107: 36–41.
23. Zaloga, G. P., A. Sager, K. W. Black, and R. Prielipp. 1992. Low dose calcium
administration increases mortality during septic peritonitis in rats. Circ. Shock 37:
226–229.
24. Sparatore, B., M. Passalacqua, M. Patrone, E. Melloni, and S. Pontremoli. 1996.
Extracellular high-mobility group 1 protein is essential for murine erythroleu-
kaemia cell differentiation. Biochem. J. 320: 253–256.
25. Tokumitsu, H., and T. R. Soderling. 1996. Requirements for calcium and cal-
modulin in the calmodulin kinase activation cascade. J. Biol. Chem. 271:
5617–5622.
26. Corcoran, E. E., and A. R. Means. 2001. Defining Ca2/calmodulin-dependent
protein kinase cascades in transcriptional regulation. J. Biol. Chem. 276:
2975–2978.
27. White, D. J., D. L. Maass, B. Sanders, and J. W. Horton. 2002. Cardiomyocyte
intracellular calcium and cardiac dysfunction after burn trauma. Crit. Care Med.
30: 14–22.
28. Miska, E. A., E. Langley, D. Wolf, C. Karlsson, J. Pines, and T. Kouzarides.
2001. Differential localization of HDAC4 orchestrates muscle differentiation. Nu-
cleic Acids Res. 29: 3439–3447.
29. Davis, F. J., M. Gupta, B. Camoretti-Mercado, R. J. Schwartz, and M. P. Gupta.
2003. Calcium/calmodulin-dependent protein kinase activates serum response
factor transcription activity by its dissociation from histone deacetylase, HDAC4:
implications in cardiac muscle gene regulation during hypertrophy. J. Biol. Chem.
278: 20047–20058.
30. Chawla, S., P. Vanhoutte, F. J. Arnold, C. L. Huang, and H. Bading. 2003.
Neuronal activity-dependent nucleocytoplasmic shuttling of HDAC4 and
HDAC5. J. Neurochem. 85: 151–159.
31. McKinsey, T. A., C. L. Zhang, J. Lu, and E. N. Olson. 2000. Signal-dependent
nuclear export of a histone deacetylase regulates muscle differentiation. Nature
408: 106–111.
32. Anderson, K. A., R. L. Means, Q. H. Huang, B. E. Kemp, E. G. Goldstein,
M. A. Selbert, A. M. Edelman, R. T. Fremeau, and A. R. Means. 1998. Com-
ponents of a calmodulin-dependent protein kinase cascade: molecular cloning,
functional characterization and cellular localization of Ca2/calmodulin-depen-
dent protein kinase kinase . J. Biol. Chem. 273: 31880–31889.
33. Howe, C. J., M. M. LaHair, J. A. Maxwell, J. T. Lee, P. J. Robinson,
O. Rodriguez-Mora, J. A. McCubrey, and R. A. Franklin. 2002. Participation of
the calcium/calmodulin-dependent kinases in hydrogen peroxide-induced IB
phosphorylation in human T lymphocytes. J. Biol. Chem. 277: 30469–30476.
34. Howe, C. J., M. M. Lahair, J. A. McCubrey, and R. A. Franklin. 2004. Redox
regulation of the calcium/calmodulin-dependent protein kinases. J. Biol. Chem.
279: 44573–44581.
35. Anderson, K. A., T. J. Ribar, F. Lin, P. K. Noeldner, M. F. Green,
M. J. Muehlbauer, L. A. Witters, B. E. Kemp, and A. R. Means. 2008. Hypo-
thalamic CaMKK2 contributes to the regulation of energy balance. Cell Metab.
7: 377–388.
5023The Journal of Immunology
Role of Phospholipase D in Parathyroid Hormone
Type 1 Receptor Signaling and Trafficking
Jose´ Luis Garrido,* David Wheeler,* Luis Leiva Vega, Peter A. Friedman,
and Guillermo Romero
Department of Pharmacology and Chemical Biology (J.L.G., D.W., L.L.V., P.A.F., G.R.) and the Medical
Scientist Training Program (D.W.), University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania
15261
The role of phospholipase D (PLD) in the regulation of the traffic of the PTH type 1 receptor
(PTH1R) was studied in Chinese hamster ovary cells stably transfected with a human PTH1R (CHO-
R3) and in rat osteosarcoma 17/2.8 (ROS) cells. PTH(1–34) increased total PLD activity by 3-fold in
CHO-R3 cells and by 2-fold in ROS cells. Overexpression of wild-type (WT) PLD1 and WT-PLD2
increased basal PLD activity in CHO-R3 but not in ROS cells. Ligand-stimulated PLD activity greatly
increased in CHO-R3 cells transfected with WT-PLD1 and WT-PLD2. However, only WT-PLD2 ex-
pression increased PTH-dependent PLD activity in ROS cells. Expression of the catalytically inactive
mutants R898K-PLD1 (DN-PLD1) and R758K-PLD2 (DN-PLD2) inhibited ligand-dependent PLD ac-
tivity in both cell lines. PTH(1–34) induced internalization of the PTH1R with a concomitant
increase in the colocalization of the receptor with PLD1 in intracellular vesicles and in a perinu-
clear, ADP ribosylation factor-1-positive compartment. The distribution of PLD1 and PLD2 re-
mained unaltered after PTH treatment. Expression of DN-PLD1 had a small effect on endocytosis
of the PTH1R; however, DN-PLD1 prevented accumulation of the PTH1R in the perinuclear com-
partment. Expression of DN-PLD2 significantly retarded ligand-induced PTH1R internalization in
both cell lines. The differential effects of PLD1 and PLD2 on receptor traffic were confirmed using
isoform-specific short hairpin RNA constructs. We conclude that PLD1 and PLD2 play distinct roles in
regulating PTH1R traffic; PLD2 primarily regulates endocytosis, whereas PLD1 regulates receptor in-
ternalization and intracellular receptor traffic. (Molecular Endocrinology 23: 2048–2059, 2009)
PTH regulates calcium and phosphate homeostasis byacting primarily on target cells in bone and kidney. PTH
function is mediated by the PTH type 1 receptor (PTH1R),
a member of the B family of G protein-coupled receptors
(GPCR). Agonist binding to the PTH1R leads to activation
of adenylyl cyclase and phosphatidylinositol-specific phos-
pholipase C (1–3). PTHbinding to the PTH1R results in the
internalization of the ligand-receptor complex via clathrin-
coated pits by a mechanism that involves arrestin (4–7).
Recent data suggest that regulated GPCR endocytosis is a
complex multistep process that involves the catalytic action
of several lipid-modifying enzymes (8, 9).
Phospholipases D (PLD) hydrolyze phosphatidylcho-
line to generate choline and the bioactive lipid phospha-
tidic acid. These enzymes have been implicated in signal
transduction, membrane trafficking, transformation, and
cytoskeletal reorganization (10–15). Two mammalian
PLD isoforms have been identified, PLD1 (10) and PLD2
(16). Both are expressed in a wide but selective variety of
tissues and cells (17, 18). Numerous reports based on
overexpression have proposed that PLD2 acts at the
plasma membrane to regulate cortical cytoskeletal reor-
ganization, endocytosis, and receptor signaling (14, 19–
23). Overexpression of catalytically inactive mutants of
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PLD1 inhibited the down-regulation of epidermal growth
factor receptor in response to epidermal growth factor
(24), and expression of a catalytically inactive mutant of
PLD2 perturbed agonist-induced internalization of an-
giotensin (19) and -opioid receptors (13). Phagocytosis
was also inhibited by expression of truncated or catalyt-
ically inactive PLD2 (25, 26).
Previous work showed that PTH stimulates PLD activ-
ity in UMR-106 osteoblastic cells (27). The pathway ap-
pears to involve the heterotrimeric G proteins G12/13 and
the subsequent activation of RhoA (27). However, the
physiological role of PLD activation in PTH function has
not been established.
In the present study, we investigated the role of PLD
activity in PTH1R internalization using two cells models:
CHO cells that express an HA-tagged human PTH1R
(CHO-R3 cells) and rat osteosarcoma ROS 17/2.8 (ROS)
cells, which express endogenous PTH receptors.We show
here that PTH(1–34) activates both PLD1 and PLD2 in
CHO-R3 cells, although activating primarily the PLD2
isoform in ROS cells. We further demonstrate that both
PLD1 and PLD2 play an important role in the regulation
of PTH1R traffic; although PLD2 activity is essential for
PTH1R endocytosis, PLD1 regulates the intracellular
traffic of the receptor.
Results
PTH(1–34) stimulates PLD activity in CHO-R3 and
ROS cells
The intracellular distribution of PLD in cultured
CHO-R3 cells was investigated by immunofluorescence
and confocal microscopy. The subcellular distributions of
enhanced green fluorescent protein (EGFP)-PLD1 and
EGFP-PLD2 are shown in Fig. 1A. PLD1 localizes primar-
ily to endosomal vesicles and to a perinuclear region, as
reported previously by us and others (28–30). Some lo-
calization of EGFP-PLD1 on the plasma membrane was
observed occasionally. In contrast, PLD2 was detected
primarily in the plasma membrane and vesicles close to
plasma membrane as described (16). Identical results
were obtained with ROS 17/2.8 cells.
The expression of PLD1 and PLD2 in CHO and ROS
cells was determined by quantitative RT-PCR. The data,
shown in Fig. 1B, confirm the endogenous expression of
PLD1 and PLD2 in both cell lines.We also determined the
levels of expression of PLD1 and PLD2 after transfection
with our PLD-EGFP constructs. The endogenous mRNA
levels for both PLDs were comparable for CHO-R3 and
ROS cells. The number of copies of PLD1 mRNA was
3.8  104 in CHO-R3 cells and 1.5  104 in ROS cells.
PLD2 mRNA was significantly less abundant (2300 and
5300 copies for CHO-R3 and ROS cells, respectively). As
shown in Fig. 1B, transfection with EGFP-PLD1 and
EGFP-PLD2 increased expression by 4- to 20-fold. Actual
protein levels could not be determined because of the lack
of good specific antibodies. Similar transfection efficien-
cies were observed for CHO-R3 and ROS cells in all
experiments.
PTH(1–34) increased PLD activity about 2.2-fold in
CHO-R3 cells in a time-dependentmanner (Fig. 2A). Sim-
ilar but less dramatic results were observed in ROS cells
(Fig. 2B). To determine which PLD isoforms are stimu-
lated by PTH treatment, CHO-R3 and ROS cells were
transfected with either wild-type (WT)-EGFP-PLD1 or
WT-EGFP-PLD2 and treated with PTH(1–34) for 30
min. Both PLD constructs increased basal PLD activity in
CHO-R3 cells (Fig. 2C) but had no significant effects on
the basal PLD activity of ROS cells (Fig. 2D). PTH(1–34)
treatment produced a pronounced increase in PLD activ-
ity in CHO-R3 cells transfected with either WT construct
(Fig. 2C). In contrast, only ROS cells transfected with
WT-EGFP-PLD2 showed an increased response to the
addition of ligand (Fig. 2D). These results suggest that the
FIG. 1. Localization of EGFP-PLD and EGFP-PLD2 in CHO-R3 cells. A,
CHO-R3 cells were transiently transfected with PLD1-EGFP or PLD2-
EGFP expression plasmids. Forty-eight hours later, images were
captured by confocal microscopy (Olympus Fluoview 1000). EGFP
fluorescence was used to determine the subcellular localization of the
transfected proteins. B, The expression of endogenous and transfected
PLD1 and PLD2 in CHO-R3 and ROS cells was determined by
quantitative RT-PCR. The numbers of copies reported in the figure
were obtained using standard curves generated by serial dilutions of
plasmid DNA coding for the WT human PLD1 and mouse PLD2.
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PTH1R can activate both PLD1 and PLD2 in CHO cells
but activates preferentially PLD2 in ROS cells. Interest-
ingly, the effects were much greater in CHO-R3 cells than
in ROS cells. This is possibly a consequence of the much
larger number of receptors expressed in the CHO-R3,
which express 650,000 receptors per cell (31), whereas
the ROS cells express about 72,000 endogenous receptors
per cell (32). Transfection of the catalytically inactive
(dominant-negative, or DN) mutants DN-PLD1 or DN-
PLD2 blocked PTH-induced PLD activity in both cell
lines (Fig. 2, C and D).
PLD activity regulates PTH1R traffic
A cell sorting-based assay was developed to investigate
the role of PLD in the regulation of PTH1R internaliza-
tion. This assay makes use of a human PTH1R tagged
with an hemagglutinin (HA) epitope near the N terminus.
This epitope faces the extracellular milieu such that only
the receptor expressed on the surface of the cell is acces-
sible to anti-HA antibodies added to intact, nonperme-
abilized cells. Upon receptor internalization, the immu-
noreactivity of the cells decreases as a function of time.
This time-dependent change is then detected by fluores-
cence-activated cell sorting (FACS) or by
indirect immunofluorescence.A represen-
tative FACS experiment performed with
CHO-R3 cells is shown in Fig. 3 (see
Materials and Methods for a complete
description of the protocol). Figure 3A
shows the selection of appropriate gates
to detect the HA-tagged receptor. These
gates were obtained by 1) transfecting
cells with untagged receptors or 2) omit-
ting the HA-specific primary antibody.
Figure 3B shows histograms of the data
shown in Fig. 3A. The 10-min points are
omitted for the sake of clarity. As
shown, the fluorescence of the cells de-
creases as a function of time after the
addition of PTH(1–34).
The effects of PLD on ligand-induced
internalizationof the PTH1R inCHO-R3
cells are shown in Fig. 4. WT-PLD2 had
no effects on the internalization of the
PTH1R (Fig. 4A). DN-PLD2, in con-
trast, significantly slowed receptor in-
ternalization (Fig. 4A). Both WT- and
DN-PLD1 decreased the rate of PTH1R
internalization after addition of ligand
(Fig. 4B). Importantly, the level of ex-
pression of the HA-tagged receptors in
cells that overexpressed WT-PLD1 or
DN-PLD1 was significantly reduced
(Fig. 4C). Thus, we conclude that the activities of PLD1
and PLD2 modulate the rate of PTH1R internalization;
furthermore, we conclude that regulated PLD1 activity is
required for efficient traffic of the PTH1R to the plasma
membrane.
Confocal studies on the regulation of the traffic of
the PTH1R by PLD1 and PLD2
PTH1R traffic was further studied by confocal micros-
copy. CHO-R3 cells were treated with PTH(1–34) for
various times and fixed, and the distribution of the HA-
tagged PTH1R was determined using anti-HA antibodies
and a tetramethylrhodamine-conjugated secondary anti-
body. Transfections with empty vectors were used as con-
trols. The distribution of EGFP-PLD1 was determined
from the GFP fluorescence of the cells. The data are
shown in Fig. 5. Before the addition of PTH(1–34), the
receptor was expressed on the cell surface and in intracel-
lular vesicles. WT-PLD1 and DN-PLD1 were primarily
localized to the cytosol or to intracellular vesicles, some of
which were also decorated with the PTH1R. Significant
reorganization of the PTH1R and PLD labels was ob-
FIG. 2. PTH1R-mediated PLD activation. A, Time course of the activation of PLD by PTH(1–
34) (100 nM) in CHO-R3 cells. B, Time course of the activation of PLD by PTH(1–34) (100 nM)
in ROS 17/2.8 cells. C, CHO-R3 cells stably expressing HA-PTH1R (control) were transfected
with EGFP-tagged WT-PLD1 and -PLD2 and with the EGFP-tagged mutants K898R-PLD1
(DN-PLD1) and R758K-PLD2 (DN-PLD2). Cells were stimulated with PTH(1–34) for 30 min.
Graphs represents a mean  SE of three independent experiments. The inset shows only the
mock, DN-PLD1, and DN-PLD2 data. D, ROS cells were transfected with EGFP-tagged WT
and mutant PLDs and treated with PTH(1–34). The graph represents a mean  SE of
three independent experiments. *, P  0.05 compared with the respective controls
(time  0 for the kinetics experiments shown in A and B and untreated cells for the data
shown in C and D).
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served within 10 min of the addition of ligand; the
PTH1R disappeared from the membrane and was local-
ized to vesicles (probably early endosomes, see Fig. 9) that
were also decorated with PLD1. Thirty minutes after li-
gand addition, the PTH1R accumulated in the perinu-
clear compartment. Importantly, WT-PLD1-EGFP colo-
calized with the receptor in this perinuclear compartment
(Fig. 5A).
The intracellular distribution of DN-PLD1 was some-
what different. DN-PLD1 was seldom found in perinu-
clear compartments before or after addition of PTH(1–
34). The expression of DN-PLD1 significantly affected
the traffic of the internalized receptor. Receptor internal-
ization appeared to be slower, and the accumulation of
the internalized PTH1R in the perinuclear region was
never observed. Rather, the internalized receptor re-
mained in small intracellular vesicles, where it colocalized
abundantly with DN-EGFP-PLD1 (Fig. 5B, 30 min). A
quantitative description of these phenomena was ob-
tained by calculating the Pearson correlation coefficient
of the red and green fluorescence of images obtained from
35–45 cells from at least 5 independent experiments. The
correlation between PTH1R andWT-PLD1 increased sig-
nificantly as a function of time (P 0.01), indicative of a
time-dependent accumulation of both labels in common
cellular compartments (Fig. 5C). Amuch slower, but sim-
ilar, phenomenon was observed with DN-PLD1. The in-
creased colocalization between PTH1R and DN-PLD1
only became significant 30 min after the addition of li-
gand (Fig. 5C).
In parallel studies, CHO-R3 cells
were transfected with WT- and DN-
PLD2 and stimulated with PTH(1–34)
for 10 and 30 min. In nontransfected or
WT-PLD2-transfected cells, the PTH1R
showed a vesicular distribution 10 and
30 min after treatment with PTH(1–
34). Significant accumulation of the re-
ceptor in the perinuclear compartment
was visible after 30min (Fig. 6A). How-
ever, most of the PLD2 remained at the
plasma membrane, although a small
fraction of the PLD2 trafficked with the
PTH1R to the perinuclear compart-
ment. Inmarked contrast, little internal-
ization of the receptor was apparent
even after 30 min in cells that were
transfected with DN-PLD2. In fact, a
significant fraction of the cells express-
ing DN-PLD2 did not internalize the re-
ceptor at all (Fig. 6B).
In contrast to PLD1, which colocal-
ized with the internalized PTH1R in
vesicles and in the perinuclear compartment, the distribu-
tion of WT-EGFP-PLD2 remained unchanged after
PTH1R stimulation, independently of the traffic of the
receptor. A quantitative analysis of the colocalization
data are shown in Fig. 6C. The Pearson correlation coef-
ficient of the fluorescent images obtained with the WT-
PLD2 construct and the HA-tagged receptor decreased as
a function of time as a consequence of the disappearance
of the PTH1R from the plasmamembrane surface and the
retention of the PLD2 construct on the surface (Fig. 6C).
In contrast, the correlation coefficients of the fluorescent
images obtainedwith theDN construct remained approx-
imately constant, indicative of the much slower internal-
ization of the PTH1R.
PTH1R internalization in ROS cells
To examine the regulation of PTH1R endocytic traffic
in a more physiologically relevant cellular system, we in-
vestigated ligand-induced redistribution of the PTH1R in
ROS cells. This was done using ROS cells transfectedwith
HA-tagged human PTH1R.
As shown in Fig. 7, HA-tagged PTH1R was localized
primarily on the plasma membrane of untreated ROS cells.
Occasionally, a fraction of the receptor was found in a pe-
rinuclear compartment,whichwasalsodecoratedwithADP
ribosylation factor-1 (ARF1), consistentwith theGolgi com-
partment. Thirty minutes after treatment with PTH(1–34),
the plasma membrane receptor had accumulated in numer-
ous intracellular vesicles and the Golgi compartment.
FIG. 3. FACS analysis of the internalization of the PTH1R. A, Representative traces showing
control cells (CHO cells not expressing HA-tagged PTH1R, left) and CHO-R3 cells after
various times (0, 10, or 30 min) of incubation with 100 nM PTH(1–34). B, Histogram
representation of the data shown in A. The 10-min point has been eliminated for the sake
of clarity.
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Further details of the endocytic traffic of the PTH1R
in ROS cells are illustrated in Fig. 8. Some colocaliza-
tion of the PTH1R with early endosome antigen 1
(EEA1) was observed even under basal conditions (red-
green correlation coefficient, 0.34  0.112) (Fig. 8).
However, addition of PTH(1–34) increased significantly
the colocalization of the PTH1R with EEA1 (red-green
correlation coefficient, 0.857 0.097) (Fig. 8). This dem-
onstrates that the receptor traffics via the standard endo-
cytic pathway. Figure 9 shows that DN-PLD2 impairs the
endocytosis of the PTH1R in ROS cells in a manner anal-
ogous to that described for CHO-R3 cells. Transfection
with DN-PLD1 greatly reduced the expression of the HA-
tagged PTH1R on the surface in ROS cells, precluding the
analysis of the effects of DN-PLD1 on receptor internal-
ization (data not shown).
To confirm that the results obtained by overexpression
of catalytically inactive PLD were a consequence of re-
duced PLD activity, we generated ROS-derived cell lines
that expressed short hairpin RNA (shRNA) targeted
against PLD1 and PLD2 in a stable manner. PLD expres-
sion was determined by semiquantita-
tive PCR. The constructs used reduced
PLD1 and PLD2 expression by at least
90% in a specific manner (Fig. 10A).
PTH1R internalization was determined
using the cell-sorting protocol described
in Materials and Methods. The knock-
down of PLD1 reduced PTH1R expres-
sion on the surface by about 50% and
reduced the rate of PTH1R internaliza-
tion (Fig. 10, B and C), confirming the
DN-PLD1 data. Likewise, PLD2 knock-
down significantly reduced PTH1R in-
ternalization (Fig. 10, B and D). Impor-
tantly, expression of mouse WT-PLD2
or addition of exogenous phosphatidic
acid normalized PTH1R internalization
(Fig. 10D). Transfection of the cells ex-
pressing PLD2-targeted shRNA with
human WT-PLD1, however, did not
rescue the effects of PLD2 knockdown
on PTH(1–34)-induced internalization
of the receptor. These data confirm that
PLD2 activation is required for PTH1R
internalization, whereas PLD1 activity
affects both internalization and traffic
of the PTH1R to the cell surface.
Phospholipase D activity is
required to couple PTH1R
activation to ERK phosphorylation
Previous work from our lab demon-
strated that PLD activity is required to couple the function
of several cell surface receptors to the activation of the
ERK cascade (14, 15, 33–36). In this work, we extended
this paradigm to PTH1R signaling in CHO-R3 cells. The
data obtained are summarized in Fig. 10. Expression of
WT-PLD1 had a small effect on the basal level of phos-
phorylation of ERK. The expression ofWT-PLD2 did not
alter the effects of PTH(1–34) on ERK phosphorylation.
Importantly, the expression of the DN mutants DN-
PLD1 and DN-PLD2, both of which block PTH-induced
PLD activation, also abolished the effects of PTH on ERK
phosphorylation.We conclude, therefore, that the activa-
tion of PLD and the generation of phosphatidic acid are
required for the activation of the ERK cascade by PTH.
Discussion
Agonist-induced activation of PLD plays an important
role in regulating numerous signal transduction path-
ways. These include receptor internalization (19, 24, 37),
FIG. 4. Phospholipase D activity regulates PTH1R internalization and traffic. A, CHO-R3 cells
stably expressing HA-PTH1R were transiently transfected with EGFP-PLD2 (WT) or R758K-
PLD2 (DN). Forty-eight hours after transfection, cells were stimulated with PTH(1–34) for 0,
10, or 30 min and analyzed by FACS using a specific anti-HA antibody. Cells successfully
transfected were identified by GFP fluorescence. Only GFP-positive cells were used in the
analysis. The data shown have been normalized to the initial integrated cell fluorescence. B,
Same as A, except that WT and R898K (DN) PLD1 were used. C, PTH1R internalization data
normalized to the mock transfection values. Notice the much lower starting points of the
cells that express WT- and DN-PLD1. D, Expression of the PTH1R on the cell membrane is
inhibited by overexpression of WT- and DN-PLD1. CHO-R3 cells transfected with PLD1
were examined by FACS after 48 h. The total cell-associated PTH1R fluorescence of the
transfected cells was compared with the fluorescence of paired, mock transfected cells or to
that of nontransfected cells. Both comparisons yielded identical results. The data shown
represent the averages from three different experiments. *, P  0.01 vs. mock.
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receptor desensitization and resensitization, and pro-
tein phosphorylation (14, 22, 23, 34, 38). Several mem-
bers of the GPCR family activate PLD (27, 35, 36,
39–41). The PTH1R activates PLD in kidney (3) and
bone (27). However, the physiological significance of
this activity has not been elucidated. We show here that
PLD activity regulates the traffic of the PTH1R to the
plasma membrane, PTH1R endocytosis, and PTH-de-
pendent ERK phosphorylation.
Mammalian cells express two main forms of PLD (10,
16, 42). Both PLD isoforms display distinct subcellular
distributions and modes of regulation. PLD1 localizes to
intracellular vesicles and was implicated initially in vari-
ous aspects of vesicular traffic (28–30). PLD2 is ex-
pressed primarily at the plasma membrane and was iden-
tified as the main target for receptor-mediated activation
and a regulator of ligand-dependent endocytosis (13, 14,
19, 35, 37). Subsequent work, however, suggests that
PLD1may play additional roles in specific signaling path-
ways. Recent evidence shows that a small fraction of
PLD1 localizes to the plasma membrane where it contrib-
utes to mediating specific signaling events (43, 44). We
investigated the activation of specific PLD isoforms by the
PTH1R using two complementary approaches based on
the overexpression of WT and DN mutants. Our results
demonstrate cell-dependent specificity
in the activation of PLD1 and PLD2 by
the PTH1R. Whereas both PLD1 and
PLD2 appear to be targets in CHO-R3
cells, only PLD2 seems to be activated
by the PTH1R in ROS osteosarcoma
cells. However, the expression of catalyt-
ically inactive mutants of both isoforms
significantly inhibited PTH-induced PLD
activity suggesting, superficially, that
the activation of both PLDs by the
PTH1R follow common signaling path-
ways. This, however, is not necessarily
the case, as will be discussed below.
Activation of PLD2 by the PTH1R is
consistent with several reports linking
receptor-dependent PLD activation to
the PLD2 isoform. (13, 15, 19, 23, 35,
37, 41). In contrast, whereas PLD2 is
expressed at the plasma membrane,
PLD1 is mostly confined to the cytosol
and intracellular membranes in CHO-R3
and ROS cells. However, localization of
the PTH1R with PLD1 increases signif-
icantly after the addition of ligand ow-
ing primarily to the accumulation of
PTH1R in endosomes enriched in PLD1.
It is possible, therefore, that the PTH1R
activates PLD1 and PLD2 in different compartments and in
a distinct temporal pattern; PLD2 is activated early and at
the plasmamembrane, whereas PLD1 activationmay occur
only after the receptor is internalized and translocated to
endosomes.
Interestingly, although PTH effectively activated PLD1
in CHO-R3 cells, we did not find evidence of PTH1R-
dependent activation of PLD1 in ROS cells. The cell and
tissue specificity of the responses to PTH1R ligands has
been abundantly described (3, 5, 45, 46). One explana-
tion for this specificity is based the relative levels of ex-
pression of NHERF1 (5, 46). However, neither CHO-R3
(7) nor ROS cells (46, 47) express endogenous NHERF1.
Therefore, different levels of NHERF1 expression cannot
explain these results.
Importantly, our data demonstrate that altered PLD1
activity, caused by overexpression of the WT protein, by
expression of a DN construct, or by shRNA knockdown,
significantly reduces the plasma membrane expression of
the PTH1R. This result strongly suggests that regulated
PLD1 activity is required for the normal traffic of the
receptor to the surface. Whether this finding can be ex-
trapolated to other receptors remains to be determined.
Nevertheless, this result raises an important issue; studies
FIG. 5. PLD1 alters PTH1R traffic in CHO cells. CHO-R3 were transiently transfected with
WT EGFP-PLD1 (A) or EGFP-tagged K898R-PLD1 (DN-PLD1; (B). Forty-eight hours after
transfection, the cells were stimulated with PTH(1–34) for 0, 10, or 30 min. Cells were
visualized using an anti-HA antibody and analyzed by confocal microscopy. Representative
images are shown from more than 45 cells analyzed across four independent experiments.
C, Correlation coefficients were calculated at different times for regions comprising most of
the cell. The graph represents the mean  SE of four independent experiments. More than
35 individual cells were analyzed for each data point.
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in which receptor-mediated PLD1 activation is perturbed
by expression of a DN or by shRNA techniques must be
carefully controlled, because reduced surface expres-
sion of the receptor may be a conse-
quence of the perturbation of PLD1
activity. Thus, the mechanism by which
PLD1 knockdown and expression of
DN-PLD1 impair receptor-mediated
PLD activation is not necessarily a conse-
quence of the interference of these treat-
ments with stimulation of endogenous
PLD. We cannot distinguish between
these alternative explanations at present.
Ligand-induced internalization of
GPCR plays a major role in the regula-
tion of signal transduction pathways, ei-
ther by propagating (48, 49) or termi-
nating (50) signals. Our data strongly
support the hypothesis that PLD activa-
tion regulates PTH1R internalization,
thereby contributing to signal termina-
tion. DN-PLD2 expression significantly
reduced the rate of receptor internaliza-
tion in CHO-R3 and ROS cells. The ex-
pression ofWT-PLD2waswithout effect.
This is the first time that the activation of
PLD2 has been linked to the internaliza-
tion of the PTH1R. This observation,
however, is consistent with results ob-
tained with other receptor systems and in
diverse cell lines (13, 19, 21, 24, 37).
The role of PLD1 on PTH1R internal-
ization is somewhat different. Both WT-
and DN-PLD1 significantly reduced the level of expression
of the PTH1R on the cell surface. In CHO-R3 cells, plasma
membrane expression of the PTH1Rwas reduced by 50 and
FIG. 6. PLD2 delays PTH1R endocytosis in CHO cells. CHO-R3 cells were transiently
transfected with WT EGFP-PLD2 (A) or EGFP-tagged K758R-PLD2 (DN-PLD2; B). Forty-eight
hours after transfection, the cells were stimulated with PTH(1–34) for 0, 10, or 30 min.
Cells were visualized using an anti-HA antibody and analyzed by confocal microscopy.
Representative images are shown from more than 45 cells analyzed across four independent
experiments. C, Correlation coefficients were calculated at different times for regions
comprising most of the cell. The graph represents the mean  SE of four independent
experiments. At least 35 individual cells were analyzed for each data point.
FIG. 7. PTH1R colocalizes with ARF1 after PTH(1–34) treatment.
CHO-R3 cells were transfected with ARF1-EGFP and stimulated with
PTH(1–34) (100 nM) for 0 or 30 min. The cells were then fixed,
permeabilized, immunostained with anti-HA antibodies, and analyzed
by confocal microscopy. Representative images are shown from more
than 25 cells analyzed per slide across three independent experiments.
FIG. 8. Internalized PTH1R colocalizes transiently with EEA1. CHO-R3
cells were stimulated with PTH(1–34) (100 nM) for 0, 10, or 30 min.
The cells were then fixed, permeabilized, immunostained with anti-HA
and anti-EEA1 antibodies, and analyzed by confocal microscopy.
Representative images are shown from more than 25 cells analyzed
per slide across three independent experiments, each in duplicate.
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75% byWT-PLD1 and DN-PLD1, respectively, whereas in
ROS cells, HA-tagged PTH1R was essentially undetectable
in cells transfected with either WT-PLD1 or DN-PLD1. In
independent experiments, PLD1 knockdown using shRNA
reduced surface PTH1R expression by about 50% in ROS
cells, whereas PLD2 knockdown had no effects. These ob-
servations imply that PLD1 plays an important role in reg-
ulating the traffic of the receptor to the plasma membrane
and thus contributing to signal propagation. The precise
function of PLD1 in PTH1R traffic, however, remains to be
elucidated.
In addition, PLD1 function also regulates the traffic of
the internalized receptor. Internalized receptor accumu-
lates initially in endosomes (Fig. 8) and, after several min-
utes, in a perinuclear compartment (Figs. 5–7). Because
this compartment is also decorated with ARF1 (Fig. 7),
we conclude it is the Golgi apparatus. In CHO-R3 cells,
PLD1 accompanies the receptor throughout this process
(see Fig. 5). However, in cells expressing DN-PLD1, ac-
cumulation of the receptor in the Golgi was not observed.
Thus, we conclude that in the absence of PLD1 activity,
the traffic of the PTH1R is interrupted, such that the
receptor never reaches the Golgi.
The present data also demonstrate the requirement for
PLD activity in the regulation of the ERK cascade by
PTH(1–34). PTH treatment induced ERK phosphoryla-
tion, as described previously (51), and this effect was
inhibited by overexpression of DN-PLD2 (Fig. 11). WT-
and DN-PLD1 had similar effects, but because of the re-
duced expression of PTH1R on the surface of cells trans-
fectedwith exogenous PLD1,we cannot conclude that the
effects of PLD1 are related to the coupling of the ERK
cascade to PTH1R function. The effects of DN-PLD2 on
ERK phosphorylation are consistent with the reduced in-
ternalization of the PTH1R caused by expression of this
mutant protein. Several lines of evidence link endocytosis
to the activation of the ERK cascade. These include spe-
cific roles for -arrestins as scaffolds (48, 50, 52) and
other less characterized effects of endocytic traffic (53–
56). More recently, a specific role for PA as a scaffold for
the coupling of the ERK cascade has emerged. This model
is based on the fact that Son of Sevenless (SOS; a Ras
guanine-nucleotide exchange factor), Raf-1, and kinase
supressor of Ras 1 (a scaffolding protein that binds
ERK1/2 and MAPK/ERK kinase 1) contain specific bind-
ing sites for phosphatidic acid and require phosphatidate
binding for function (14, 15, 23, 33, 57). Our data are
compatible with both of these models, and some addi-
tional work will be required to determine the mechanisms
by which PLD activation is required for induction of the
ERK cascade by PTH.
Finally, the details of how PTH activates PLD remain
incompletely understood. A mechanism mediated by
G12/13 and RhoA has been proposed to be responsible for
the activation of PLD in UMR-106 cells (27). This scheme,
however, is somewhat paradoxical because stimulation of
cellswith PTH leads to the accumulation of cAMP,which in
turn inhibits RhoA activity by direct phosphorylation (58).
This effect has been linked to inhibition of PLD in neutro-
phils (59) and tooverall cytoskeletal reorganization (58,60).
Thus, it remains unclear how PTH induces RhoA activation
in a cAMP background. GPCR may activate PLD function
by several other mechanisms. These include activation of
small GTPases of theARF family (61), or formation ofmac-
romolecular complexes that include PLD2 and the small
GTPase Ral (37). Some GPCR, such as the -opioid recep-
tor, interact directly with PLD2, although the regulation of
PLD activity by this assembly still requires the activation of
ARF GTPases (13). The potential role of these alternative
mechanisms on PTH-dependent PLD activation remains to
be explored.
Materials and Methods
Cell culture and transfection
ROS 17/2.8 cells were grown in DMEM/F12 medium sup-
plemented with 10% fetal bovine serum (Invitrogen, Carlsbad,
CA) and 1% penicillin/streptomycin solution at 37 C, 5% CO2.
Chinese hamster ovary cells stable expressing HA-tagged hu-
man PTH1R, CHO-N10-R3, were maintained in Ham’s F-12
FIG. 9. Inhibition of PTH1R endocytosis by DN-PLD2 in ROS 17/2.8
cells. ROS cells coexpressing HA-PTH1R (control) and EGFP-tagged DN-
PLD2 mutant were treated with PTH(1–34) for 0, 10, or 30 min and
analyzed by confocal microscopy. Representative images are shown
from more than 25 cells analyzed per slide across three independent
experiments, each in duplicate.
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medium (Mediatech Inc., Herndon, VA) with 10% fetal bovine
serum. Transient transfection was performed using FUGENE 6
(Roche, Indianapolis, IN) according to themanufacturer’s instruc-
tions. All experiments were performed 48 h after transfection.
Plasmids encoding scrambled shRNA, rat PLD1 shRNA, and
rat PLD2 shRNAwere described previously (19).The sequences
used to silence PLD1 and PLD2 were 547CTGGAAGAT TACT-
TGACAA (for PLD1) and 723GGACTCC
TTCCTGCTGTACA (for PLD2). PLD2 res-
cue experiments were performed using a
mouse EGFP-PLD2 construct with a single
nucleotide substitution (730T3A). Expres-
sion of the rescue construct was verified
measuring EGFP fluorescence. ROS cells
stably expressing each shRNA were selected
using 500 g/ml G418 (Invitrogen).
PLD mutants
WT and catalytically inactive variants of
PLD1 and PLD2 (K898R-PLD1 and K758R-
PLD2) were previously described (14, 15) and
fused to green fluorescent protein by subclon-
ing into pEFGP-C1. Transfection efficiency
was estimated from fluorescence microscopy
data by determining the fraction of cells ex-
pressing the green fluorescent constructs.
Transfection efficiency was better than 30%
in all experiments.
PLD assays
Cells cultivated in six-well plates at 75%
confluence were serum starved and labeled
overnight with [3H]palmitate (5 mCi/ml) in
culture medium containing 0.1% BSA. Cells
were stimulated with PTH(1–34) (100 nM)
in the presence of 0.5% ethanol for the indi-
cated times. At the end of the incubation, the
cells were scraped and transferred to Eppen-
dorf tubes, and the reaction was stopped by
addition of chloroform/methanol (1:1). The lipid phase was ex-
tracted and developed by thin-layer chromatography (TLC) on
silica gel 60 plates using ethyl acetate/trimethylpentane/acetic
acid (9:5:2) as solvent. The position of major phospholipids was
determined using standards (Avanti Biochemicals, Birmingham,
AL) and autoradiography. The TLC plates were developed by
autoradiography, and the radioactivity associated with each
band was estimated by densitometry and quantified using Im-
ageJ. In some cases, the TLC plates were scraped, and the total
amount of radioactivity associated with each lipid species was
determined by liquid scintillation counting. The data are ex-
pressed as band intensity/number of counts associated with the
phosphatidylethanol spot normalized by total intensity/number
of counts of lipid loaded.
RT-PCR
Quantification of PLD mRNA was conducted as previously
described (35). Briefly, total cellular RNA was isolated using
Trizol (Invitrogen) and transcribed into cDNA using a Clontech
(Palo Alto, CA) Advantage RT-for-PCR kit. The resulting
cDNA was used to amplify PLD1, PLD2, and GAPDH as de-
scribed previously (35). PCR products were resolved using a
1.5% agarose gel, digitally photographed, and measured using
ImageJ (National Institutes of Health, Bethesda, MD). Quanti-
tative real-time PCR was performed on an Applied BioSystems
(Foster City, CA) StepOne real-time PCR system using SYBR
Green (QIAGEN, Valencia, CA) with the primers previously
described. Negative control wells containing nuclease-free wa-
ter instead of cDNA were used to check for amplicon contami-
FIG. 10. Knockdown of PLD1 and PLD2 affects differentially the traffic of the PTH1R in ROS
17/2.8 cells. A, Knockdown of PLD1 and PLD2 with shRNA. ROS cells were transfected with
plasmids coding for PLD1- and PLD2-specific shRNA (shPLD2) or with a plasmid coding for a
scrambled shRNA construct. Transfected cells were selected with G418 for at least 2 wk.
PLD1 and PLD2 expression was measured using semiquantitative PCR. Glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) expression was used as internal control. As shown, the
transfected cells express reduced levels of PLD1 or PLD2 mRNA. B, Knockdown of PLD1 and
PLD2 reduces the rate of internalization of the PTH1R. C, PLD1 knockdown reduces the
expression of the PTH1R on the surface. D, Treatment with PA (100 M dioleoyl PA) or
overexpression of mouse WT-PLD2 reverts the effects of PLD2 knockdown on PTH1R
internalization. In contrast, expression of human PLD1 cannot normalize PTH1R
internalization. ***, P  0.005.
FIG. 11. PLD activity is necessary for PTH-dependent ERK
phosphorylation. CHO-R3 cells were transfected with empty vector
(mock), WT-, or DN-PLD1 and -PLD2 where indicated. Forty-eight
hours after transfection, the cells were treated with 100 nM PTH(1–34)
for 15 min. After incubation, the cells were scraped in Laemmli buffer.
Extracted proteins were resolved by SDS-PAGE. Phosphorylated ERK
(pERK) and total ERK were determined by immunoblotting (IB). A,
Representative blot; B, summary of results obtained from three
independent experiments. *, P  0.05; **, P  0.01 for the depicted
comparisons.
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nation. All samples were run in duplicate and normalized using
GAPDH. A standard curve was generated using 10-fold dilu-
tions of EGFP-PLD1 and EGFP-PLD2 plasmid. Both standard
curves had a correlation coefficient greater than 0.98. Total
copy number of each target was extrapolated from the standard
curve. Copy number per cell was calculated by dividing the total
copy number by the cell count and adjusting for transfection
efficiency.
Immunocytochemistry and confocal microscopy
Cells were cultured on glass coverslips, transfected with the
desired plasmids, and allowed to grow until 80% confluent. The
coverslips were washed in PBS and fixed for 10 min in 4%
paraformaldehyde in PBS at room temperature. Cells were per-
meabilized with 0.1% Triton X-100 in PBS for 10 min at room
temperature. The samples were blocked with 3% BSA in PBS
and then stained with either anti-HA, anti-EEA1, or anti ARF1
antibodies in 1% BSA in PBS for 2 h at room temperature. The
samples were washed three times with PBS and incubated with
respective secondary antibody (antimouse IgG or antirabbit IgG
conjugated with either tetraethylrhodamine or fluorescein iso-
thiocyanate). The cells were then washed with PBS (3),
mounted with gelvatol, and examined. An Olympus Fluoview
1000 confocal microscope was used for all experiments.
FACS
CHO-R3 cells were transiently transfected with EGFP fusion
constructs ofWT-PLD1, DN-PLD1,WT-PLD2, andDN-PLD2,
as described above, using Fugene6. Forty-eight hours after
transfection, the cells were switched to serum-free F-12 medium
and stimulated with PTH(1–34) (100 nM) for 0, 10, or 30 min.
After incubation, the cells were washed with PBS (pH 7.4) and
fixed with 0.5% p-formaldehyde in PBS for 5 min at 4 C. The
cells were washed with PBS and incubated with 3% BSA in PBS
for 30min to block nonspecific antibody binding. Subsequently,
the cells were incubated with rabbit anti-HA antibody [Covance
(Madison, WI) HA.11, 1:200] and antirabbit-Alexa-680 (In-
vitrogen; 1:500) for 1.5 h at room temperature, respectively.
Finally, cells were scraped and analyzed by FACS. EGFP/cher-
ryFP fluorescence was used to gate cells transfected with the
PLD or shRNA constructs.
Statistical analysis
Each experiment was repeated at least three times. Statistical
significance was determined using ANOVA followed by column
statistic comparisons using the analysis routines built in Graph-
Pad Prism. Quantitative image analyses were performed using
ImageJ. Colocalization analyses were done using the ImageJ
built-in plug-ins for Pearson correlation. The Pearson correla-
tion coefficient is defined as the ratio of the covariance of the red
and green color images divided by the product of the SD of the
normalized image intensities. Differences with P  0.05 were
considered significant.
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Parathyroid Hormone Receptor Directly Interacts with
Dishevelled to Regulate -Catenin Signaling and
Osteoclastogenesis*□S
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Bone growth and remodeling depend upon the opposing rates
of bone formation and resorption.These functions are regulated
by intrinsic seven transmembrane-spanning receptors, the par-
athyroid hormone receptor (PTH1R) and frizzled (FZD),
through their respective ligands, parathyroid hormone (PTH)
and Wnt. FZD activation of canonical -catenin signaling
requires the adapter protein Dishevelled (Dvl). We identified a
Dvl-binding motif in the PTH1R. Here, we report that the
PTH1R activates the -catenin pathway by directly recruiting
Dvl, independent ofWnt or LRP5/6. PTH1R coimmunoprecipi-
tated with Dvl. Deleting the carboxyl-terminal PTH1R PDZ-
recognition domain did not abrogate PTH1R-Dvl interactions;
nor did truncating the receptor at position 480. However, fur-
ther deletion eliminating the putative Dvl recognition domain
abolished PTH1R interactions with Dvl. PTH activated -cate-
nin in a time- and concentration-dependent manner and trans-
located -catenin to the nucleus. -Catenin activation was
inhibited byDvl2 dominant negatives and by short hairpin RNA
sequences targeted against Dvl2. PTH-induced osteoclastogen-
esis was also inhibited by Dvl2 dominant negative mutants.
These findings demonstrate that G protein-coupled receptors
other than FZD directly activate -catenin signaling, thereby
mimicking many of the functions of the canonical Wnt-FZD
pathway. The distinct modes whereby FZD and PTH1R activate
-catenin control convergent or divergent effects on osteoblast
differentiation, and osteoclastogenesis may arise from PTH1R-
induced second messenger phosphorylation.
Wnts are secreted lipid-modified glycoproteins that act as
ligands to stimulate signal transduction pathways through FZD
(frizzled) receptors and LRP5/6 (lipoprotein receptor-related
protein 5/6) co-receptors. Canonical and non-canonical Wnt
signaling pathways have been described (1). In the canonical
pathway, in the absence ofWnt ligands,-catenin is targeted to
a destruction complex with APC (adenomatous polyposis coli),
CK1 (casein kinase 1), GSK3 (glycogen synthase kinase 3),
and axin. Amino-terminal phosphorylation byCK1 andGSK3
followed by subsequent ubiquitination targets -catenin for
proteasomal degradation (2). Wnt binding to cognate FZD
receptors and LRP5/6 causes recruitment of the PDZ (PSD-95,
Discs-large, and ZO-1) protein Dvl (Dishevelled) to the plasma
membrane by direct interaction with FZD receptors. The
recruitment of Dvl to the plasma membrane results in the for-
mation of Dvl oligomers, which interact with axin. Parallel
phosphorylation of the co-receptors LRP5 and LRP6 induces
binding to axin, resulting in disruption of the destruction com-
plex. As a consequence, -catenin escapes proteasomal degra-
dation and translocates to the nucleus, where it regulates the
activity of the transcription factors TCF (T cell factor) and Lef
(lymphocyte enhancer-binding factor).
Ten FZD receptors constitute a distinct family of seven
transmembrane-spanning receptors (3). Whether or not they
couple to G proteins remains controversial (4). Notably, they
bear the closest phylogenetic relation to Family B1 GPCRs
including the type 1 parathyroid hormone receptor (PTH1R)
(5). Four of the 10 frizzled receptors (FZD1, -2, -4, and -7) con-
tain a canonical carboxyl-terminal PDZ recognition domain,
(D/E)(S/T)X, where represents a hydrophobic residue, gen-
erally L/I/V but sometimes M, as in the PTH1R (6, 7). This
motif mediates interactions with PDZ proteins, such as
NHERF1 (Na/H exchange regulatory factor-1) (8).
Bone growth and remodeling are regulated by parallel signal-
ing pathways involving the PTH1R and FZD (9). Considerable
evidence now strongly implicates Wnt/FZD signaling in regu-
lating bone formation (9–11). -Catenin signaling is required
for suppression of chondrocyte differentiation and induction of
osteoblastogenesis. Multiple lines of genetic evidence establish
the critical participation of canonical -catenin activity for
early osteoblast differentiation (12). Acting on mature osteo-
blasts, stimulation of the PTH1R produces RANKL (receptor
activator of NFB ligand), which binds the RANK (receptor
activator of NFB) receptor on osteoclast precursors and
induces formation of osteoclasts by signaling through NFB2
and JNK. Homologous recombination of PTH1R, RANKL, or
RANK results inmicewith profound bone phenotypes (13–15).
Gene knock-out of elements of FZD and the canonical -cate-
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nin signaling pathway likewise produce profound disruption of
normal bone formation or turnover (9–11). Recent work shows
that PTH promotes -catenin activation (16–18). The interac-
tion between PTH1R and FZD signaling pathways is largely
unexplored. Nissenson and co-workers (19) observed that PTH
increased FZD1/2 mRNA levels in UMR cells. Other findings
establish that PTH increases-catenin levels in UMR,MC3T3-
E1, and SAOS cells (16, 17, 20) and that ablation of the Wnt
antagonist, secreted frizzled-related protein, blunts the ana-
bolic action of PTH (21). More recently, Cao and co-workers
(18) showed that PTH1R signals through LRP6. Further evi-
dence for the interaction of PTH and -catenin pathways in
regulating bone turnover comes from studies showing that
overexpression of sFRP1 attenuates PTH-dependent bone
anabolism (22). Together, these and other studies imply that
the actions of PTH may be partially mediated through -cate-
nin signaling. The mechanisms underlying PTH1R and FZD
cross-talk are unknown. We now describe multiple lines of
cross-talk between the two pathways and show that PTH acti-
vates -catenin in an LRP- and Wnt-independent manner.
EXPERIMENTAL PROCEDURES
Cell Culture—CHOcells (Invitrogen)were cultured inHam’s
F-12 medium supplemented with 10% fetal bovine serum, 100
units/ml penicillin, 100 g/ml streptomycin, and 10 g/ml
blasticidin. UMR-106 and UAMS-32P cells were cultured in
Dulbecco’s modified Eagle’s medium/F-12 medium supple-
mented with 10% fetal bovine serum, 100 units/ml penicillin,
and 100g/ml streptomycin.MC4 cells were obtained fromDr.
G. Xiao (University of Pittsburgh) and cultured in -modified
minimum essential medium with 10% fetal bovine serum, 100
units/ml penicillin, and 100 g/ml streptomycin. Cells were
maintained at 37 °C in a humidified atmosphere of 5%CO2, 95%
air.
Short Hairpin RNA Treatments—The expression of Dvl1,
Dvl2, and Dvl3 in UMR cells was determined by quantitative
RT-PCR.Dvl2mRNAaccounted for over 90%of theDisheveled
mRNA expressed in these cells (not shown). Constructs coding
for specific shRNA targeted against rat Dvl2 were purchased
fromSABiosciences (Frederick,MD). Four different constructs
were screened for their ability to knock down Dvl2 expression
in UMR cells. The two most efficient constructs were selected
for further use. The sequences targeted by these constructs
(shDvl2-1 and shDvl2-2, respectively) are GCCTACCTTCTC-
CTACCAATACC and TTCAACTTGGTGCTCTTCTTAGT.
UMR-106 cells were co-transfected with 1 g of TOP-Flash
luciferase reporter and 2 g of either a scrambled shRNA or
shDvl2 plasmids. Two days following transfection, the cells
were treated with either vehicle, 100 ng/ml recombinant
Wnt3a, 100 nM PTH(1–34), or 5 mM LiCl for 24 h. Cell lysates
were assayed for luciferase expression using a commercial lucif-
erase assay system (Promega, Madison, WI) as per the manu-
facturer’s instructions.
Coimmunoprecipitation and Immunoblot Analysis—Inter-
actions of PTH1R or FZD with Dvl were analyzed as described
(23). Briefly, 6-well plates of the indicated cells were transiently
transfected with HA-PTH1R, HA-PTH1R(ETVA), HA-
PTH1R(480-stop), HA-PTH1R(470-stop), HA-FZD, Myc-Dvl,
or the respective empty vector. 48 h later, the cells were lysed
with Nonidet P-40 (50 mM Tris, 150 mM NaCl, 5 mM EDTA,
0.5%Nonidet P-40) supplemented with protease inhibitormix-
ture I and incubated for 15 min on ice. Solubilized materials
were incubated overnight at 4 °CwithHA.11monoclonal affin-
ity matrix. Total lysates and immunoprecipitated protein,
eluted by the addition of SDS sample buffer, were analyzed by
SDS-polyacrylamide gels and transferred to Immobilon-P
membranes (Millipore) using the semidry method (Bio-Rad).
Membranes were blocked overnight at 4 °C with 5% nonfat
dried milk in Tris-buffered saline plus Tween 20 (TBST) and
incubated with the indicated antibodies (HA (Covance, catalog
no. MMS-101R), Myc (Santa Cruz Biotechnology, Inc. (Santa
Cruz, CA), catalog no. SC-40), active -catenin (Millipore, cat-
alog no. 05-665), or -catenin (Millipore, catalog no. 06-734))
for 2 h at room temperature. Themembraneswere thenwashed
and incubated with goat anti-rabbit IgG or sheep anti-mouse
IgG conjugated to horseradish peroxidase at a 1:5000 dilution
for 1 h at room temperature. Protein bandswere visualizedwith
a luminol-based enhanced chemiluminescence substrate.
-Catenin—MC4 cells were passaged onto 6-well plates and
24 h later were transfected with 1 g/well TopFlash (Super 8
TopFlash, Addgene) and 1 g/well Xdd1, a mutant of Xenopus
Xdsh1 harboring a PDZ domain deletion (24), or empty vector,
as indicated, using FuGENE 6 (Roche Applied Science). 48 h
after transfection, cells were treated with 100 nM PTH(1–34)
for 6 h. Lysates were prepared using Reporter Lysis Buffer (Pro-
mega, catalog no. E-3971). Luciferase activity was assayed using
the BrightGlo luciferase assay system (Promega, catalog no.
E-2620). 10 l of lysate was added to a single tube. An equal
volume of BrightGlo substrate was then added, and lumines-
cence was measured for 10 s in a Turner BioSystems luminom-
eter (model TD-20/20).
Imaging—Myc- and mRFP1-tagged Dvl2 constructs were
obtained from T. Kirchhausen (Harvard Medical School). Live
cell imaging of the translocation of mRFP1-Dvl2 to the plasma
membrane was done by confocal microscopy using a Zeiss
LSM5 equipped with a Harvard Biosystems incubation cham-
ber maintained at 37 °C. Images were collected every 20 s.
To measure -catenin translocation to the nucleus, ROS
17/2.8 cells were treated with 100 nM PTH(1–34) for 8 h, fixed,
permeabilized, blockedwith 5%goat serum, and incubatedwith
a commercial anti--catenin antibody (Millipore). -Catenin
was detected using a TRITC-labeled secondary antibody. The
cells were then examined using an Olympus Fluoview 1000
confocal microscope equipped with 405- and 561-nm lasers.
To measure PTH1R internalization, cells were co-trans-
fected with a human EGFP-tagged PTH1R and mRFP-Dvl2.
Receptor internalization was measured using total internal
reflection fluorescence (TIRF) microscopy as described (25).
Briefly, cells expressing both PTH1R-EGFP and mRFP-Dvl2
were identified by epifluorescence. The cells were then chal-
lenged with 100 nM PTH(1–34), and the disappearance of the
surface-delimitedPTH1R-EGFPwas determined byTIRF.Data
were collected at 20-s intervals for up to 20 min. The rate of
internalizationwas determined from the fit of the collected data
to a single exponential (25).
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Osteoclastogenesis—Nonadherent bone marrow cells were
prepared by removing femurs from 30–90-day-old C57BL/6J
mice and flushing the marrow cavity with minimum essential
medium (Invitrogen) containing 15% fetal bovine serum
(Hyclone). Marrow cells were seeded at a density of 2.5  105
cells/cm2 in the same medium and cultured for 48 h. Nonad-
herent cells were collected and seeded at a density of 2  104
cells/cm2 on a cushion of UAMS-32 osteoblastic cells in mini-
mum essential medium containing 10% fetal bovine serum.
PTH(1–34) was added at the indicated concentrations, and the
co-cultures were maintained at 37 °C in 5% CO2. On day 3,
one-half of the mediumwas replaced with fresh medium. After
6–8 days, cells were fixed and stained for tartrate-resistant acid
phosphatase. The plate was scanned, and staining density was
determined with Image J (National Institutes of Health,
Bethesda, MD).
Statistics—Data are presented as the mean S.E., where n
indicates the number of independent experiments. Curve
fitting and data analysis were performed using GraphPad
Prism (GraphPad Software, Inc., San Diego, CA). Multiple
comparisons were evaluated by analysis of variance with
post-test repeated measures analyzed by the Bonferroni pro-
cedure. Differences greater than p 0.05 were assumed to be
significant.
RESULTS
Direct Interactions between PTH1RandDvl—Recruitment of
Dvl to the plasmamembrane is mediated by direct interactions
between FZDand the PDZdomain ofDvl proteins. These inter-
actions occur primarily through the binding of a critical region
(KTXXXW)within the proximal portion of the carboxyl termi-
nus of all 10 FZD receptors (26). Analysis of the PTH1R
sequence revealed the presence of a similar motif (KSWSRW;
see Fig. 1A). The putative Dvl-binding domain of the PTH1R
starts at position 472 in a portion of the intracellular tail topo-
logically comparable with that of FZD. We hypothesized that
the PTH1R controls the -catenin pathway by binding to this
domain of Dvl.
To determine if the PTH1R interacts with Dvl proteins, we
performed co-immunoprecipitation experiments using HA-
tagged PTH1R and Myc-tagged Dvl2. As shown in Fig. 1, B
and C, the PTH1R co-immunoprecipitates with Dvl2. To
identify the structural determinants required for PTH1R
interactions with Dvl2, we co-transfected theMyc-Dvl2 con-
struct with various HA-tagged PTH1R mutants and per-
formed additional coimmunoprecipitation studies. The
results are shown in Fig. 1D. Wild-type PTH1R (ETVM) co-
immunoprecipitated with Dvl2 (lane 1). It should be noted
that the PTH1R sequence contains a canonical carboxyl-ter-
minal PDZ ligand (590ETVM). This motif is not responsible
for Dvl binding because a PTH1R harboring a mutated car-
boxyl-terminal PDZ recognition domain (ETVA) bound
Dvl2 comparably with the wild type receptor (lane 2). Muta-
tion of ETVM to ETVA is sufficient to abolish PTH1R inter-
action with the PDZ protein NHERF1 (27). Likewise, a trun-
cated PTH1R lacking the PDZ-binding domain but bearing
the putative Dvl recognition domain (480-stop) also co-im-
munoprecipitated with Dvl2 (lane 3). This finding demon-
strates that PTH1R interactions with Dvl are not mediated
by the carboxyl-terminal canonical PDZ-binding motif of
the PTH1R. Importantly, a PTH1R lacking the putative Dvl-
binding domain (470-stop) failed to co-immunoprecipitate
with Dvl (lane 4), although it was well expressed (bottom).
These findings show that the PTH1R interacts with Dvl
through a specific recognition sequence located between
residues 470 and 480. This result supports the hypothesis
that the 472KSWSRW sequence in PTH1R (Fig. 1A) consti-
tutes the Dvl-binding motif.
PTH Activation and Stabilization of -Catenin—A defining
characteristic of Wnt signaling pathways is ligand-induced
redistribution and subsequent oligomerization of Dvl proteins
(28). Fig. 2A shows that PTH promotes translocation of Dvl to
the cellmembrane. CHOcells expressing PTH1R-EGFP (green)
were transiently transfected with red fluorescent mRFP1-Dvl2.
Images were collected at 20-s intervals. Before the addition of
PTH(1–34), the PTH1R was membrane-delimited, and Dvl2
FIGURE1.Dvl interactionswith thePTH1R.A, seven-transmembrane recep-
tor model showing sequence and common location of the Dvl-binding
domain in PTH1R and FZD. A PDZ recognitionmotif is present at the carboxyl
terminus of the PTH1R and of FZD1, -2, -4, and -7. B, interactions between
PTH1R and Dvl. Coimmunoprecipitation experiments were conducted on
CHO-N10 cells stably expressing a human HA-tagged PTH1R construct (23)
thatwere transfectedwithMyc-Dvl2.Where indicated, cellswere treatedwith
100 nM PTH(1–34) (15 min). The HA-PTH1R construct was immunoprecipi-
tated (IP), and the presence ofMyc-Dvl2 in the immunoprecipitatewas deter-
mined by immunoblotting (IB). C, interactions between PTH1R andDvl. CHO-
N10 cells stably expressing HA-PTH1R were transfected with Myc-Dvl2. Cell
lysates were immunoprecipitated with specific anti-Myc antibody, and the
presence of the PTH1R in the immunoprecipitate was determined using
anti-HA antibodies. D, the interactions of the PTH1R with Dvl2 are mediated
by an amino acid sequence contained between residues 470 and 480 of the
PTH1R. CHO-N10 cells were transfected with wild-type PTH1R (ETVM), a
receptor harboring a carboxyl-terminal mutation that abolishes classical
PDZ-PDZdomain interactions (ETVA), or receptor forms truncated at position
480or 470. Immunoprecipitation anddetectionwereperformedasdescribed
(23, 51).
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was diffusely expressed throughout the cytoplasm (Fig. 2A and
supplemental Video 1). Following the addition of PTH, Dvl was
recruited to the cell membrane, where it concentrated in dis-
crete puncta a few min after treatment (Fig. 2A, arrows),
whereas the PTH1R internalized. Unlike FZD4, which signifi-
cantly co-localizes with Dvl2 even in the absence of ligand (29),
the PTH1R and Dvl2 co-localize only transiently after receptor
activation. This result suggests somewhat weaker interactions
between PTH1R and Dvl or the presence of additional regula-
tory proteins. Importantly, Fig. 2A and supplemental Video 1
also show cells expressing only one of the fluorescent con-
structs. In this situation, PTH treatment failed to induce Dvl2
FIGURE2.RecruitmentofDvland-cateninactivation, stabilization,andnuclear translocation followingactivationofPTH1R.A, PTH treatment induces
translocation of Dvl2 to the plasmamembrane. CHO cells expressing EGFP-PTH1R (green) were transiently transfectedwithmRFP-Dvl2. Confocal imageswere
collected at 20-s intervals after the addition of 100 nM PTH(1–34). The images shown correspond to t  0 and 8 min. Note the accumulation of red Dvl2 in
discrete puncta (arrows, center panels). See supplemental Video 1. B, PTH-dependent -catenin activation in CHO cells. CHO cells were transfected with
HA-tagged human PTH1R and reporter TOP/FOP plasmids as described under “Experimental Procedures.” C, CHO cells do not express LRP6. The expression of
LRP6 in UMR-106 cells is shown for comparative purposes.D, concentration-dependent stimulation of -catenin activation by PTH. MC4 cells were transiently
transfectedwith TOPFlash and 48 h laterwere studied as described under “Experimental Procedures.” E, stabilized-catenin (i.e.dephosphorylated-catenin)
in MC4 bone cells after stimulation with PTH(1–34). F, translocation of activated -catenin to the nucleus. ROS 17/2.8 cells were challenged with 100 nM
PTH(1–34) for 8 h and then fixed and stained for dephosphorylated -catenin and 4,6-diamidino-2-phenylindole (DAPI), to stain nuclei.
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translocation in cells that did not express the PTH1R. Thus,
activation of the PTH1R causes translocation of the Dvl2 to the
cell surface.
To determine if recruitment of Dvl2 to the cell surface cor-
relates with downstream functions of the PTH1R, wemeasured
-catenin activation using a TCF/Lef reporter (30). The results
shown in Fig. 2B demonstrate that PTH stimulates -catenin
activity in CHO cells transfected with the human PTH1R.
Notably, LRP5/6 expression in CHO cells determined by quan-
titative RT-PCR is negligibly low. mRNA for LRP5 were unde-
tectable, and LRP6 was at background levels (data not shown).
Immunoblots with specific antibodies confirm the low expres-
sion of LRP6 (Fig. 2C), strengthening the conclusion that
-catenin activation by the PTH1R is independent of LRP5/6 in
CHO cells.
The above results demonstrate activation of -catenin by
PTH in heterologous expression systems. These findings were
validated in bone cells expressing endogenous levels of the
PTH1R. Fig. 2D shows that inMC4 cells, PTH activated-cate-
nin in a concentration-dependent manner. Activation of
-catenin occurs upon dissociation of the axin-APC-GSK3
complex, which results in reduced phosphorylation and stabi-
lization of non-phosphorylated -catenin. -Catenin then
accumulates in the cytoplasm before being translocated to the
nucleus, where it exerts its transcriptional effects. The results in
Fig. 2, E and F, illustrate the time course of -catenin accumu-
lation and nuclear translocation after challenge with PTH(1–
34), respectively. Therefore, stimulation of the PTH1R results
in the translocation and oligomerization of Dvl2 at the plasma
membrane and the inhibition of -catenin phosphorylation,
which in turn leads to the activation and nuclear translocation
of -catenin. These phenomena are benchmarks of the activa-
tion of the canonical Wnt signaling pathway.
Dvl Mediates PTH1R Actions—To analyze the role of Dvl
proteins in mediating the effects of PTH, we used two different
Dvl mutants. Xdd1 is a well characterized dominant negative
mutant of Xenopus Dishevelled (Xdsh) lacking amino acids
301–381, which include the core of the Xdsh PDZ domain (31).
AHEA-Dvl2 is a double point mutant that blocks FZD4 inter-
nalization and planar cell polarity signaling (29). As shown in
Fig. 3A, the stimulation of -catenin signaling by PTH was
blocked by expression of either Dvl mutant compared with the
empty vector control. These results support the conclusion that
the activation of -catenin by PTH is mediated by the interac-
tions of the PTH1R with Dvl proteins. To confirm the role of
Dvl in PTH1R-mediated activation of -catenin, the endoge-
nous levels of Dvl proteins were manipulated using short hair-
pin RNAconstructs. The expression of the isoformsDvl1, Dvl2,
andDvl3 inUMR cells was examined using quantitative reverse
transcription-PCR, which demonstrated that Dvl2 accounted
for 90% of the Dvl message present (supplemental Fig. 1).
Therefore, we transfected UMR cells with shRNA constructs
that specifically targeted Dvl2. This treatment reduced Dvl2
protein levels by over 50% (supplemental Fig. 2). This number is
an underestimate of the actual silencing effects of the shRNA
constructs because the data shown were not corrected to
account for transfection efficiency. -Catenin activation was
measured in cells co-transfected with Dvl2-targeted shRNA or
scrambled control vectors (Fig. 3B). As shown, PTH-dependent
-catenin activity was severely impaired by expression of Dvl2-
specific shRNA.
We further examined the effects of Dvl2 mutants on the
function of the PTH1R. Neither Xdd1 nor AHEA-Dvl2 inter-
fered with PTH-induced activation of adenylyl cyclase (sup-
plemental Fig. 3). However, overexpression of AHEA-Dvl2
interfered with PTH1R endocytosis (Fig. 4, A and B). Notably,
both mutants blocked PTH-induced osteoclastogenesis as
determined by tartrate-resistant acid phosphatase (TRAP)
staining (Fig. 4, C and D). These results strongly support the
hypothesis that some crucial effects of PTH are mediated by
direct binding of Dvl proteins by the PTH1R.
The present results strongly support the hypothesis that
some crucial effects of PTH are mediated by direct binding of
Dvl proteins by the PTH1R. We excluded the possibility that
the inhibitory actions of the Dvlmutants arose from interfering
with PTH1R signaling through adenylyl cyclase by measuring
the effects of XDD1 and AHEA-Dvl2 constructs on PTH-stim-
ulated cAMP. Neither Xdd1 nor AHEA-Dvl2 interfered with
PTH-induced activation of adenylyl cyclase (supplemental
Fig. 3).
DISCUSSION
The findings described here identify Dvl as a molecular
router, integrating signals derived from FZD and PTH1R to
FIGURE 3.Dvl requirement for PTH1Ractivationof-catenin.A, inhibition
of -catenin activation by the expression of dominant negative Dvl con-
structs, XDD1 and AHEA-Dvl2. UMR-106 cells were co-transfected with TOP-
Flash reporter (or the control plasmid, FOPFlash) and either empty vector or
the specified Dvl mutant (XDD1 or AHEA-Dvl2). -Catenin activation was
determined fromchemiluminescencedata as describedunder “Experimental
Procedures.” B, Dvl2-specific shRNA inhibits PTH- and Wnt3A-dependent
-catenin activation in UMR-109 cells. In these experiments, Dvl2 expression
was inhibitedby co-transfecting twoplasmids coding forDvl2-specific shRNA
together with the TOPFlash or FOPFlash reporters.
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control osteoclast formation. Regulation of Wnt signaling by
GPCRs other than FZD has been described (32–34). However,
we demonstrate here for the first time that Dvl proteins play an
important role in the activation of -catenin by classical
GPCRs. In all previous studies, the activation of -catenin has
been linked to the activation of classical G-protein mediated
pathways. For instance, stimulation of -adrenergic and endo-
thelin-1 receptors in cardiomyocytes leads to the activation of
-catenin by a mechanism that involves the recruitment of Akt
to the -catenin degradation complex and the subsequent
phosphorylation and inactivation of GSK3 (32). Likewise, the
lysophosphatidic acid receptors LPA2 and LPA3 activate -
catenin-dependent pathways by a mechanism downstream of
the activation of PKC (33). Finally, PGE2 receptors, acting
through protein kinase A, stabilize -catenin in colon cancer
cells (34). Importantly, -arrestins interact with phosphoryla-
ted Dvl, and transient co-expression of -arrestin-1 with either
Dvl1 or Dvl2 stimulates a -catenin reporter even in the
absence of Wnt (35). More recently, it has been suggested that
-arrestin is required for the Dvl-mediated disruption of the
-catenin destruction complex (36). The work presented here
demonstrates that the PTH1R activates -catenin signaling by
direct interactions with Dvl.
Dvl contains three functional
domains: an amino-terminal Dix
domain, a centrally located type 1
PDZ domain, and a carboxyl-ter-
minal Dep domain (37). The struc-
tural basis for the interaction of
FZD with Dvl is somewhat uncon-
ventional. Thus, despite the pres-
ence of a carboxyl-terminal PDZ
binding motif, it has been argued
that Dvl interacts with FZD
through a non-canonical, internal
sequence (38, 39). Interestingly,
Dvl binds to the PTH1R through
the comparable K(S/T)XXXW se-
quence despite the presence of a
carboxyl-terminal PDZ recogni-
tion motif. Thus, Dvl interacted
robustly with the PTH1R even fol-
lowing mutation of the PDZ-bind-
ing motif or truncation of the
PTH1R distal to the putative Dvl-
binding sequence.
The mechanism by which the
PTH1R promotes the redistribution
of Dvl involves direct interactions of
the receptorwithDvl.Arrestin-medi-
ated Dvl2 binding can be ruled out
because the PTH1R(480-stop) binds
Dvl2 with an efficiency comparable
with thatof thewild typereceptor (see
Fig. 1D). This truncated receptor is
devoid of the core of serines that are
phosphorylated by G-protein recep-
torkinasesandmediate thebindingof
arrestin, located between residues 489 and 501 (40, 41). The direct
involvement of Dvl in the signaling pathways leading to-catenin
activation is further supportedby the finding that twodifferentDvl
mutantsblockTCF/-catenin-dependent transcriptionandPTH-
induced osteoclastogenesis. Were the PTH1R modulating these
downstream effects through the activation of protein kinase A or
Akt and the phosphorylation ofGSK3, the actions of PTHwould
be expected to be insensitive to the expression of dominant nega-
tive Dvl mutants, and this was not the case.
Recent studies show that PTH can activate Wnt signaling
despite overexpression of Dkk1 (42). The results described here
are consistent with these findings and may explain the results
with Dkk1. Upon stimulation by PTH, the PTH1R recruits Dvl
and does so independent of FZD and LRP5/6 (and therefore of
Dkk1).
The present work demonstrates for the first time thatGPCRs
other than the members of the FZD subfamily may interact
with and activate Dvl proteins. The possibility that additional
receptors may also use this mechanism to activate -catenin-
dependent protein expression remains to be explored.
The dominant negative effects of the AHEA-Dvl2 mutant
require additional comment. AHEA-Dvl2 interacts normally
with FZD4 but cannot bind AP-2 and, as a consequence, acts as
FIGURE 4. Dvl is required for PTH-dependent PTH1R internalization and osteoclastogenesis. A, AHEA-
Dvl2 blocks ligand-induced PTH1R internalization. Rat osteosarcoma cells transfected with PTH1R-EGFP and
mRFP1-Dvl2were imagedat 20-s intervals after the additionof 100nMPTH(1–34) usingTIRF. Thedataobtained
with cells that express wild-type Dvl2 are shown in the top panel. The bottom panel shows the results of the
expression of AHEA-Dvl2. B, summary of the PTH1R internalization results obtained. The rate constant of
internalization of the PTH1Rwas calculated fromTIRFmicroscopydata. Only cells that expressedbothproteins
(as determined from green and red fluorescence measurements) were used in these calculations. The data
show the average of five different cell plates examined in three independent experiments. C, PTH promotes
osteoclastogenesis through a -catenin-mediated pathway. UAMS-32P cells were co-cultured with non-ad-
herent bone marrow cells (52). PTH(1–34) at increasing concentrations was added in the presence of empty
vector, XDD1 dominant negative Dvl, or AHEA dominant negative Dvl. After 6 days, tartrate-resistant acid
phosphatase activity was determined using naphthol phosphate as a substrate and fast garnet to label the
product as a red-purple precipitate. D, low and high magnification views of the cells shown in C. Tartrate-
resistant acid phosphatase staining was primarily localized to multinucleated osteoclasts (arrowheads). Bar,
100 m.
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a dominant negative for Wnt5a-induced FZD4 internalization
(29). This effect was recapitulated with the PTH1R (Fig. 4, A
and B). However, although AHEA-Dvl2 interferes withWnt5a-
dependent JNK phosphorylation, it does not block Wnt5a-in-
duced -catenin activation in HEK-293 (human embryonic
kidney) cells (29). AHEA-Dvl2 clearly disrupted PTH-induced
PTH1R osteoclastogenesis and -catenin-dependent gene
transcription in the bone-derived cell models used here.
Because AHEA-Dvl2 blocked PTH1R endocytosis, this phe-
nomenon can be explained by a requirement for PTH1R inter-
nalization in the activation of the -catenin pathway. This is
consistent with recent reports showing that -arrestin plays an
important role in the coupling of Wnt signaling to -catenin
activation (36).
The results described here regarding the effects of PTH ver-
sus Wnt activation of -catenin present an apparent paradox.
Although both ligands lead to activation of-catenin, they have
opposite actions on osteoclastogenesis. Although -catenin
mediates convergent actions of PTH1R and FZD upon miner-
alization, it promotes divergent actions on osteoclastogenesis
as we propose here. A model incorporating this scheme is
shown in Fig. 5.
PTH promotes osteoclastogenesis, whereasWnt stimulation
of -catenin blocks osteoclastogenesis. One crucial difference
in the signaling cascades downstream ofWnt ligands and PTH
is the activation of cAMP production by the latter. We propose
that the modulation of -catenin signaling by cAMP and pro-
tein kinase A during stimulation with PTH contributes signifi-
cantly to the differences observed between Wnt- and PTH-
driven responses. These effects may be due to differential
phosphorylation of -catenin (43, 44) or of GSK3 (45) by pro-
tein kinase A. Alternatively, the generation of cAMP activates
the cAMP-response element-binding protein (CREB), which in
turn interacts with-catenin and regulates its function (46, 47).
Phosphorylation, whether of -catenin or GSK3, may occur at
different sites or may be of different duration (i.e. transient
versus sustained). A clear distinction between Wnt- and PTH-
dependent -catenin activation is that the latter proceeds in an
environment with elevated cAMP and protein kinase A activity
and, perhaps, CREB.We propose that phosphorylation by pro-
tein kinase A of -catenin (43, 44) or of GSK3 (45) modifies the
-catenin response, leading to divergent patterns of gene
expression (Fig. 5). Consistent with this theory, independent
studies established that even in the same cell type, protein
kinase A can promote or prevent -catenin-dependent effects,
depending on the particular agonist (48). Thus,we envision that
Wnt or PTH-stimulated -catenin activation may evoke oppo-
site actions on osteoclastogenesis by eliciting similar -catenin
responses in a different intracellular background.
PTH promotes bone accretion when administered intermit-
tently but promotes bone resorption when continuously
applied. Intermittent PTH administration of PTH causes phos-
phorylation of LRP6 and stabilization of -catenin in mouse
osteoblasts (18). By contrast, continuous PTH treatment failed
to stimulate -catenin. Thus, the anabolic action of PTH may
arise in part from the participation of the canonical -catenin
pathway but independent of Wnt.
Other explanations can be advanced for the different effects
of -catenin activation by Wnt and PTH. For instance, diver-
gent effects of PTH and Wnt on -catenin may arise from the
expression patterns of PTH1R and FZD, respectively, during
osteoblast maturation (49, 50). Additionally or alternatively,
differences in -catenin actions upon osteoclastogenesis could
be due to distinct actions of PTH orWnt upon apoptosis. Irre-
spective of the mechanism, it is likely to have important impli-
cations for understanding and treating skeletal disorders.
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ORIGINAL ARTICLE
Direct interaction between NHERF1 and Frizzled regulates b-catenin
signaling
DS Wheeler1,2, SR Barrick1, MJ Grubisha1,2, AM Brufsky3,4, PA Friedman1,3 and G Romero1,4
1Laboratory for GPCR Biology, Department of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine,
Pittsburgh, PA, USA; 2Medical Scientist Training Program, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA;
3Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA and 4University of Pittsburgh Cancer
Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
Although Wnt-Frizzled (Fzd) signaling is critical in the
pathophysiology of carcinomas, its role in human breast
cancer has been difficult to establish. We show here that
the adaptor protein Naþ/Hþ exchange regulatory factor1
(NHERF1), a protein abundantly expressed in normal
mammary epithelium, regulates Wnt signaling, maintaining
low levels of b-catenin activation. NHERF1’s effects are
mediated by direct interactions between one of its PSD-95/
drosophila discs large/ZO-1 (PDZ) domains and the
C-terminus of a subset of Fzd receptors. Loss of NHERF1
in breast cancer cell lines enhances canonical Wnt signaling
and Wnt-dependent cell proliferation. Furthermore, the
mammary glands of NHERF1-knockout mice exhibit
increased mammary duct density accompanied by increased
proliferation and b-catenin activity. Finally, we demonstrate
a negative correlation between NHERF1 expression and
nuclear b-catenin in human breast carcinomas. Taken
together, these results provide a novel insight into the
regulation of Wnt signaling in normal and neoplastic breast
tissues, and identify NHERF1 as an important regulator of
the pathogenesis of breast tumors.
Oncogene advance online publication, 30 August 2010;
doi:10.1038/onc.2010.389
Keywords: NHERF1; EBP50; breast cancer; Wnt;
Frizzled; beta-catenin
Introduction
Aberrant Wnt signaling causes breast neoplasia in
animal models (reviewed in Fantozzi and Christofori,
2006). In humans, however, the involvement of Wnt
signaling in breast cancer pathogenesis remains unclear.
Stable, ectopic expression of specific Wnts can trans-
form primary human mammary epithelium, which can
form invasive tumors in mouse xenograft models
(Ayyanan et al., 2006). About 60% of the breast cancers
show evidence of increased b-catenin activity but the
mechanism and significance of these observations have
not been elucidated (Lin et al., 2000; Ryo et al., 2001).
The Naþ/Hþ exchange regulatory factor 1 (NHERF1,
also known as the Ezrin-binding phosphoprotein of
50kDa, EBP50) is a cytosolic PSD-95/Drosophila discs
large/ZO-1 (PDZ) adaptor protein abundantly expressed
in human mammary epithelium. NHERF1 was initially
identified as a regulator of the localization, signaling and
traffic of G protein-coupled receptors, ion channels and
transporters (reviewed in Weinman et al., 2006). Recently,
NHERF1 has been proposed to function as a tumor
suppressor (Dai et al., 2004; Pan et al., 2006; Kreimann
et al., 2007). Knockdown of NHERF1 increases cell-
ular proliferation and migration of various breast can-
cer cell lines (Pan et al., 2006, 2008). Furthermore, when
introduced in a mouse xenograft model, NHERF1-
knockout cells were more aggressive and produced greater
numbers of metastases (Pan et al., 2006). NHERF1
mutations occur in 3% of the human breast tumors,
whereas loss of heterozygosity at the NHERF1 locus
(17q25.1) occur in over 50% of primary beast tumors (Dai
et al., 2004). Both are correlated with poor prognosis and
early death (Dai et al., 2004).
The mechanism by which NHERF1 regulates tumor
growth and migration is unclear. The search for
potential NHERF1 targets revealed that 8 out of 10
human Frizzled (Fzd) receptors terminate in a canonical
PDZ ligand (x-S/T-x-V/L; see Figure 1a) (Songyang
et al., 1997). In this study, we investigated the hypothesis
that NHERF1 directly interacts with Fzd receptors
and regulates Wnt signaling. We show that NHERF1
interacts directly with a subset of Fzd receptors, and
that ablation of NHERF1 increases Wnt signaling and
Wnt-dependent proliferation. Furthermore, NHERF1-
knockout mice exhibit enhanced b-catenin activation
and increased mammary duct density. Finally, NHERF1
expression and b-catenin activation are negatively corre-
lated in human breast tumors. Therefore, we con-
clude that NHERF1’s function as a tumor suppressor is
a consequence of its role in the regulation of canonical
Wnt signaling.
Results
NHERF1 binds Fzd receptors
We developed a Chinese hamster ovary cell model
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undetectable under basal conditions and induced by the
addition of tetracycline (Wheeler et al., 2007). These
cells express low levels of endogenous Fzd receptors
(Supplementary Table 1). To investigate the interaction
between NHERF1 and Fzd, CHO-N10 cells were
transfected with hemagglutinin (HA)-tagged human
Fzd4 and induced by tetracycline to express NHERF1.
As seen in Figure 1b, NHERF1 coimmunoprecipitated
with Fzd4. To demonstrate that the interaction between
Fzd4 and NHERF1 is governed by PDZ domain–PDZ
ligand interactions, the C-terminal valine of Fzd4 was
mutated to alanine (Fzd4 V537A). We previously
showed that the equivalent mutation abrogates the
interactions of NHERF1 with the parathyroid hormone
receptor type 1 (Wheeler et al., 2007). The interaction
between the Fzd4 V537A and NHERF1 was reduced by
95% when compared with the wild type (Figure 1b,
lanes 2 and 4). Therefore, NHERF1 binds Fzd4 via the
receptor’s terminal PDZ ligand.
To determine which of the two PDZ domains of
NHERF1 was responsible for these interactions, we
transfected CHO cells with NHERF1 variants in which
the cores of PDZ1, PDZ2 and both PDZ1þPDZ2 had
been mutated: S1 (defective PDZ1), S2 (defective PDZ2)
and S1S2 (defective PDZ1 and PDZ2) (Wheeler et al.,
2007). The data shown in Figure 1c demonstrate that the
S1 mutant binds Fzd4 as effectively as wild-type
NHERF1, whereas Fzd4 binding to the S2 and S1S2
variants is very significantly reduced. We conclude,
therefore, that Fzd4 interacts preferentially with PDZ2.
Finally, to demonstrate that the interactions of Fzd4
and NHERF1 are direct, we performed an overlay assay
using recombinant His-tagged NHERF1 purified from
E. coli. The results, shown in Figure 1d, demonstrate
that recombinant NHERF1 binds Fzd4, supporting
the hypothesis that the interactions between NHERF1
and Fzd receptors are direct. Further, support to
the conclusion that these interactions are direct is the
demonstration that the interaction of recombinant
NHERF1 with V537A-Fzd4 is very significantly redu-
ced when compared with the wild-type receptor
(Figure 1d).
Previous work demonstrated that NHERF1 tethers
membrane proteins to the actin cytoskeleton localizing
them to distinct stress fiber domains and decreasing their
lateral mobility (Bates et al., 2006; Wheeler et al., 2007).
NHERF1 expression caused Fzd4 to aggregate along
phalloidin-positive fibers in stark contrast to the uni-
form distribution observed in control cells (Figures 2a
and b). The distribution of Fzd4 V537A was diffuse
independently of NHERF1 expression (Figures 2c
and d). Expression of S1-NHERF1 caused induced
redistribution of Fzd4 into bundle-like structures indis-
tinguishable from those formed by the expression of
Figure 1 NHERF1 interacts with the C-terminal PDZ ligand of Fzd receptors. (a) Human Fzd receptors cluster into three groups
based on their alignment of their C-termini. Fzd1, 2, 4 and 7 terminate in the consensus sequence E-T-x-V which is predicted to have
high affinity for the PDZ domains of NHERF1 (Karthikeyan et al., 2001). The C-terminal sequences of Fzd5, 8, 9 and 10 are also
expected to bind PDZ domains but are predicted to have lower affinity for NHERF1. Fzd3 and 6 do not terminate in a consensus PDZ
ligand and thus are not expected to interact with NHERF1. (b) NHERF1 coimmunoprecipitates with HA-Fzd4 in CHO-N10 cells.
Mutation of the C-terminal valine to alanine (V537A) abrogates this interaction. (c) Fzd4 interacts primarily with the second PDZ
domain of NHERF1 (PDZ2). CHO cells were transfected with NHERF1 mutants (S1: mutated PDZ1, S2: mutated PDZ2; S1S2:
mutated in both PDZ domains; WT: wild type). (d) The binding of NHERF1 to Fzd4 is caused by direct interactions. HA-tagged Fzd4
was expressed in CHO cells, extracted and incubated with specific agarose beads linked to anti-HA antibody or with beads in the
absence of anti-HA antibody. The material bound to the beads was resolved by SDS-PAGE and blotted onto nitrocellulose. The blot
was developed with recombinant His-tagged NHERF1 isolated from Escherichia coli followed by horseradish peroxidase-tagged anti-
His antibody. The only NHERF1-positive bands present in the gel corresponded to the molecular weight of the immunoprecipitated
HA-Fzd4. ctrl, control.
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wild-type NHERF1 (Supplementary Figure 1a). As
expected, this redistribution was not observed upon
expression of the S2 or S1S2 NHERF1 constructs
(Supplementary Figure 1b, c). When the lateral mobility
of Fzd4-eGFP was measured using fluorescence recover
after photobleaching, NHERF1 expression decreased
the diffusion coefficient of Fzd4-eGFP by 54% and
increased the immobile fraction by over fivefold
(Figures 2e and f). These results demonstrate that the
interaction of PDZ2 of NHERF1 with the terminal
PDZ ligand of Fzd4 tether the receptor to the actin
cytoskeleton.
Direct interaction with NHERF1 regulates Wnt signaling
To determine the effects of NHERF1 on Fzd signaling,
Fzd2, 3, 4 and 7 were transfected into CHO-N10
cells and b-catenin activation was measured using the
TOP/FOP luciferase reporter assay. On the basis of
their terminal amino acid sequence, Fzd2, 4 and 7 are
predicted to interact with NHERF1, whereas Fzd3 is
not (Figure 1a). Wnt3a-conditioned medium induced
b-catenin activation in cells expressing Fzd2, 3 and 7,
whereas Wnt5a-conditioned medium stimulated b-cate-
nin activity in Fzd4-transfected cells. Fzd2, 4 and 7
showed impaired Wnt-induced b-catenin activation in
the presence of NHERF1 (76, 86 and 74% decrease,
respectively) (Figure 3a). In contrast, Wnt signaling
via Fzd3 was unaffected by NHERF1 expression
(Figure 3a). Likewise, the Fzd4 V537A was significantly
less sensitive to NHERF1-induced inhibition, consistent
with its inability to bind NHERF1 (Figure 3b).
We next examined the effects of the S1, S2 and S1S2
NHERF1 mutants on Wnt-induced b-catenin activation.
Figure 2 NHERF1 modulates the distribution and dynamics of Fzd4. (a) CHO-N10 cells were transiently transfected with Fzd4-eGFP
and stained with Texas Red isothiocyanate conjugated phalloidin. Fzd4-eGFP has a uniform membrane distribution and does not
colocalize with phalloidin-stained actin fibers. (b) Expression of NHERF1 causes Fzd4-eGFP to aggregate along phalloidin-positive actin
fibers. (c, d) Expression of NHERF1 does not alter membrane distribution of Fzd4 V537A-eGFP consistently with the inability of this
mutant to bind PDZ domains. Scale bar represents 5mm. (e, f) The lateral mobility of Fzd-eGFP in control and NHERF1 expressing
CHO-N10 cells was measured by fluorescence recovery after photobleaching. NHERF1 expression decreased the diffusion coefficient of
Fzd4-eGFP from 0.17 to 0.07mm2/s. NHERF1 expression also caused a concomitant fivefold increase in the immobile fraction (*Po0.05,
Students’ t-test).
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S1-NHERF1 functioned identically to wild type, whereas
NHERF1 containing mutations in the second PDZ
domain (S2 and S1S2) showed no inhibition of Wnt
signaling (Figure 3c). Thus, interaction between the sec-
ond PDZ domain of NHERF1 and Fzd govern
NHERF1-mediated regulation of Wnt signaling. Impor-
tantly, two of the three mutations detected in the human
breast cancer (K172N and R180W) are located within the
second PDZ domain of NHERF1 (Dai et al., 2004).
Loss of NHERF1 expression in breast cancer cells
enhances Wnt-induced b-catenin activation and cell
proliferation
As NHERF1 regulates Wnt signaling in CHO-N10
cells, we hypothesized that the tumor suppressor acti-
vity of NHERF1 in breast cancer may result from the
modulation of Wnt signaling. To investigate this, MCF7
and MDA MB-231 human breast cancer cell lines were
selected because they have similar Fzd repertoires
(Supplementary Table 1), while representing two ex-
tremes of NHERF1 expression. MCF7 cells express high
levels of NHERF1, whereas MDA MB-231 cells express
trace amounts (Figure 3d, Supplementary Figure 2a and
Supplementary Table 1). Transient transfection with
short hairpin RNA targeted against NHERF1 decreased
protein expression by 95% in MCF7 cells (Figure 3d).
Transfection of MDA MB-231 cells with NHERF1 was
able to reconstitute NHERF1 expression to levels
comparable with those observed in MCF7 cells (Supple-
mentary Figure 2a).
At baseline, both MCF7 and MDA MB-231 cells
showed little b-catenin activation, suggesting that Wnt
secretion and autocrine stimulation are not active.
MCF7 cells showed no significant increase in b-catenin
activation when stimulated with either Wnt3a- or
Figure 3 Enhanced Wnt signaling occurs in the absence of NHERF1. (a) CHO-N10 cells were cotransfected with the indicated Fzd
receptors and either TOP or FOP luciferase reporter plasmid. NHERF1 expression blunted Wnt-induced luciferase expression via
Fzd2, 4 and 7 but had no effect on Wnt signaling through Fzd3 (**Po0.01, *Po0.05, Two-way analysis of variance (ANOVA) with
Bonferroni post-hoc tests). (b) Mutational ablation of the Fzd4 PDZ ligand (Fzd4 V573A) rescues Wnt signaling from NHERF1
inhibition. This mutation has no effect on Wnt singaling in the absence of NHERF1. (c) Wnt-induced b-catenin activation was blocked
by wild-type NHERF1 and NHERF1 containing a mutated PDZ1 domain (S1). This inhibition was not caused by expression of
NHERF1 containing a mutated PDZ2 domain (S2) or with both PDZ domains mutated (S1S2) (***Po0.001, One-way ANOVA with
Tukey post-hoc tests). (d) Transfection of MCF7 cells with NHERF1 targeted short hairpin shRNA reduced expression by 95%.
(e) NHERF1 knockdown enhanced Wnt-induced b-catenin activation in MCF7 cells (*Po0.05, **Po0.01, Two-way ANOVA with
Bonferroni post-hoc tests). (f) Following 8 h of treatmnent with Wnt, NHERF1-knockdown cells shown increased levels of cyclin-D1.
(***Po0.001, Two-way ANOVA with Bonferroni post-hoc tests). (g) Wnt-induced proliferation was measured using a 24 h
radiolabeled-thymidine incorporation assay. MCF7 cells lacking NHERF1 showed marked proliferative responses to both Wnt3a and
Wnt5a compared with scrambled controls (**Po0.01, ***Po0.001, Two-way ANOVA with Bonferroni post-hoc tests).
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Wnt5a-conditioned medium. In contrast, NHERF1-
knockdown MCF7 cells responded to both Wnt3a
and Wnt5a stimulation with approximately fourfold
increases in b-catenin activity (Figure 3e).
Cyclin-D1 is a well established target gene of b-
catenin known to influence cellular proliferation and
breast cancer prognosis (Gillett et al., 1996; Tetsu and
McCormick, 1999; Umekita et al., 2002). Cyclin-D1
levels were evaluated by quantitative PCR in control
and NHERF1-knockdown MCF7 cells after the treat-
ment with Wnt5a. As expected, NHERF1-knockdown
cells expressed significantly greater amounts of cyclin-
D1 in response to Wnt (Figure 3f). Furthermore, both
Wnt3a and Wnt5a significantly increased the rate of
proliferation NHERF1-knockdown MCF7 cells com-
pared with control cells (Figure 3g).
This trend was recapitulated in the MDA MB-231
cells. Stimulation of control MDA MB-231 cells
(lacking NHERF1) resulted in a significant activation
of b-catenin. These effects were blocked by transfection
with NHERF1 (Supplementary Figure 2).
Increased duct density and b-catenin levels
in the mammary glands of NHERF1-knockout mice
Our in vitro data predict that the loss of NHERF1 in
mammary tissue should result in increased Wnt signaling
and a hyperproliferative phenotype. We examined the
fourth and fifth mammary glands from 10–week-old virgin
NHERF1/ mice and compared them with those of
wild-type littermates. Breast tissue from the NHERF1/
mice exhibited greater density of mammary ducts (Figures
4a and b). A subset of the knockout mice (30–40%)
manifested a more severe phenotype consisting of adipose
atrophy accompanied by capillary and ductal dilation
(Figure 4c). Overall, the loss of NHERF1 expression
resulted in a three- to fourfold increase in duct density
(Figure 4d). Because the total body weight and fat
contents of NHERF1/ mice were comparable with
those of wild-type animals, the observed increase in duct
density is most likely the result of increased breast
proliferation. This was confirmed by using an in vivo
5-bromo 20-deoxy-uridine (BrdU) staining protocol to
identify proliferating cells in the mammary ducts. The
results show increased incorporation of BrdU in the
knockout mammary ducts (Figure 4e; Po0.03, n¼ 4).
Mammary ducts from wild-type animals showed
strong NHERF1 staining along the apical membrane
of epithelial cells and faint b-catenin staining along
all epithelial membranes (Figure 4f). Ducts from
NHERF1/ animals had increased levels of b-catenin
staining and a greater percentage of b-catenin localized
within the nucleus (Figures 4f and g). Taken together,
these results suggest that the loss of NHERF1 leads to
the increased ductal proliferation and density, which
correlate with enhanced b-catenin activation.
Correlation between NHERF1 expression and b-catenin
activation in human breast cancer tissues
b-Catenin activation is a negative predictor of prognosis
and survival in human breast cancer (Lin et al., 2000;
Dolled-Filhart et al., 2006). Because our data link loss of
NHERF1 expression to increased Wnt signal transduc-
tion, we predicted a negative correlation between
NHERF1 expression and b-catenin activity in human
tumor samples. To test this hypothesis, breast cancer
biopsies of varying stages and estrogen receptor/
progesterone receptor status were stained for NHERF1
and b-catenin (see Supplementary Table 2 for detailed
characteristics of the clinical samples). Antibody stain-
ing demonstrated low levels of b-catenin in tumors
expressing high levels of NHERF1, independently of
their estrogen receptor/progesterone receptor status.
Furthermore, b-catenin staining was weak and mem-
brane delimited in high-NHERF1 tumors, resembling
the pattern observed in mammary tissues from wild-type
mice (Figure 5a). In contrast, b-catenin expression was
greater in tumors that expressed little or no NHERF1
(Figure 5b). This increased expression was accompanied
by an increase in the percent of b-catenin observed
within the nucleus. Furthermore, the aggregated data
demonstrated a strong negative correlation between
NHERF1 expression and the fraction of b-catenin
within the nucleus (r¼ 0.69, F¼ 8.729, P¼ 0.0105)
(Figure 5c). Further analysis demonstrated this negative
correlation to be independent of estrogen receptor/
progesterone receptor status and tumor stage. In normal
control tissues, nuclear b-catenin staining was uniformly
low and unrelated to NHERF1 staining (r¼ 0.03,
F¼ 0.046, P¼ 0.8386; Figure 5d).
NHERF1 interferes with Fzd-Dvl binding
Because of the short C-terminal tail of Fzd receptors,
the Dvl and NHERF1 binding sites are separated by as
few as 13 amino acids. Therefore, we hypothesized that
the interaction between NHERF1 and Fzd may alter the
recruitment and the activation of Dvl. To investigate
this, we coimmunoprecipitated HA-Fzd4 and myc-Dvl2
in the presence or absence of NHERF1. In the absence
of NHERF1, Fzd4 coimmunoprecipitated notably
greater amounts of Dvl2 (Figure 6a, compare lane 1
and 2). After stimulation with Wnt, identical amounts of
Dvl were coimmunoprecipitated suggesting that Wnt
binding induces dissociation of NHERF1 and binding
to Dvl (Figure 6a, lanes 3 and 4). To confirm that this
was the case, the effects of Wnt-conditioned medium on
the coimmunoprecipitation of HA-Fzd4 and NHERF1
was examined using CHO-N10 cells. The results
demonstrate that Wnt induces dissociation of NHERF1
and Fzd4 (Supplementary Figure 3).
Total internal reflection fluorescence (TIRF) micro-
scopy was used to investigate the effects of NHERF1 on
Fzd-Dvl interactions with greater temporal resolution.
TIRF allows imaging of a very thin optical section
containing the plasma membrane, such that changes in
the fluorescence intensity detected by TIRF reflect traffic
of the fluorescent protein to and from the plasma
membrane. mRed-Dvl2 was found to be uniformly
distributed in the cytoplasm of CHO-N10 cells expres-
sing NHERF1 (Figure 6b). On stimulation with Wnt5a,
Dvl2 was recruited to the membrane (Figure 6d).
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In control cells, Dvl2 was localized to the plasma
membrane under basal conditions (Figure 6c). The
addition of Wnt had no effect on the amount of
Dvl2 at the plasma membrane (Figure 6d). These data
suggest that Wnt binding causes a slow dissociation
of NHERF1 resulting in a retardation of the coupling
of Fzd and Dvl. These observations imply, there-
fore, that the effects of NHERF1 on Wnt signaling
are a consequence of the inhibition of Fzd-Dvl pre-
coupling, which results in slower, significantly attenu-
ated responses.
Coupling between Fzd receptors and Dvl has been
shown to be critical for proper Fzd internalization and
signaling (Chen et al., 2003; Yu et al., 2007). Thus, the
binding of NHERF1 to Fzd should reduce Fzd-Dvl
precoupling and result in impaired Wnt-induced Fzd
internalization. Consistent with this hypothesis, CHO-
N10 cells lacking NHERF1 internalized a remarkable
Figure 4 Mammary glands of NHERF1 knockout mice exhibit increased b-catenin signaling, elevated ductal density, and increased
cell proliferation. The fourth and fifth breasts from virgin NHERF1þ /þ and NHERF1/ littermates were removed
and histologically prepared. (a) Representative images from 10-week-old NHERF1þ /þ mouse. (b) Representative images from
a 10-week-old NHERF1/ mouse. (c) A subset of NHERF1/ mice presented a more severe phenotype characterized by a
loss of adipose tissue, capillary dilation and ductal dilation. Scale bar represents 200mm. (d) Quantification of ductal density in
NHERF1þ /þ and NHERF1/ mice (*Po0.05, Students’ t-test). (e) Increased mammary duct proliferation in NHERF1/
females. (f) Individual duct from NHERF1þ /þ mouse stained with 40,6-diamidino-2-phenylindole (DAPI; blue), anti-b-catenin
(green) and anti-NHERF1 (red). NHERF1 decorates the apical surface, whereas b-catenin staining is observed along all membranes of
the epithelial cells. Scale bar represents 20 mm. (g) Individual duct from NHERF1/ mouse. b-catenin staining is augmented and is
no longer restricted to the membrane. Scale bar represents 20mm.
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70% of their Fzd4 receptors in response to Wnt5a,
whereas o20% of the surface Fzd4 is internalized in
cells expressing NHERF1 (Figure 6e). In contrast, the
endocytosis of the V537A-Fzd4 mutant is insensitive to
the expression of NHERF1, internalizing readily
whether NHERF1 is expressed or not (Figure 6e).
On the basis of results presented here, we propose the
following model for the regulatory role of NHERF1 in
breast cancer (Figure 6f). Normal breast tissues and
low-grade ductal carcinomas express NHERF1, which
attenuates Wnt signaling by impairing Fzd-Dvl precou-
pling. Under these conditions, the growth of breast
epithelia is mainly controlled by estrogen-regulated
signals. As the tumor progresses NHERF1 expression
diminishes due to genetic changes or as a consequence of
treatment with anti-estrogens. Reduced levels of
NHERF1 facilitate coupling of Fzd receptors to Dvl
and, subsequently, enhanced Wnt signaling. Wnt then
becomes a driving force in the proliferation of the
tumor, inducing epithelial-to-mesenchymal transition
and resulting in increasing malignancy and tumor
metastasis.
Discussion
Our findings show that NHERF1 regulates canonical
Wnt signaling. We demonstrate that NHERF1 modu-
lates Dvl recruitment and Wnt-induced b-catenin
activation through a direct interactions between the
second PDZ domain of NHERF1 and the C-terminal
PDZ ligand of a selected subset of Fzd receptors. In the
absence of NHERF1, Fzd precouples with Dvl,
resulting in augmented canonical Wnt signaling. This
conclusion is further supported by the finding that
NHERF1-knockout mice show increased mammary
duct proliferation and density correlated with increased
b-catenin activation. Likewise, human breast tumors
show a significant negative correlation between
NHERF1 expression and b-catenin activation.
We conclude, therefore, that NHERF1 expression is
required for proper Wnt signaling in normal mammary
epithelium. Loss of NHERF1 results in dysregulation of
Wnt function that leads to increased proliferation and
possibly dysplastic changes of the mammary epithelium.
Whether this is NHERF1’s main role in the regulation
Figure 5 b-catenin activation and NHERF1 expression are negatively correlated in human breast cancer samples. Human breast
cancer biopsies were stained with 40,6-diamidino-2-phenylindole (DAPI; blue), anti-b-catenin (green) and anti-NHERF1 (red).
(a) Samples which robustly expressed NHERF1 had a faint, membranous b-catenin staining pattern. There was minimal colocalization
between b-catenin staining and nuclear DAPI staining (insert). (b) Samples with nominal NHERF1 staining exhibited a large
percentage of b-catenin staining within the nucleus. Scale bar represents 20 mm in the main panel and 10mm in insert. (c) NHERF1
expression is negatively correlated with the percentage of b-catenin staining occurring within the nucleus. (d) No correlation between
NHERF1 expression and nuclear b-catenin is observed in adjacent normal tissue.
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of mammary tissues remains to be determined. A recent
report has linked NHERF1 to the regulation of the
tumor suppressor PTEN and the subsequent attenua-
tion of platelet-derived growth factor signaling in breast
cancer (Pan et al., 2008). Thus, in mammary epithelium,
NHERF1 seems to have multiple functions that
converge in the regulation of normal cell proliferation.
Our findings show that NHERF1 inhibits Fzd2, 4
and7 but not Fzd3-dependent b-catenin activation.
Thus, Wnt signaling is expected to be insensitive to
NHERF1 expression in cells harboring high levels of
Fzd3. Likewise, because Fzd6 does not contain a
canonical PDZ ligand sequence in its C-terminus, we
predict that Fzd6 signaling will be insensitive to
NHERF1 expression. Thus, as only a subset of Fzd
receptors are targets for NHERF1 regulation, the
expression profile of the Fzd receptors in breast tumors
is of primary interest. Importantly, the Fzd expression
profile of breast cancer cells shows a predominance of
Fzd5,2 and 1, which account for well over 90% of the
Figure 6 Fzd-Dvl precoupling is disrupted by NHERF1. (a) Coimmunoprecipitation between myc-Dvl2 with HA-Fzd4 was assessed
in CHO-N10 cells before and 10min after Wnt5a treatment. Interaction between Dvl2 and Fzd was clearly enhanced in the absence of
NHERF1 before Wnt5a addition. The amount of Dvl2-Fzd complex after treatment with Wnt5a was independent of NHERF1
expression. (b) mRed-Dvl2 has a uniform cytoplasmic distribution in CHO-N10 cells expressing Fzd4 and NHERF1. (c) In the absence
of NHERF1, mRed-Dvl2 localizes predominantly to the membrane. Scale bar represents 5mm. (d) CHO-N10 cells expressing mRed-
Dvl2 and Fzd4-GFP were rapidly imaged using TIRF microscopy. All intensity measurements are normalized to Fzd4-GFP to account
for receptor internalization. Addition of Wnt5a is indicated by an arrow. In NHERF1 expressing cells, the addition of Wnt5a induced
a translocation of Dvl2 to the plasma membrane. The amount of membrane associated Dvl2 did not change with addition of Wnt5a in
control cells. (e) Fzd4 internalization was inferred from decreases in surface staining as measured by flow cytometry. In the absence of
NHERF1, Wnt5a trigger extensive Fzd4 internalization (**P¼ 0.002, Student’s t-test). As expected, the internalization of the V537A-
Fzd4 mutant is insensitive to NHERF1 expression. (f) In normal mammary epithelium, NHERF1 occupies the C-terminus of Fzd
receptors tethering it to the actin cytoskeleton. Loss of NHERF1 allows abnormal Fzd-Dvl precoupling, which results in
pathologically enhanced Wnt-induced b-catenin activation and hyper-proliferation.
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Fzd mRNA produced by MCF7 cells (Supplementary
Table 1) and contain canonical PDZ ligand sequences.
A similar expression profile was found in MDAMB-231
cells, suggesting that this pattern of expression may
be typical for breast epithelium. Furthermore, our
data demonstrate that Wnt signaling is attenuated by
NHERF1 expression in both MCF7 and MDA-MB231
cells, confirming the hypothesis that NHERF1 regulates
Wnt signaling in breast cancer.
Normal and malignant breast tissues express several
other PDZ proteins that reportedly interact with Fzd
receptors. For instance, syntenin, an adaptor protein
that, like NHERF1, contains two PDZ domains in
tandem, reportedly interacts with a subset of Fzd
receptors and modulates non-canonical Wnt signaling
during the embryonic development of Xenopus (Luyten
et al., 2008). Furthermore, syntenin is highly expressed
in breast cancer tissues, also mediating non-canonical
Wnt signaling and inducing cell migration and invasion
(Koo et al., 2002). However, there is no evidence that
syntenin regulates canonical Wnt signaling in any way.
In fact, neither the knockdown nor the overexpression
of syntenin have any effects on the activation of the
b-catenin pathway during the development of Xenopus
(Luyten et al., 2008).
A second PDZ protein expressed in epithelial tissues
is the membrane-associated guanylate kinase family
member MAGI-3 (Laura et al., 2002). MAGI-3 contains
six PDZ domains in tandem, and reportedly interacts
with Fzd4 via its second PDZ domain (Yao et al., 2004).
This interaction modulates the activation of Jnk and the
non-canonical Wnt signaling pathway. However, as in
the case of syntenin, the interactions of MAGI-3 and
Fzd receptors do not affect b-catenin signaling in any
measurable way (Yao et al., 2004). Associations between
Fzd receptors and several other PDZ proteins have been
reported in mammalian systems (Wawrzak et al., 2009).
However, most reported interactions have been linked
exclusively to the positive modulation of non-canonical
Wnt signaling. In general, no evidence of the regulation
of Wnt-dependent b-catenin activation by PDZ proteins
has been reported to date in mammalian systems.
NHERF1 is, therefore, unique among PDZ proteins
in its role as a negative regulator of Wnt-dependent
b-catenin signaling in breast epithelium.
Some recent reports have suggested that NHERF1 is
overexpressed in breast cancer cells as compared with
normal mammary tissues (Cardone et al., 2007; Song
et al., 2007; Mangia et al., 2009). Although this is not
surprising because NHERF1 expression is positively
regulated by the estrogen receptor (Ediger et al., 1999),
it implies that loss of NHERF1 is unlikely to be the
primary cause of the transformed phenotype. However,
NHERF1 expression is greatly reduced in the more
invasive ER-negative tumors (Stemmer-Rachamimov
et al., 2001; Song et al., 2007). These findings sug-
gest a unique role for NHERF1 in the evolution of
estrogen-driven ER-positive tumors into more aggres-
sive Wnt-driven tumors. In ER-positive ductal carcino-
mas, which express NHERF1, proliferation is driven by
classical ER-dependent pathways with relatively little
contribution from Wnt signaling. We propose that the
loss of NHERF1 via genetic or epigenetic changes
increases the contribution of Wnt signaling in tumor
growth, thus allowing the loss of the ER, promoting
epithelial-to-mesenchymal transition and increasing
tumor aggressiveness.
If true, this hypothesis may have significant implica-
tions for the treatment of ER-positive breast cancer.
The majority of ER-positive carcinomas are success-
fully treated with antiestrogens, such as tamoxifen,
which inhibit ER-dependent growth. However, tamox-
ifen treatment reduces NHERF1 expression by approxi-
mately 70% in cell culture systems (Ediger et al., 1999).
Chronic treatment with antiestrogens will likely
decrease NHERF1 expression in the tumor, which
would increase its sensitivity to Wnt ligands, thus
switching the proliferative drive from estrogen depen-
dent to Wnt dependent. This model explains the
paradoxical observation that ER-positive tumors recur-
ring after prolonged antiestrogen treatment are inhi-
bited by the administration of estrogens (Ellis et al.,
2009). We propose that this inhibition is mediated
by estrogen-induced expression of NHERF1, which
then inhibits Wnt-dependent proliferation. This model
highlights the importance of NHERF1 as a marker
for Wnt sensitivity and the importance of targeting the
Wnt signaling pathways for the treatment of breast
carcinomas.
Materials and methods
Breast biopsies
All biopsy samples were obtained in accordance with the
University of Pittsburgh Internal Review Board. Sample
characteristics are summarized in Supplementary Table 2.
Materials and constructs
Anti-NHERF1, anti-b-catenin, anti-myc and anti-HA (HA.11)
antibodies were purchased from Upstate Biotechnology (Lake
Placid, NY, USA), Millipore (Billerica, MA, USA), Sigma
(St Louis, MO, USA) and Covance (Princeton, NJ, USA).
Secondary antibodies were from Jackson ImmunoResearch
(West Grove, PA, USA). Texas Red isothiocyanate conjugated
phalloidin was purchased from Invitrogen (Carlsbad, CA,
USA). All other materials were purchased from Sigma unless
otherwise indicated. Human Fzd2, 3 and 7 were purchased
from OpenBiosystems Inc (Huntsville, AL, USA) and sub-
cloned into pcDNA3.1(þ ) using EcoRI and XhoI. NHERF1-
targeted short hairpin RNA plasmids have been previously
described (Wang et al., 2007). TOP and FOP plasmids were
supplied by Dr Paul Monga. Fzd4-HA, Fzd4-eGFP, myc-Dvl2
and mRed-Dvl2 plasmids were kindly provided by Dr T
Kirchhausen (Yu et al., 2007).
Cell culture
CHO-N10 cells were grown as described (Wheeler et al., 2007).
MCF7 and MDA MB-231 cells were grown in DMEM/F12
medium (Mediatech Inc, Manassas, VA, USA) supplemented
with 10% fetal bovine serum (Invitrogen) and 1% penicillin/
streptomycin. Wnt3a, Wnt5a and control L-cells were pur-
chased from American Type Culture Collection and grown in
Dulbecco0s modied Eagle0s medium supplemented with 10%
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fetal bovine serum and 1% penicillin/streptomycin. Condi-
tioned media was removed from cells after 4 days in culture
and returned to a pH of 7.4 by addition of 4-(2-hydroxyethyl)-
1-piperazineethanesulfonic acid buffer. FuGENE 6 (Roche
Applied Sciences, Indianapolis, IN, USA) was used for all
transfections.
Fluorescence recovery after photobleaching
Fluorescence recovery after photobleaching was conducted as
described previously (Wheeler et al., 2007). Briefly, cells seeded
onto Mattek dishes were transfected with the indicated
plasmids. Small circular regions of the plasma membrane were
bleached with a 405 nm laser line and images were collected
every second for 1–2min. The images were exported to ImageJ
(National Institute of Health) and the average fluorescent
intensity of the bleached region was measured. The diffusion
coefficient was calculated using the Stokes–Einstein equation
for two-dimensional diffusion. The bar graph represents
aggregate data from B20 cells imaged over three sessions.
TIRF microscopy
TIRF studies were carried out as previously described
(Wheeler et al., 2007). Red and green TIRF images were
collected sequentially every 5 s for 15min. A baseline was
established with 2min of imaging before the addition of
Wnt5a. The average Dvl2 intensity was normalized to the
average Fzd intensity and graphed using GraphPad Prism.
Receptor internalization
Internalization of membrane proteins was measured using flow
cytomerty as described (Garrido et al., 2009). CHO-N10 cells
stably transfected with HA-Fzd4 containing an extracellular
HA epitope were treated with Wnt5a, washed twice with ice-
cold phosphate-buffered saline and fixed with 0.5% parafor-
maldehyde for 5min. This protocol left the cell membrane
intact and impermeant to antibodies. Cells were scraped and
incubated in 3% bovine serum albumin for 30min to block
nonspecific binding. The cells were stained with anti-HA
(Covance) followed by anti-rabbit-Alexa-680. The fluorescence
of each cell was measured using a flow cytometer and reflected
the amount of Fzd4 on the surface. Percentage Fzd
internalization was calculated as: 100 (1geometric mean
fluorescence (t)/geometric mean fluorescence (t¼ 0)).
Quantitative breast histology
The fourth and fifth breasts of 10-week-old NHERF1þ /þ
and NHERF1/ mice were removed and fixed in buffered
formalin. After fixation, they were embedded in paraffin and
sectioned. Slides from different depth in the breast tissue were
stained with haematoxylin and eosin. Each slide was imaged 10
times at  20 magnification. Coordinates were randomly
generated; if breast tissue did not occupy 90% of the visual
field, new coordinates were generated. The average number of
ducts per field was calculated for each slide. The bar chart
represent average ducts per field measured from three
NHERF1 þ /þ animals and five NHERF1/ animals
(two having the more severe phenotype). For BrdU staining
the animals were injected with 50mg/g of body weight 6 h
before harvesting the breast tissues. BrdU incorporation was
determined with anti-BrdU antibody (GE Healthcare, Piscat-
away, NJ, USA).
TOP/FOP Luciferase assay
Cells were stimulated with control, Wnt3a-, or Wnt5a-enriched
medium for 8 h. Cells were lysed with Reporter Lysis Buffer
(Promega, Madison, WI, USA) and transferred to a 96-well
plate. The luminescence of each well was recorded for 5 s after
addition of BioGlo Luciferase substrate (Promega). The ratio
of TOP/FOP signal was calculated and normalized to control
conditions. Bars represent data from at least three experiments
conducted in duplicate.
Quantitative real-time PCR
RNA was extracted using Trizol (Invitrogen) and transcribed
into complementary DNA using a Clontech (Mountain View,
CA, USA) Advantage RT–for-PCR kit. Quantitative real-time
PCR was performed on an Applied BioSystems (Carlsbad,
CA, USA) StepONe real-time PCR system using SYBR Green
(Qiagen, Valencia, CA, USA) with the primers listed in
Supplementary Table 3. All samples were run in duplicate and
normalized to glyceraldehyde 3-phosphate dehydrogenase.
Statistical analysis
Each experiment was repeated at least three times. All
statistical tests were conducted using GraphPad Prism.
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